

CITATION REPORT

List of articles citing

Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence

DOI: 10.1038/sj.mp.4001558

Molecular Psychiatry, 2005, 10, 40-68; image 5.

Source: <https://exaly.com/paper-pdf/38219496/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1783	LRRTM1:. 181-196		1
1782	The status of genetic investigations of schizophrenia. 288-308		
1781	Schizophrenia spectrum disorders in people with intellectual disabilities. 2001 , 131-142		2
1780	SCHIZOPHRENIA AND SCHIZOPHRENIA-LIKE PSYCHOSIS. 2003 , 223-233		20
1779	Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. 2004 , 27, 683-90		512
1778	Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. 2004 , 75, 807-21		1333
1777	DISC1 and neurocognitive function in schizophrenia. 2005 , 16, 1399-402		96
1776	Schizophrenia: update on genetics, cognitive behavioural therapy and early intervention. 2005 , 22, 62-66		1
1775	Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia. <i>Neuroscience and Biobehavioral Reviews</i> , 2005 , 29, 913-47	9	377
1774	Differential expression of calcineurin A subunit mRNA isoforms during rat hippocampal and cerebellar development. 2005 , 22, 3017-24		20
1773	Investigating the neurodevelopmental hypothesis of schizophrenia. 2005 , 32, 687-96		56
1772	A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development. 2005 , 7, 1167-78		483
1771	GAD1 (2q31.1), which encodes glutamic acid decarboxylase (GAD67), is associated with childhood-onset schizophrenia and cortical gray matter volume loss. <i>Molecular Psychiatry</i> , 2005 , 10, 581-8	15.1	169
1770	The neurodevelopmental model of schizophrenia: update 2005. <i>Molecular Psychiatry</i> , 2005 , 10, 434-49	15.1	749
1769	Association between the TRAX/DISC locus and both bipolar disorder and schizophrenia in the Scottish population. <i>Molecular Psychiatry</i> , 2005 , 10, 657-68, 616	15.1	149
1768	A haplotype within the DISC1 gene is associated with visual memory functions in families with a high density of schizophrenia. <i>Molecular Psychiatry</i> , 2005 , 10, 1097-103	15.1	129
1767	Cytogenetics and gene discovery in psychiatric disorders. 2005 , 5, 81-8		25

1766	Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action?. 2005 , 5, 298-304	130
1765	Psychiatric disease: all in the mind of a mouse. 2005 , 438, 151-2	12
1764	Schizophrenia. 2005 , 15, R980-4	15
1763	Schizophrenia: genes at last?. 2005 , 21, 518-25	241
1762	No evidence for association between polymorphisms in GRM3 and schizophrenia. 2005 , 5, 23	41
1761	Genetics of schizophrenia. 2005 , 4, 14-17	2
1760	Neuropathology of schizophrenia. 2005 , 4, 18-21	5
1759	[One decade of functional imaging in schizophrenia research. From visualisation of basic information processing steps to molecular-genetic oriented imaging]. 2005 , 45, 113-8, 120-3	6
1758	The potential role of lamotrigine in schizophrenia. 2005 , 181, 415-36	45
1757	Stereological studies of capillary length density in the frontal cortex of schizophrenics. 2005 , 109, 510-8	58
1756	First- and second-generation antipsychotic medication and cognitive processing in schizophrenia. 2005 , 7, 304-10	33
1755	Comparison of genotype- and haplotype-based approaches for fine-mapping of alcohol dependence using COGA data. 2005 , 6 Suppl 1, S65	6
1754	Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. 2005 , 6, 7	190
1753	Prenatal viral infection in mouse causes differential expression of genes in brains of mouse progeny: a potential animal model for schizophrenia and autism. 2005 , 57, 91-9	128
1752	Modelos fisiopatológicos de la esquizofrenia; de dopamina a glutamato, de glutamato a GABA. 2005 , 43, 314	0
1751	[Dopamine D3 receptors as a novel target for improving the treatment of schizophrenia]. 2005 , 21, 434-42	4
1750	Psychiatric genetics--the new era: genetic research and some clinical implications. 2005 , 73-74, 107-22	33
1749	Pharmacologic implications of neurobiological models of schizophrenia. 2005 , 13, 352-9	5

1748	Predicting drug efficacy for cognitive deficits in schizophrenia. 2005 , 31, 830-53		95
1747	Genes and schizophrenia: beyond schizophrenia: the role of DISC1 in major mental illness. 2006 , 32, 409-16		72
1746	A form of DISC1 enriched in nucleus: altered subcellular distribution in orbitofrontal cortex in psychosis and substance/alcohol abuse. 2005 , 102, 1187-92		92
1745	Importance of animal models in schizophrenia research. 2005 , 39, 550-7		73
1744	Generation and characterization of Rgs4 mutant mice. 2005 , 25, 4221-8		97
1743	Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia. 2005 , 102, 15533-8		271
1742	Neuregulin-1 reverses long-term potentiation at CA1 hippocampal synapses. <i>Journal of Neuroscience</i> , 2005 , 25, 9378-83	6.6	150
1741	Genetics. Two genes link two distinct psychoses. 2005 , 310, 1128-9		47
1740	Modulation of NMDA receptors by pituitary adenylate cyclase activating peptide in CA1 neurons requires G alpha q, protein kinase C, and activation of Src. <i>Journal of Neuroscience</i> , 2005 , 25, 11374-84	6.6	94
1739	Disconnection and cognitive dysmetria in schizophrenia. 2005 , 162, 429-32		71
1738	Schizophrenia: a genetic disorder of the synapse?. 2005 , 330, 158-9		53
1737	The long and winding road of schizophrenia research. 2005 , 14, 179-83		4
1736	Would regional government have been good for your health?. 2005 , 330, 159-60		1
1735	Does the CAPON gene confer susceptibility to schizophrenia?. 2005 , 2, e348		12
1734	Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. 2005 , 77, 918-36		323
1733	Genetics and epigenetics in major psychiatric disorders: dilemmas, achievements, applications, and future scope. 2005 , 5, 149-60		118
1732	Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. 2005 , 102, 15653-8		482
1731	Differential modulation of gene expression in the NMDA postsynaptic density of schizophrenic and control smokers. 2005 , 139, 317-32		78

1730	A functional link between Disrupted-In-Schizophrenia 1 and the eukaryotic translation initiation factor 3. 2005 , 338, 771-6		44
1729	Apoptotic mechanisms in the pathophysiology of schizophrenia. 2005 , 29, 846-58		148
1728	DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. 2005 , 310, 1187-91		542
1727	COMT genetic variation confers risk for psychotic and affective disorders: a case control study. 2005 , 1, 19		97
1726	Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. 2005 , 31, 672-96		409
1725	Cortical glutamatergic markers in schizophrenia. 2005 , 30, 1521-31		55
1724	Decreased hippocampal expression of the susceptibility gene PPP3CC and other calcineurin subunits in schizophrenia. 2005 , 57, 702-10		62
1723	Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study. 2005 , 58, 724-30		132
1722	Comments on risk for schizophrenia. <i>Schizophrenia Research</i> , 2005 , 79, 15-21	3.6	20
1721	NMDA receptor subunit NR1 and postsynaptic protein PSD-95 in hippocampus and orbitofrontal cortex in schizophrenia and mood disorder. <i>Schizophrenia Research</i> , 2005 , 80, 323-30	3.6	134
1720	Functional imaging research in schizophrenia. 2005 , 67, 95-118		13
1719	The primacy of cognition in schizophrenia. 2005 , 60, 229-42		257
1718	Aktuelle Aspekte genetischer Forschung bei Schizophrenie. 2006 , 69-79		
1717	Decreased D-serine levels in CSF of schizophrenia patients. 2006 , 16, S10		1
1716	Differential accumulation of cortisol and corticosterone in the murine brain. 2006 , 16, S10-S11		
1715	Increased water diffusivity in the frontal and temporal cortices of schizophrenic patients. 2006 , 30, 1285-91		60
1714	COMT genotype predicts BOLD signal and noise characteristics in prefrontal circuits. 2006 , 32, 1722-32		119
1713	Is there an association between the COMT gene and P300 endophenotypes?. 2006 , 21, 70-3		37

1712	Lack of association between COMT gene and deficit/nondeficit schizophrenia. 2006 , 2, 42	19
1711	Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia. 2006 , 18, 119-31	65
1710	Pharmacogenomics and antidepressant drugs. 2006 , 38, 82-94	86
1709	Endophenotypes in the genetic analyses of mental disorders. 2006 , 2, 267-90	312
1708	A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities. 2006 , 59, 721-9	199
1707	Synaptic plasticity and dysconnection in schizophrenia. 2006 , 59, 929-39	647
1706	Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. 2006 , 60, 132-40	373
1705	Mechanisms of action of medicines for schizophrenia and bipolar illness: status and limitations. 2006 , 59, 1039-45	8
1704	Genetic mouse models of schizophrenia: from hypothesis-based to susceptibility gene-based models. 2006 , 59, 1180-8	97
1703	Subchronic phencyclidine treatment decreases the number of dendritic spine synapses in the rat prefrontal cortex. 2006 , 60, 639-44	54
1702	Prefrontal-hippocampal coupling during memory processing is modulated by COMT val158met genotype. 2006 , 60, 1250-8	146
1701	Making the case for a candidate vulnerability gene in schizophrenia: Convergent evidence for regulator of G-protein signaling 4 (RGS4). 2006 , 60, 534-7	82
1700	Functional magnetic resonance imaging study of cognitive control in the healthy relatives of schizophrenia patients. 2006 , 60, 1241-9	38
1699	Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder?. 2006 , 59, 1198-207	271
1698	Schizophrenia genes - famine to feast. 2006 , 60, 81-3	64
1697	Critical factors in gene expression in postmortem human brain: Focus on studies in schizophrenia. 2006 , 60, 650-8	204
1696	Glutamate transport inhibitors as targets for treating psychosis. 2006 , 3, 533-537	4
1695	Meta-analysis of association between ApoE epsilon4 allele and schizophrenia. <i>Schizophrenia Research</i> , 2006 , 84, 228-35	3.6 54

1694	Gene regulation by hypoxia and the neurodevelopmental origin of schizophrenia. <i>Schizophrenia Research</i> , 2006 , 84, 253-71	3.6	100
1693	Schizophrenia susceptibility genes converge on interlinked pathways related to glutamatergic transmission and long-term potentiation, oxidative stress and oligodendrocyte viability. <i>Schizophrenia Research</i> , 2006 , 86, 1-14	3.6	101
1692	COMT genotype and manic symptoms in schizophrenia. <i>Schizophrenia Research</i> , 2006 , 87, 28-31	3.6	19
1691	A volumetric MRI and magnetization transfer imaging follow-up study of patients with first-episode schizophrenia. <i>Schizophrenia Research</i> , 2006 , 87, 100-8	3.6	36
1690	Genetics of antipsychotic treatment emergent weight gain in schizophrenia. 2006 , 7, 863-87		127
1689	Immunological stress at the maternal-foetal interface: a link between neurodevelopment and adult psychopathology. 2006 , 20, 378-88		233
1688	Behavioral and biochemical characterization of a mutant mouse strain lacking D-amino acid oxidase activity and its implications for schizophrenia. 2006 , 32, 324-34		90
1687	Clozapine and haloperidol differentially regulate dendritic spine formation and synaptogenesis in rat hippocampal neurons. 2006 , 32, 356-65		68
1686	Chromosomal fragility, structural rearrangements and mobile element activity may reflect dynamic epigenetic mechanisms of importance in neurobehavioural genetics. 2006 , 66, 276-85		11
1685	Disrupted in schizophrenia 1: building brains and memories. 2006 , 12, 255-61		43
1684	Repeated injection of MK801: an animal model of schizophrenia?. 2006 , 48, 541-6		56
1683	Recent progress in animal modeling of immune inflammatory processes in schizophrenia: implication of specific cytokines. 2006 , 56, 2-13		145
1682	Maternal infection and white matter toxicity. 2006 , 27, 658-70		9
1681	Creativity and evolution. 2006 , 1296, 95-105		1
1680	Nicotinic modulation of human auditory sensory memory: Evidence from mismatch negativity potentials. 2006 , 59, 49-58		86
1679	Impact of the DISC1 Ser704Cys polymorphism on risk for major depression, brain morphology and ERK signaling. 2006 , 15, 3024-33		216
1678	Schizophrenia: a unique translational opportunity in behavioral neuroendocrinology. 2006 , 50, 602-11		22
1677	Genetically predisposed offspring with schizotypal features: an ultra high-risk group for schizophrenia?. 2006 , 30, 230-8		70

1676	Neurobiology of schizophrenia. 2006 , 52, 139-53	526
1675	The adhesion molecule CHL1 regulates uncoating of clathrin-coated synaptic vesicles. 2006 , 52, 1011-25	71
1674	Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia. 2006 , 137, 807-19	140
1673	Peri-pubertal maturation after developmental disturbance: a model for psychosis onset in the rat. 2006 , 143, 395-405	105
1672	The schizophrenic faces of PICK1. 2006 , 27, 574-9	37
1671	Neuregulin 1 Transcripts Are Differentially Expressed in Schizophrenia and Regulated by 5? SNPs Associated With the Disease. 2006 , 4, 350-359	3
1670	Mutations, developmental instability, and the Red Queen. 2006 , 29, 412-413	11
1669	The social environment compresses the diversity of genetic aberrations into the uniformity of schizophrenia manifestations. 2006 , 29, 406-408	1
1668	Evolutionary psychiatry is dead ¶Long liveth evolutionary psychopathology. 2006 , 29, 408-408	
1667	High mental disorder rates are based on invalid measures: Questions about the claimed ubiquity of mutation-induced dysfunction. 2006 , 29, 424-426	2
1666	The evolution of evolutionary epidemiology: A defense of pluralistic epigenetic modes of transmission. 2006 , 29, 427-429	2
1665	Mental disorders are not a homogeneous construct. 2006 , 29, 418-419	3
1664	Mental disorders, evolution, and inclusive fitness. 2006 , 29, 419-420	35
1663	Praise for a critical perspective. 2006 , 29, 405-405	2
1662	Genes for susceptibility to mental disorder are not mental disorder: Clarifying the target of evolutionary analysis and the role of the environment. 2006 , 29, 405-406	48
1661	Finland's Galapagos: Founder effect, drift, and isolation in the inheritance of susceptibility alleles. 2006 , 29, 409-410	3
1660	Multiple timescales of evolution. 2006 , 29, 426-427	1
1659	Heritable mental disorders: You can't choose your relatives, but it is they who may really count. 2006 , 29, 414-415	

1658	Bipolar disorder evolved as an adaptation to severe climate. 2006 , 29, 421-422	2
1657	The romance of balancing selection versus the sober alternatives: Let the data rule. 2006 , 29, 417-418	4
1656	The evolutionary genetics of personality: Does mutation load signal relationship load?. 2006 , 29, 409-409	15
1655	Reconciling the mutation-selection balance model with the schizotypy-creativity connection. 2006 , 29, 418-418	15
1654	An evolutionary framework for mental disorders: Integrating adaptationist and evolutionary genetic models. 2006 , 29, 429-441	7
1653	Autism: Common, heritable, but not harmful. 2006 , 29, 413-414	41
1652	Adaptationism and medicalization: The Scylla and Charybdis of Darwinian psychiatry. 2006 , 29, 422-423	3
1651	Why the adaptationist perspective must be considered: The example of morbid jealousy. 2006 , 29, 411-412	28
1650	Population genetical musings on suicidal behavior as a common, harmful, heritable mental disorder. 2006 , 29, 423-424	20
1649	Are common, harmful, heritable mental disorders common relative to other such non-mental disorders, and does their frequency require a special explanation?. 2006 , 29, 415-416	
1648	The natural selection of psychosis. 2006 , 29, 410-411	4
1647	Behavioural ecology as a basic science for evolutionary psychiatry. 2006 , 29, 420-421	1
1646	. 2006 ,	8
1645	Imaging Genetics and Psychiatry. 2006 , 4, 327-338	5
1644	Reinvestigation of the dysbindin subunit of BLOC-1 (biogenesis of lysosome-related organelles complex-1) as a dystrobrevin-binding protein. 2006 , 395, 587-98	63
1643	A microcircuit model of prefrontal functions: ying and yang of reverberatory neurodynamics in cognition. 92-127	9
1642	Association of G72/G30 polymorphisms with early-onset and male schizophrenia. 2006 , 17, 1899-902	23
1641	Defining a DSM Infrastructure. 2006 , 163, 1873-4	1

1640	Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. 2006 , 21 Suppl 2, S11-5		76
1639	Variation at the DAOA/G30 locus influences susceptibility to major mood episodes but not psychosis in schizophrenia and bipolar disorder. 2006 , 63, 366-73		124
1638	Behavioral and Neurological Phenotyping in the Mouse. 135-175		3
1637	[Pharmacological action of antipsychotic drugs]. 2006 , 128, 173-6		1
1636	Postictal psychosis: presymptomatic risk factors and the need for further investigation of genetics and pharmacotherapy. 2006 , 5, 9		10
1635	Psychosis pathways converge via D2high dopamine receptors. 2006 , 60, 319-46		252
1634	Retinoic acid delineates the topography of neuronal plasticity in postnatal cerebral cortex. 2006 , 24, 329-40		30
1633	Susceptibility genes for schizophrenia. 2006 , 60, S4-S10		8
1632	Up-regulation of NMDA receptor subunit and post-synaptic density protein expression in the thalamus of elderly patients with schizophrenia. 2006 , 98, 1114-25		51
1631	Sustained brain-derived neurotrophic factor up-regulation and sensorimotor gating abnormality induced by postnatal exposure to phencyclidine: comparison with adult treatment. 2006 , 99, 770-80		44
1630	Gene-environment interplay and psychopathology: multiple varieties but real effects. 2006 , 47, 226-61		776
1629	Effects of repeated maternal separation on prepulse inhibition of startle across inbred mouse strains. <i>Genes, Brain and Behavior</i> , 2006 , 5, 346-54	3.6	68
1628	Psychiatric endophenotypes and the development of valid animal models. <i>Genes, Brain and Behavior</i> , 2006 , 5, 113-9	3.6	392
1627	Brainwaves. 2006 , 18, 234-5		2
1626	Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. 2006 , 12, 824-8		479
1625	Pathophysiologically based treatment interventions in schizophrenia. 2006 , 12, 1016-22		280
1624	Intermediate phenotypes and genetic mechanisms of psychiatric disorders. 2006 , 7, 818-27		1011
1623	Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. <i>Molecular Psychiatry</i> , 2006 , 11, 143-9	15.1	187

1622	A novel protein isoform of catechol O-methyltransferase (COMT): brain expression analysis in schizophrenia and bipolar disorder and effect of Val158Met genotype. <i>Molecular Psychiatry</i> , 2006 , 11, 116-7	15.1	31
1621	Polymorphism in the 5'-promoter region of serine racemase gene in schizophrenia. <i>Molecular Psychiatry</i> , 2006 , 11, 325-6	15.1	43
1620	Association of the NRG1 gene and schizophrenia: a meta-analysis. <i>Molecular Psychiatry</i> , 2006 , 11, 539-46	15.1	185
1619	Subtyping schizophrenia: implications for genetic research. <i>Molecular Psychiatry</i> , 2006 , 11, 815-36	15.1	191
1618	Impact of complex genetic variation in COMT on human brain function. <i>Molecular Psychiatry</i> , 2006 , 11, 867-77, 797	15.1	279
1617	Six degrees of separation: on the prior probability that schizophrenia susceptibility genes converge on synapses, glutamate and NMDA receptors. <i>Molecular Psychiatry</i> , 2006 , 11, 981-3	15.1	27
1616	Two isoforms of GABA(A) receptor beta2 subunit with different electrophysiological properties: Differential expression and genotypical correlations in schizophrenia. <i>Molecular Psychiatry</i> , 2006 , 11, 1092-105	15.1	42
1615	Neuropathological, neurogenetic and neuroimaging evidence for white matter pathology in schizophrenia. <i>Neuroscience and Biobehavioral Reviews</i> , 2006 , 30, 918-48	9	119
1614	Catechol-O-methyltransferase polymorphisms and some implications for cognitive therapeutics. 2006 , 3, 97-105		39
1613	Imaging genomics and response to treatment with antipsychotics in schizophrenia. 2006 , 3, 117-30		24
1612	Prefrontal electrophysiologic "noise" and catechol-O-methyltransferase genotype in schizophrenia. 2006 , 60, 578-84		62
1611	Investigating gene-to-behavior pathways in psychiatric disorders: the use of a comprehensive behavioral test battery on genetically engineered mice. 2006 , 1086, 144-59		36
1610	Imaging phenotypes and genotypes in schizophrenia. 2006 , 4, 21-49		26
1609	Lissencephaly 1 linking to multiple diseases: mental retardation, neurodegeneration, schizophrenia, male sterility, and more. 2006 , 8, 547-65		31
1608	Glutamate and schizophrenia: beyond the dopamine hypothesis. 2006 , 26, 365-84		658
1607	Effect of antipsychotic drugs on DISC1 and dysbindin expression in mouse frontal cortex and hippocampus. 2006 , 113, 1337-46		45
1606	Impaired working speed and executive functions as frontal lobe dysfunctions in young first-degree relatives of schizophrenic patients. 2006 , 15, 400-8		23
1605	[Advances in neurobiological understanding of schizophrenia. Perspectives for new therapeutic concepts]. 2006 , 77 Suppl 2, S65-74; quiz S75-6		4

1604	Prenatal and postnatal maternal contributions in the infection model of schizophrenia. 2006 , 173, 243-57	110
1603	How antipsychotics work-from receptors to reality. 2006 , 3, 10-21	68
1602	New directions in psychiatric therapeutics. 2006 , 3, 1-2	2
1601	An overview of the genetics of substance use disorders. 2006 , 8, 133-43	28
1600	Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. 2006 , 10, 131-48	183
1599	Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms. 2006 , 10, 221-33	64
1598	Glutamatergic mechanisms in schizophrenia: Current concepts. 2006 , 4, 27-34	2
1597	Ketamine enhances the expression of serine racemase and D-amino acid oxidase mRNAs in rat brain. 2006 , 540, 82-6	9
1596	Postnatal effect of embryonic neurogenesis disturbance on reelin level in organotypic cultures of rat hippocampus. 2006 , 1097, 43-51	12
1595	Thyroid hormones and retinoids: a possible link between genes and environment in schizophrenia. 2006 , 51, 61-71	47
1594	Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. 2006 , 52, 293-304	308
1593	Glutathione deficit during development induces anomalies in the rat anterior cingulate GABAergic neurons: Relevance to schizophrenia. 2006 , 22, 624-37	79
1592	Reduced auditory M100 asymmetry in schizophrenia and dyslexia: applying a developmental instability approach to assess atypical brain asymmetry. 2006 , 44, 289-99	53
1591	Social brain dysfunctions in schizophrenia: a review of neuroimaging studies. 2006 , 148, 75-92	233
1590	Neuropathology of mood disorders. 2006 , 5, 180-182	1
1589	Synaptophysin protein and mRNA expression in the human hippocampal formation from birth to old age. 2006 , 16, 645-54	32
1588	Analysis of polymorphisms in AT-rich domains of neuregulin 1 gene in schizophrenia. 2006 , 141B, 102-9	32
1587	Association study of a functional promoter polymorphism in the XBP1 gene and schizophrenia. 2006 , 141B, 71-5	13

1586	A family-based and case-control association study of SOX10 in schizophrenia. 2006 , 141B, 477-81	14
1585	PhenoChipping of psychotic disorders: a novel approach for deconstructing and quantitating psychiatric phenotypes. 2006 , 141B, 653-62	37
1584	Early visual sensory deficits as endophenotypes for schizophrenia: high-density electrical mapping in clinically unaffected first-degree relatives. 2006 , 63, 1180-8	119
1583	Retinoic acid signaling in the functioning brain. 2006 , 2006, pe10	36
1582	Long homopurine*homopyrimidine sequences are characteristic of genes expressed in brain and the pseudoautosomal region. 2006 , 34, 2663-75	52
1581	Reflections on the relationship between psychiatric genetics and psychiatric nosology. 2006 , 163, 1138-46	106
1580	Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers. 2006 , 63, 731-40	210
1579	Toward a prefrontal microcircuit model for cognitive deficits in schizophrenia. 2006 , 39 Suppl 1, S80-7	31
1578	Animal Models of Schizophrenia. 2006 , 337-402	2
1577	Chromosome 22 deletion syndrome and schizophrenia. 2006 , 73, 1-27	11
1576	Implications for the practice of psychiatry. 2006 , 158, 275-93	1
1575	DTNBP1 (dysbindin) gene variants modulate prefrontal brain function in healthy individuals. 2006 , 31, 2002-10	76
1574	Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics. 2006 , 31, 1249-63	137
1573	Schizophrenia: do the genetics and neurobiology of neuregulin provide a pathogenesis model?. 2006 , 14, 64-77	8
1572	Genetic counseling in psychiatry. 2006 , 14, 109-21	44
1571	The Consortium on the Genetics of Schizophrenia: neurocognitive endophenotypes. 2007 , 33, 49-68	286
1570	The association between the Val158Met polymorphism of the catechol-O-methyl transferase gene and morphological abnormalities of the brain in chronic schizophrenia. 2006 , 129, 399-410	134
1569	Neuroimaging-genetic paradigms: a new approach to investigate the pathophysiology and treatment of cognitive deficits in schizophrenia. 2006 , 14, 78-91	42

1568	Resolving the paradox of common, harmful, heritable mental disorders: which evolutionary genetic models work best?. 2006 , 29, 385-404; discussion 405-52	410
1567	p90 ribosomal S6 kinase 2 exerts a tonic brake on G protein-coupled receptor signaling. 2006 , 103, 4717-22	43
1566	Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. 2007 , 33, 69-94	436
1565	Expression of DISC1 binding partners is reduced in schizophrenia and associated with DISC1 SNPs. 2006 , 15, 1245-58	140
1564	Cellular basis of reduced cortical reelin expression in schizophrenia. 2006 , 163, 540-2	86
1563	Stress, the hippocampus and the hypothalamic-pituitary-adrenal axis: implications for the development of psychotic disorders. 2006 , 40, 725-41	151
1562	Analysis of synapsin III-196 promoter mutation in schizophrenia and bipolar disorder. 2006 , 53, 57-62	20
1561	Dysbindin-1 is a synaptic and microtubular protein that binds brain snapin. 2006 , 15, 3041-54	134
1560	RGS3 and RGS4 differentially associate with G protein-coupled receptor-Kir3 channel signaling complexes revealing two modes of RGS modulation. Precoupling and collision coupling. 2006 , 281, 34549-60	44
1559	BLOC-1 interacts with BLOC-2 and the AP-3 complex to facilitate protein trafficking on endosomes. 2006 , 17, 4027-38	170
1558	Genetic variation in DTNBP1 influences general cognitive ability. 2006 , 15, 1563-8	146
1557	Gene expression profiling in schizophrenia and related mental disorders. 2006 , 12, 349-61	71
1556	A public health genetic approach for schizophrenia. 2006 , 15, 185-93	6
1555	Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5' SNPs associated with the disease. 2006 , 103, 6747-52	345
1554	Cholinergic circuits and signaling in the pathophysiology of schizophrenia. 2007 , 78, 193-223	32
1553	Epistasis between catechol-O-methyltransferase and type II metabotropic glutamate receptor 3 genes on working memory brain function. 2007 , 104, 12536-41	158
1552	RGS4 modulates serotonin signaling in prefrontal cortex and links to serotonin dysfunction in a rat model of schizophrenia. 2007 , 71, 1030-9	57
1551	Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. 2007 , 104, 16621-6	247

1550	DISC1 regulates neurotrophin-induced axon elongation via interaction with Grb2. <i>Journal of Neuroscience</i> , 2007 , 27, 4-14	6.6	90
1549	Allelic variation in RGS4 impacts functional and structural connectivity in the human brain. <i>Journal of Neuroscience</i> , 2007 , 27, 1584-93	6.6	91
1548	NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. <i>Journal of Neuroscience</i> , 2007 , 27, 11496-500	6.6	861
1547	Application of electroencephalography to the study of cognitive and brain functions in schizophrenia. 2007 , 33, 955-70		72
1546	Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia. 2007 , 17 Suppl 1, i171-81		195
1545	Neurogenetics of Psychiatric Disorders. 2007 ,		
1544	The role of caspase-3 activation in phencyclidine-induced neuronal death in postnatal rats. 2007 , 32, 1178-94		43
1543	Cannabis Use, First-Episode Psychosis, and Schizotypy: A Summary and Synthesis of Recent Literature. 2007 , 3, 161-171		16
1542	Dissecting cause and effect in the pathogenesis of psychiatric disorders: genes, environment and behaviour. 2007 , 7, 470-8		17
1541	Volume, neuron density and total neuron number in five subcortical regions in schizophrenia. 2007 , 130, 678-92		141
1540	Families with the risk allele of DISC1 reveal a link between schizophrenia and another component of the same molecular pathway, NDE1. 2007 , 16, 453-62		70
1539	Structural cerebral variations as useful endophenotypes in schizophrenia: do they help construct "extended endophenotypes"?. 2008 , 34, 774-90		74
1538	Frontal release signs and cognition in people with schizophrenia, their siblings and healthy controls. 2007 , 191, 120-5		21
1537	Schizophrenia: a common disease caused by multiple rare alleles. 2007 , 190, 194-9		257
1536	Genetic variations of the NR3A subunit of the NMDA receptor modulate prefrontal cerebral activity in humans. 2007 , 19, 59-68		32
1535	Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment. 2007 , 7, 418-26		64
1534	On the Effects of Partial Agonists of Dopamine Receptors for the Treatment of Schizophrenia. 2007 , 40, S34-S39		5
1533	Smoking, Genetics and Schizophrenia: Evidence for Self Medication. 2007 , 3, 43-59		99

1532	Pathophysiology of early onset schizophrenia. 2007 , 19, 315-24		47
1531	Schizophrenia seen as a deficit in the modulation of cortical minicolumns by monoaminergic systems. 2007 , 19, 361-72		14
1530	Dopamine genes and schizophrenia: case closed or evidence pending?. 2007 , 33, 1071-81		33
1529	Specific developmental disruption of disrupted-in-schizophrenia-1 function results in schizophrenia-related phenotypes in mice. 2007 , 104, 18280-5		188
1528	Neuregulin1 (NRG1) signaling through Fyn modulates NMDA receptor phosphorylation: differential synaptic function in NRG1+/- knock-outs compared with wild-type mice. <i>Journal of Neuroscience</i> , 2007 , 27, 4519-29	6.6	153
1527	DISC1 regulates the transport of the NUDEL/LIS1/14-3-3epsilon complex through kinesin-1. <i>Journal of Neuroscience</i> , 2007 , 27, 15-26	6.6	194
1526	Insights from spatially mapped gene expression in the mouse brain. 2007 , 16 Spec No. 2, R209-19		37
1525	Comparing genes and phenomenology in the major psychoses: schizophrenia and bipolar 1 disorder. 2008 , 34, 734-42		42
1524	Molecular cloning of a brain-specific, developmentally regulated neuregulin 1 (NRG1) isoform and identification of a functional promoter variant associated with schizophrenia. 2007 , 282, 24343-51		108
1523	Genetic evidence implicating DARPP-32 in human frontostriatal structure, function, and cognition. 2007 , 117, 672-82		177
1522	Dopamine and Glutamate Hypotheses of Schizophrenia. 2007 ,		
1521	Structural and functional magnetic resonance imaging in psychiatric disorders. 2007 , 52, 158-66		27
1520	Neurobiology and Functional Progression in Schizophrenia. 2007 , 12, 9-12		
1519	Innovative clinical assessment technologies: challenges and opportunities in neuroimaging. 2007 , 19, 58-73		27
1518	Neuregulin-1 signaling in schizophrenia. 2007 , 2, 477-480		
1517	Neurocognitive endophenotypes in a multiplex multigenerational family study of schizophrenia. 2007 , 164, 813-9		217
1516	Nur77 and retinoid X receptors: crucial factors in dopamine-related neuroadaptation. 2007 , 30, 22-30		75
1515	Stress during development: Impact on neuroplasticity and relevance to psychopathology. 2007 , 81, 197-217		169

1514	Possible antipsychotic effects of minocycline in patients with schizophrenia. 2007 , 31, 304-7	83
1513	Association study of polymorphisms in the mitochondrial aspartate/glutamate carrier SLC25A12 (aralar) gene with schizophrenia. 2007 , 31, 1510-3	6
1512	The neuregulin-1 receptor erbB4 controls glutamatergic synapse maturation and plasticity. 2007 , 54, 583-97	285
1511	Behavioral phenotypes of Disc1 missense mutations in mice. 2007 , 54, 387-402	445
1510	Phenotypic characterization of spatial cognition and social behavior in mice with 'knockout' of the schizophrenia risk gene neuregulin 1. 2007 , 147, 18-27	193
1509	Developmental profile of neuregulin receptor ErbB4 in postnatal rat cerebral cortex and hippocampus. 2007 , 148, 126-39	20
1508	Homer splice variants modulation within cortico-subcortical regions by dopamine D2 antagonists, a partial agonist, and an indirect agonist: implication for glutamatergic postsynaptic density in antipsychotics action. 2007 , 150, 144-58	40
1507	G protein-coupled receptors in major psychiatric disorders. 2007 , 1768, 976-93	81
1506	Exploratory and habituation phenotype of heterozygous and homozygous COMT knockout mice. 2007 , 183, 236-9	43
1505	Disrupted-In-Schizophrenia 1 regulates integration of newly generated neurons in the adult brain. 2007 , 130, 1146-58	515
1504	Role of phosphodiesterases in neurological and psychiatric disease. 2007 , 7, 86-92	59
1503	Regulation of ErbB-4 endocytosis by neuregulin in GABAergic hippocampal interneurons. 2007 , 73, 210-9	25
1502	How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia?. 2007 , 50, 291-301	67
1501	Oxygen restriction of neonate rats elevates neuregulin-1alpha isoform levels: possible relationship to schizophrenia. 2007 , 51, 447-50	14
1500	Molecular mechanism of schizophrenia with reference to disrupted-in-schizophrenia 1 (DISC1). 2007 , 51, 165-72	28
1499	Impact of brain-behavior phenotyping of genetically-engineered mice on research of neuropsychiatric disorders. 2007 , 58, 124-32	68
1498	Abnormal brain connectivity in first-episode psychosis: a diffusion MRI tractography study of the corpus callosum. 2007 , 35, 458-66	101
1497	Does Schizophrenia Exist?. 2007 , 63, 104-6	

1496	Overview of animal models of schizophrenia. 2007 , Chapter 9, Unit 9.24		18
1495	Functional genomics and schizophrenia: endophenotypes and mutant models. 2007 , 30, 365-99		38
1494	Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. 2007 , 78, 69-108		400
1493	microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. 2007 , 8, R27		420
1492	Molecular mechanisms of schizophrenia. 2007 , 20, 687-702		214
1491	Monoaminergic Modulation of Cortical Excitability. 2007 ,		2
1490	Psychotherapy and mental health teams. 2007 , 19, 63-80		48
1489	Comparative genome hybridization suggests a role for NRXN1 and APBA2 in schizophrenia. 2008 , 17, 458-65		315
1488	Potential genetic variants in schizophrenia: a Bayesian analysis. 2007 , 8, 12-22		23
1487	Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia. 2007 , 16, 129-41		252
1486	Glutamate and dopamine dysregulation in schizophrenia—a synthesis and selective review. 2007 , 21, 440-52		283
1485	The neurodevelopmental impact of prenatal infections at different times of pregnancy: the earlier the worse?. 2007 , 13, 241-56		189
1484	Successful multi-site measurement of antisaccade performance deficits in schizophrenia. <i>Schizophrenia Research</i> , 2007 , 89, 320-9	3.6	65
1483	The child and adolescent first-episode psychosis study (CAFEPS): design and baseline results. <i>Schizophrenia Research</i> , 2007 , 91, 226-37	3.6	74
1482	Effects of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism on executive function in schizophrenia. <i>Schizophrenia Research</i> , 2007 , 92, 181-8	3.6	52
1481	Association study between the dystrobrevin binding protein 1 gene (DTNBP1) and schizophrenia: a meta-analysis. <i>Schizophrenia Research</i> , 2007 , 96, 112-8	3.6	30
1480	A reduced number of cortical neurons show increased Calbindin protein levels in chronic schizophrenia. <i>Schizophrenia Research</i> , 2007 , 96, 246-56	3.6	23
1479	Molecular analysis of a chromosome 4 inversion segregating in a large schizophrenia kindred from Hong Kong. <i>Schizophrenia Research</i> , 2007 , 95, 228-35	3.6	

1478	MRI brain volume abnormalities in young, nonpsychotic relatives of schizophrenia probands are associated with subsequent prodromal symptoms. <i>Schizophrenia Research</i> , 2007 , 96, 1-13	3.6	34
1477	[COMT Val158Met polymorphism and schizophrenia in a series of Spanish patients]. 2007 , 128, 41-4		1
1476	Association between the DTNBP1 gene and intelligence: a case-control study in young patients with schizophrenia and related disorders and unaffected siblings. 2007 , 3, 19		53
1475	Interactions among genes in the ErbB-Neuregulin signalling network are associated with increased susceptibility to schizophrenia. 2007 , 3, 31		96
1474	Chronic nicotine doses down-regulate PDE4 isoforms that are targets of antidepressants in adolescent female rats. 2007 , 61, 56-64		16
1473	GABRB2 association with schizophrenia: commonalities and differences between ethnic groups and clinical subtypes. 2007 , 61, 653-60		41
1472	Relationship of catechol-O-methyltransferase variants to brain structure and function in a population at high risk of psychosis. 2007 , 61, 1127-34		102
1471	Reduction of corticostriatal glutamatergic fibers in basic fibroblast growth factor deficient mice is associated with hyperactivity and enhanced dopaminergic transmission. 2007 , 62, 235-42		19
1470	Post-pubertal disruption of medial prefrontal cortical dopamine-glutamate interactions in a developmental animal model of schizophrenia. 2007 , 62, 730-8		134
1469	Increased prefrontal gyrification in a large high-risk cohort characterizes those who develop schizophrenia and reflects abnormal prefrontal development. 2007 , 62, 722-9		97
1468	Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex. 2007 , 62, 739-46		95
1467	Altered dimerization of metabotropic glutamate receptor 3 in schizophrenia. 2007 , 62, 747-55		70
1466	Schizophrenia susceptibility genes and neurodevelopment. 2007 , 61, 1119-20		26
1465	From animal models to model animals. 2007 , 62, 1337-9		78
1464	Neuroprotection and enhancement of neurite outgrowth with small molecular weight compounds from screens of chemical libraries. 2007 , 77, 247-89		8
1463	White matter and cognitive function in schizophrenia. 2007 , 10, 513-36		62
1462	Schizophrenia: new pathological insights and therapies. 2007 , 58, 49-61		95
1461	Further evidence for altered myelin biosynthesis and glutamatergic dysfunction in schizophrenia. 2007 , 10, 557-63		78

1460	Positive selection within the Schizophrenia-associated GABA(A) receptor beta(2) gene. 2007 , 2, e462	33
1459	Sp1 expression is disrupted in schizophrenia; a possible mechanism for the abnormal expression of mitochondrial complex I genes, NDUFV1 and NDUFV2. 2007 , 2, e817	64
1458	Pharmacotherapy of Schizophrenia. 2007 ,	1
1457	Troubles psychiatriques, génétique ou environnement? : vers la fin du débat?. 2007 , 83, 117	1
1456	Molecular Genetics of Schizophrenia. 2007 ,	
1455	Neuroimaging and other neurobiological indices in schizophrenia: relationship to measurement of functional outcome. 2007 , 50, s52-7	15
1454	Paliperidone: the evidence of its therapeutic value in schizophrenia. <i>Core Evidence</i> , 2007 ,	4-9
1453	Developmental aspects of schizophrenia and related disorders: possible implications for treatment strategies. 2007 , 13, 384-391	5
1452	Analysis of TBX1 variation in patients with psychotic and affective disorders. 2007 , 13, 407-14	11
1451	Phenomenology and Clinical Science of Schizophrenia. 2007 ,	
1450	Schizophrenia. 15-38	
1449	Positive association of schizophrenia to JARID2 gene. 2007 , 144B, 45-51	28
1448	Association between the 5q31.1 gene neurogenin1 and schizophrenia. 2007 , 144B, 207-14	13
1447	Synaptotagmin XI as a candidate gene for susceptibility to schizophrenia. 2007 , 144B, 332-40	26
1446	Towards understanding the schizophrenia code: an expanded convergent functional genomics approach. 2007 , 144B, 129-58	108
1445	Chronic haloperidol treatment results in a decrease in the expression of myelin/oligodendrocyte-related genes in the mouse brain. 2007 , 85, 757-65	51
1444	Expression pattern of STOP lacZ reporter gene in adult and developing mouse brain. 2007 , 85, 1515-27	16
1443	Susceptibility genes for schizophrenia: characterisation of mutant mouse models at the level of phenotypic behaviour. <i>Neuroscience and Biobehavioral Reviews</i> , 2007 , 31, 60-78	9 131

1442	Abnormal oscillatory brain dynamics in schizophrenia: a sign of deviant communication in neural network?. 2007 , 7, 44		23
1441	An organelle proteomic method to study neurotransmission-related proteins, applied to a neurodevelopmental model of schizophrenia. 2007 , 7, 3569-79		28
1440	Schizophrenia drug says goodbye to dopamine. 2007 , 13, 1018-9		37
1439	Drug development for CNS disorders: strategies for balancing risk and reducing attrition. 2007 , 6, 521-32		238
1438	Neuregulin 1 (8p12) and childhood-onset schizophrenia: susceptibility haplotypes for diagnosis and brain developmental trajectories. <i>Molecular Psychiatry</i> , 2007 , 12, 195-205	15.1	97
1437	A novel DISC1-interacting partner DISC1-Binding Zinc-finger protein: implication in the modulation of DISC1-dependent neurite outgrowth. <i>Molecular Psychiatry</i> , 2007 , 12, 398-407	15.1	76
1436	New genes associated with schizophrenia in neurite formation: a review of cell culture experiments. <i>Molecular Psychiatry</i> , 2007 , 12, 620-9	15.1	55
1435	Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and gene expression. <i>Molecular Psychiatry</i> , 2007 , 12, 854-69	15.1	218
1434	Neuregulin1-induced cell migration is impaired in schizophrenia: association with neuregulin1 and catechol-o-methyltransferase gene polymorphisms. <i>Molecular Psychiatry</i> , 2007 , 12, 946-57	15.1	62
1433	Significant correlation in linkage signals from genome-wide scans of schizophrenia and schizotypy. <i>Molecular Psychiatry</i> , 2007 , 12, 958-65	15.1	70
1432	fMRI evidence for functional epistasis between COMT and RGS4. <i>Molecular Psychiatry</i> , 2007 , 12, 893-5, 885	15.1	38
1431	Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. <i>Molecular Psychiatry</i> , 2007 , 12, 707-47	15.1	288
1430	LRRTM1 on chromosome 2p12 is a maternally suppressed gene that is associated paternally with handedness and schizophrenia. <i>Molecular Psychiatry</i> , 2007 , 12, 1129-39, 1057	15.1	260
1429	The pipeline and future of drug development in schizophrenia. <i>Molecular Psychiatry</i> , 2007 , 12, 904-22	15.1	153
1428	d-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia. 2007 , 26, 1657-69		143
1427	Netrin-1 receptor-deficient mice show enhanced mesocortical dopamine transmission and blunted behavioural responses to amphetamine. 2007 , 26, 3215-28		52
1426	Neuropathology of schizophrenia: a mini review. 2007 , 27, 604-8		78
1425	Neurodevelopmental involvement in schizophrenia: the olfactory epithelium as an alternative model for research. 2007 , 102, 587-94		34

1424	Is the modulation of retinoid and retinoid-associated signaling a future therapeutic strategy in neurological trauma and neurodegeneration?. 2008 , 104, 584-95		28
1423	Developmental mechanisms and experimental models to understand forebrain malformative diseases. <i>Genes, Brain and Behavior</i> , 2007 , 6 Suppl 1, 45-52	3.6	8
1422	Genetic variation in COMT and PRODH is associated with brain anatomy in patients with schizophrenia. <i>Genes, Brain and Behavior</i> , 2008 , 7, 61-9	3.6	35
1421	Brain phylogeny, ontogeny and dysfunction: integrating evolutionary, developmental and clinical perspectives in cognitive neuroscience. 2007 , 19, 149-58		6
1420	Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. 2007 , 116, 41-9		267
1419	PADB: published association database. 2007 , 8, 348		3
1418	Differential gene expression in the hippocampus of the Df1/+ mice: a model for 22q11.2 deletion syndrome and schizophrenia. 2007 , 1139, 48-59		31
1417	Role of DISC1 in neural development and schizophrenia. 2007 , 17, 95-102		103
1416	The impact of pharmacogenetics on the development and use of antipsychotic drugs. 2007 , 12, 953-9		32
1415	PDE inhibitors in psychiatry--future options for dementia, depression and schizophrenia?. 2007 , 12, 870-8		80
1414	Effects of MK-801 on the expression of serine racemase and d-amino acid oxidase mRNAs and on the D-serine levels in rat brain. 2007 , 555, 17-22		16
1413	Strain differences in the disruption of prepulse inhibition of startle after systemic and intra-accumbens amphetamine administration. 2007 , 87, 1-10		27
1412	Interaction between serotonin transporter gene, catechol-O-methyltransferase gene and stressful life events in mood disorders. 2007 , 10, 437-47		94
1411	Neonatal dopamine depletion induces changes in morphogenesis and gene expression in the developing cortex. 2007 , 11, 107-30		26
1410	Are some genetic risk factors common to schizophrenia, bipolar disorder and depression? Evidence from DISC1, GRIK4 and NRG1. 2007 , 11, 73-83		87
1409	Comorbidity of substance abuse with other psychiatric disorders. 2007 , 12, 17-27		19
1408	Genetic variation and shared biological susceptibility underlying comorbidity in neuropsychiatry. 2007 , 12, 29-42		14
1407	Association analyses of the DAOA/G30 and D-amino-acid oxidase genes in schizophrenia: further evidence for a role in schizophrenia. 2007 , 9, 169-77		45

1406	Alterations in prefrontal glutamatergic and noradrenergic systems following MK-801 administration in rats prenatally exposed to methylazoxymethanol at gestational day 17. 2007 , 192, 373-83	15
1405	Genetics and diagnostic refinement. 2007 , 37, 535-45	4
1404	Evidence for statistical epistasis between catechol-O-methyltransferase (COMT) and polymorphisms in RGS4, G72 (DAOA), GRM3, and DISC1: influence on risk of schizophrenia. 2007 , 120, 889-906	119
1403	A neural plasticity perspective on the schizophrenic condition. 2007 , 16, 400-20	7
1402	Schizopsychotic symptom-profiles and biomarkers: beacons in diagnostic labyrinths. 2008 , 14, 79-96	5
1401	Chromosome abnormalities, mental retardation and the search for genes in bipolar disorder and schizophrenia. 2008 , 14, 113-20	18
1400	The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. 2008 , 196, 431-40	159
1399	Pharmacological modulation of the neural basis underlying inhibition of return (IOR) in the human 5-HT2A agonist and NMDA antagonist model of psychosis. 2008 , 200, 573-83	28
1398	Impaired associative learning in schizophrenia: behavioral and computational studies. 2008 , 2, 207-19	33
1397	Genetics of clinical features and subtypes of schizophrenia: a review of the recent literature. 2008 , 10, 164-70	43
1396	The role of cerebellar genes in pathology of autism and schizophrenia. 2008 , 7, 279-94	43
1395	Two-stage designs to identify the effects of SNP combinations on complex diseases. 2008 , 53, 739-746	10
1394	Comprehensive analysis of polymorphisms throughout GAD1 gene: a family-based association study in schizophrenia. 2008 , 115, 513-9	25
1393	PRODH variants and risk for schizophrenia. 2008 , 35, 673-9	46
1392	Physiogenomic analysis of localized FMRI brain activity in schizophrenia. 2008 , 36, 877-88	16
1391	Associations of SNAP-25 polymorphisms with cognitive dysfunctions in Caucasian patients with schizophrenia during a brief trial of treatment with atypical antipsychotics. 2008 , 258, 335-44	30
1390	Eye movement deficits in schizophrenia: investigation of a genetically homogenous Icelandic sample. 2008 , 258, 373-83	23
1389	Age-related changes in the expression of schizophrenia susceptibility genes in the human prefrontal cortex. 2008 , 213, 255-71	45

1388	Association analyses of the interaction between the ADSS and ATM genes with schizophrenia in a Chinese population. 2008 , 9, 119	11	
1387	The estrogen hypothesis of schizophrenia implicates glucose metabolism: association study in three independent samples. 2008 , 9, 39	26	
1386	Association study of polymorphisms in the neutral amino acid transporter genes SLC1A4, SLC1A5 and the glycine transporter genes SLC6A5, SLC6A9 with schizophrenia. 2008 , 8, 58	17	
1385	Effect of MK-801 on gene expressions in the amygdala of rats. 2008 , 62, 1-7	21	
1384	Altered hippocampal expression of glutamate receptors and transporters in GRM2 and GRM3 knockout mice. 2008 , 62, 842-50	43	
1383	RNA from Borna disease virus in patients with schizophrenia, schizoaffective patients, and in their biological relatives. 2008 , 22, 314-20	26	
1382	PLC-beta1 knockout mice as a model of disrupted cortical development and plasticity: behavioral endophenotypes and dysregulation of RGS4 gene expression. 2008 , 18, 824-34	48	
1381	An association study of RGS4 polymorphisms with clinical phenotypes of schizophrenia in a Chinese population. 2008 , 147B, 77-85	29	
1380	Divergent backward masking performance in schizophrenia and bipolar disorder: association with COMT. 2008 , 147B, 223-7	16	
1379	Replication study and meta-analysis of the genetic association of GRM3 gene polymorphisms with schizophrenia in a large Japanese case-control population. 2008 , 147, 392-6	19	
1378	Regulation of a novel alphaN-catenin splice variant in schizophrenic smokers. 2008 , 147B, 759-68	23	
1377	The XVth World Congress of Psychiatric Genetics, October 7-11, 2007: Rapporteur summaries of oral presentations. 2008 , 147B, 233-77	4	
1376	Comprehensive analysis of tagging sequence variants in DTNBP1 shows no association with schizophrenia or with its composite neurocognitive endophenotypes. 2008 , 147B, 1159-66	31	
1375	Candidate genes for schizophrenia: a survey of association studies and gene ranking. 2008 , 147B, 1173-81	86	
1374	Neurotransmission and bipolar disorder: a systematic family-based association study. 2008 , 147B, 1270-7	22	
1373	An entropy-based approach for testing genetic epistasis underlying complex diseases. 2008 , 250, 362-74	42	
1372	Interactive memory systems and category learning in schizophrenia. <i>Neuroscience and Biobehavioral Reviews</i> , 2008 , 32, 206-18	9	17
1371	Lectures. 2008 , 20 Suppl 1, 1-50		

1370	Nuclear DISC1 regulates CRE-mediated gene transcription and sleep homeostasis in the fruit fly. <i>Molecular Psychiatry</i> , 2008 , 13, 1138-48, 1069	15.1	87
1369	Modelling prefrontal cortex deficits in schizophrenia: implications for treatment. 2008 , 153 Suppl 1, S465-70		113
1368	Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. 2008 , 9, 437-52		770
1367	Neuroimaging and molecular genetics of schizophrenia: pathophysiological advances and therapeutic potential. 2008 , 153 Suppl 1, S120-4		26
1366	Neurophysiological biomarkers for drug development in schizophrenia. 2008 , 7, 68-83		249
1365	Psychiatric genetics: progress amid controversy. 2008 , 9, 527-40		377
1364	Phospholipase C-beta1 knockout mice exhibit endophenotypes modeling schizophrenia which are rescued by environmental enrichment and clozapine administration. <i>Molecular Psychiatry</i> , 2008 , 13, 661-72	15.1	106
1363	Replication of linkage on chromosome 7q22 and association of the regional Reelin gene with working memory in schizophrenia families. <i>Molecular Psychiatry</i> , 2008 , 13, 673-84	15.1	81
1362	Mice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminergia and 'schizophrenia-related' behaviors. <i>Molecular Psychiatry</i> , 2008 , 13, 631-40	15.1	144
1361	Inducible expression of mutant human DISC1 in mice is associated with brain and behavioral abnormalities reminiscent of schizophrenia. <i>Molecular Psychiatry</i> , 2008 , 13, 173-86, 115	15.1	288
1360	The myelin-pathogenesis puzzle in schizophrenia: a literature review. <i>Molecular Psychiatry</i> , 2008 , 13, 245-60	15.1	82
1359	Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder. <i>Molecular Psychiatry</i> , 2008 , 13, 1102-17	15.1	182
1358	Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. <i>Molecular Psychiatry</i> , 2008 , 13, 544-56	15.1	127
1357	Intermediate phenotypes in schizophrenia genetics redux: is it a no brainer?. <i>Molecular Psychiatry</i> , 2008 , 13, 233-8	15.1	89
1356	Genomic imprinting in the development and evolution of psychotic spectrum conditions. 2008 , 83, 441-93		49
1355	A protein interaction based model for schizophrenia study. 2008 , 9 Suppl 12, S23		9
1354	Altered gene expression in the superior temporal gyrus in schizophrenia. 2008 , 9, 199		61
1353	Mice lacking d-amino acid oxidase activity exhibit marked reduction of methamphetamine-induced stereotypy. 2008 , 586, 221-5		19

1352	Association of schizophrenia with DTNBP1 but not with DAO, DAOA, NRG1 and RGS4 nor their genetic interaction. 2008 , 42, 278-88		74
1351	Rat strain differences in startle gating-disruptive effects of apomorphine occur with both acoustic and visual prepulses. 2008 , 88, 306-11		20
1350	Schizophrenia. 2008 , 36, 405-409		12
1349	Neuropathology of schizophrenia. 2008 , 7, 421-424		6
1348	Implication of neuronal Ca ²⁺ -sensor protein VILIP-1 in the glutamate hypothesis of schizophrenia. 2008 , 32, 162-75		17
1347	Emerging opportunities for antipsychotic drug discovery in the postgenomic era. 2008 , 51, 1077-107		45
1346	The emperors of the schizophrenia polygene have no clothes. 2008 , 38, 1681-5		37
1345	Expression of Kruppel-like factor 5 gene in human brain and association of the gene with the susceptibility to schizophrenia. <i>Schizophrenia Research</i> , 2008 , 100, 291-301	3.6	26
1344	Association of RGS2 and RGS5 variants with schizophrenia symptom severity. <i>Schizophrenia Research</i> , 2008 , 101, 67-75	3.6	31
1343	Failure to replicate the association between NRG1 and schizophrenia using Japanese large sample. <i>Schizophrenia Research</i> , 2008 , 101, 1-8	3.6	30
1342	Schizophrenia, "Just the Facts": what we know in 2008 part 1: overview. <i>Schizophrenia Research</i> , 2008 , 100, 4-19	3.6	232
1341	A polymorphism of the metabotropic glutamate receptor mGluR7 (GRM7) gene is associated with schizophrenia. <i>Schizophrenia Research</i> , 2008 , 101, 9-16	3.6	49
1340	PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia. <i>Schizophrenia Research</i> , 2008 , 101, 36-49	3.6	103
1339	Verbal working memory impairments in individuals with schizophrenia and their first-degree relatives: findings from the Consortium on the Genetics of Schizophrenia. <i>Schizophrenia Research</i> , 2008 , 103, 218-28	3.6	89
1338	Neuregulin-1 and the P300 waveform--a preliminary association study using a psychosis endophenotype. <i>Schizophrenia Research</i> , 2008 , 103, 178-85	3.6	37
1337	Genetic variation in the DAOA gene complex: impact on susceptibility for schizophrenia and on cognitive performance. <i>Schizophrenia Research</i> , 2008 , 103, 169-77	3.6	27
1336	An association study of ADSS gene polymorphisms with schizophrenia. 2008 , 4, 39		0
1335	Impaired long-term memory retention and working memory in sdy mutant mice with a deletion in Dtnbp1, a susceptibility gene for schizophrenia. 2008 , 1, 11		107

1334	Alpha-CaMKII deficiency causes immature dentate gyrus, a novel candidate endophenotype of psychiatric disorders. 2008 , 1, 6	204
1333	Impact of genetic variant BDNF (Val66Met) on brain structure and function. 2008 , 289, 180-8; discussion 188-95	81
1332	Genetic variation in catechol-O-methyltransferase: effects on working memory in schizophrenic patients, their siblings, and healthy controls. 2008 , 63, 72-9	105
1331	Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia. 2008 , 63, 32-41	54
1330	Evidence of missense mutations on the neuregulin 1 gene affecting function of prepulse inhibition. 2008 , 63, 17-23	67
1329	A diffusion tensor imaging study of white matter in early-onset schizophrenia. 2008 , 63, 519-23	131
1328	Is gray matter volume an intermediate phenotype for schizophrenia? A voxel-based morphometry study of patients with schizophrenia and their healthy siblings. 2008 , 63, 465-74	169
1327	AKT1 is associated with schizophrenia across multiple symptom dimensions in the Irish study of high density schizophrenia families. 2008 , 63, 449-57	131
1326	Modulation of D-serine levels in brains of mice lacking PICK1. 2008 , 63, 997-1000	38
1325	Strain differences in the gating-disruptive effects of apomorphine: relationship to gene expression in nucleus accumbens signaling pathways. 2008 , 63, 748-58	34
1324	Novel linkage to chromosome 20p using latent classes of psychotic illness in 270 Irish high-density families. 2008 , 64, 121-7	48
1323	Genetic variation in the DAOA (G72) gene modulates hippocampal function in subjects at high risk of schizophrenia. 2008 , 64, 428-33	46
1322	N-methyl-D-aspartate receptor and calbindin-containing neurons in the anterior cingulate cortex in schizophrenia and bipolar disorder. 2008 , 64, 803-9	43
1321	Loss of glial glutamate and aspartate transporter (excitatory amino acid transporter 1) causes locomotor hyperactivity and exaggerated responses to psychotomimetics: rescue by haloperidol and metabotropic glutamate 2/3 agonist. 2008 , 64, 810-4	86
1320	Abnormal auditory N100 amplitude: a heritable endophenotype in first-degree relatives of schizophrenia probands. 2008 , 64, 1051-9	101
1319	Prepulse inhibition of the startle reflex depends on the catechol O-methyltransferase Val158Met gene polymorphism. 2008 , 38, 1651-8	71
1318	Mechanisms of neuregulin action. 2008 , 289, 74-84; discussion 84-93	46
1317	Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions. 2008 , 34, 1066-82	476

1316	How has DISC1 enabled drug discovery?. 2008 , 37, 187-95	30
1315	Aspects of Piaget's cognitive developmental psychology and neurobiology of psychotic disorders - an integrative model. 2008 , 71, 426-33	10
1314	Association study of polymorphisms between DISC1 and schizophrenia in a Korean population. 2008 , 430, 60-3	37
1313	Impact of postnatal blockade of N-methyl-D-aspartate receptors on rat behavior: a search for a new developmental model of schizophrenia. 2008 , 153, 1370-9	32
1312	Phenotypic characterization of cognition and social behavior in mice with heterozygous versus homozygous deletion of catechol-O-methyltransferase. 2008 , 155, 1021-9	80
1311	Neuronal distribution in the neocortex of schizophrenic patients. 2008 , 158, 267-77	32
1310	Reduced auditory evoked potential component N100 in schizophrenia--a critical review. 2008 , 161, 259-74	170
1309	BanI polymorphism of cytosolic phospholipase A2 gene is associated with age at onset in male patients with schizophrenia and schizoaffective disorder. 2008 , 78, 351-60	14
1308	Disruption to social dyadic interactions but not emotional/anxiety-related behaviour in mice with heterozygous 'knockout' of the schizophrenia risk gene neuregulin-1. 2008 , 32, 462-6	81
1307	The association of genotypic combination of the DRD3 and BDNF polymorphisms on the adhesio interthalamica and medial temporal lobe structures. 2008 , 32, 1236-42	19
1306	Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. 2008 , 31, 234-42	765
1305	Dendritic spine dynamics--a key role for kalirin-7. 2008 , 31, 419-27	120
1304	Developing New Drugs for Schizophrenia: From Animals to the Clinic. 2008 , 199-261	11
1303	Behavioral abnormalities and dopamine reductions in sdy mutant mice with a deletion in Dtnbp1, a susceptibility gene for schizophrenia. 2008 , 373, 298-302	93
1302	Genetic causality in schizophrenia and bipolar disorder: out with the old and in with the new. 2008 , 18, 229-34	45
1301	Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology. <i>Schizophrenia Research</i> , 2008 , 102, 1-18	3.6 509
1300	White matter tracts in first-episode psychosis: a DTI tractography study of the uncinate fasciculus. 2008 , 39, 949-55	103
1299	Association of 5' end neuregulin-1 (NRG1) gene variation with subcortical medial frontal microstructure in humans. 2008 , 40, 712-718	80

1298	Evidence for abnormalities of cortical development in adolescent-onset schizophrenia. 2008 , 43, 665-75		117
1297	Polymorphisms in catechol-O-methyltransferase and methylenetetrahydrofolate reductase in relation to the risk of schizophrenia. 2008 , 18, 99-106		21
1296	Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology. 2008 , 18, 773-86		93
1295	Psychiatric neuroimaging: joining forces with epidemiology. 2008 , 23, 315-9		10
1294	Expression of D-serine and glycine transporters in the prefrontal cortex and cerebellum in schizophrenia. <i>Schizophrenia Research</i> , 2008 , 102, 283-94	3.6	33
1293	A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects. 2008 , 51, 2858-62		20
1292	Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. 2008 , 320, 539-43		1443
1291	Modeling the Developing Drosophila Brain: Rationale, Technique, and Application. 2008 , 58, 823-836		8
1290	Phencyclidine and dizocilpine induced behaviors reduced by N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors. 2008 , 63, 86-91		48
1289	Glial cell number and nuclear size in the mediodorsal thalamic nucleus (MDNT) in schizophrenia. <i>Schizophrenia Research</i> , 2008 , 102, 344-5	3.6	9
1288	Regulation of pituitary adenylyl cyclase-activating polypeptide (PACAP, ADCYAP1: adenylyl cyclase-activating polypeptide 1) in the treatment of schizophrenia. 2008 , 12, 1097-108		9
1287	Evidence for impaired long-term potentiation in schizophrenia and its relationship to motor skill learning. 2008 , 18, 990-6		160
1286	Neuregulin-1 regulates LTP at CA1 hippocampal synapses through activation of dopamine D4 receptors. 2008 , 105, 15587-92		107
1285	Three-dimensional brain growth abnormalities in childhood-onset schizophrenia visualized by using tensor-based morphometry. 2008 , 105, 15979-84		103
1284	Dual constraints on synapse formation and regression in schizophrenia: neuregulin, neuroligin, dysbindin, DISC1, MuSK and agrin. 2008 , 42, 662-77		24
1283	Developmental disruptions in neural connectivity in the pathophysiology of schizophrenia. 2008 , 20, 1297-327		114
1282	A neonatal ventral hippocampal lesion causes functional deficits in adult prefrontal cortical interneurons. <i>Journal of Neuroscience</i> , 2008 , 28, 12691-9	6.6	118
1281	Type III neuregulin-1 is required for normal sensorimotor gating, memory-related behaviors, and corticostriatal circuit components. <i>Journal of Neuroscience</i> , 2008 , 28, 6872-83	6.6	175

1280	Copy variations in schizophrenia and bipolar disorder. 2008 , 123, 27-35		7
1279	Meta-analysis, database, and meta-regression of 98 structural imaging studies in bipolar disorder. 2008 , 65, 1017-32		417
1278	Genes and neuroimaging: advances in psychiatric research. 2008 , 5, 277-85		15
1277	. 2008 ,		
1276	Imaging of molecular dynamics regulated by electrical activities in neural circuits and in synapses. 2008 , 16, 260-77		6
1275	Postnatal phencyclidine administration selectively reduces adult cortical parvalbumin-containing interneurons. 2008 , 33, 2442-55		121
1274	Brain neuroplasticity in healthy, hyperactive and psychotic children: insights from neuroimaging. 2008 , 33, 181-97		94
1273	Insolubility of disrupted-in-schizophrenia 1 disrupts oligomer-dependent interactions with nuclear distribution element 1 and is associated with sporadic mental disease. <i>Journal of Neuroscience</i> , 2008 , 28, 3839-45	6.6	95
1272	Presynaptic type III neuregulin 1 is required for sustained enhancement of hippocampal transmission by nicotine and for axonal targeting of alpha7 nicotinic acetylcholine receptors. <i>Journal of Neuroscience</i> , 2008 , 28, 9111-6	6.6	60
1271	Identification of YWHAЕ, a gene encoding 14-3-3epsilon, as a possible susceptibility gene for schizophrenia. 2008 , 17, 3212-22		88
1270	Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. 2008 , 17, 1156-68		271
1269	The evolutionarily conserved G protein-coupled receptor SREB2/GPR85 influences brain size, behavior, and vulnerability to schizophrenia. 2008 , 105, 6133-8		47
1268	Inhibitors of GlyT1 affect glycine transport via discrete binding sites. 2008 , 74, 1705-15		58
1267	Decreased mRNA expression of netrin-G1 and netrin-G2 in the temporal lobe in schizophrenia and bipolar disorder. 2008 , 33, 933-45		55
1266	Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings. 2008 , 33, 2048-60		69
1265	The evolution of drug development in schizophrenia: past issues and future opportunities. 2008 , 33, 2061-79		157
1264	Functional polymorphisms in PRODH are associated with risk and protection for schizophrenia and fronto-striatal structure and function. 2008 , 4, e1000252		84
1263	Molecular and Cellular Mechanisms of Learning Disabilities: A Focus on Neurofibromatosis Type I. 2008 , 77-92		

1262	Neuroactive Steroids in Brain Function, Behavior and Neuropsychiatric Disorders. 2008,	1
1261	DNA methylation changes in schizophrenia and bipolar disorder. 2008, 3, 55-8	70
1260	Neuroplasticity of neocortical circuits in schizophrenia. 2008, 33, 141-65	296
1259	Validating endophenotypes for schizophrenia using statistical modeling of twin data. 2008, 39, 78-81	6
1258	New Approaches to Treatment of Schizophrenia by Enhancing N-methyl-d-aspartate Neurotransmission. 2008, 3,	
1257	Orbitofrontal cortex neurons as a common target for classic and glutamatergic antipsychotic drugs. 2008, 105, 18041-6	61
1256	The molecular and cellular neurobiology of nicotine abuse in schizophrenia. 2008, 41 Suppl 1, S51-9	38
1255	Alternative biologische Therapien - In der Behandlung der Negativsymptomatik und der kognitiven Störungen. 2008, 34, 201-206	
1254	Role of glutamate in schizophrenia: integrating excitatory avenues of research. 2008, 8, 1389-406	39
1253	Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT Val158Met polymorphism. 2008, 33, 3058-68	114
1252	Drug discovery based on genetic and metabolic findings in schizophrenia. 2008, 1, 773-89	7
1251	[Schizophrenia as a brain disorder and its development]. 2008, 76 Suppl 1, S63-7	5
1250	Expression of a GRM3 splice variant is increased in the dorsolateral prefrontal cortex of individuals carrying a schizophrenia risk SNP. 2008, 33, 2626-34	62
1249	DTNBP1, a schizophrenia susceptibility gene, affects kinetics of transmitter release. 2008, 181, 791-801	130
1248	Genetic-linkage mapping of complex hereditary disorders to a whole-genome molecular-interaction network. 2008, 18, 1150-62	57
1247	Metabotropic glutamate receptor agonists for schizophrenia. 2008, 192, 86-7	21
1246	The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia. 2008, 22, 308-22	136
1245	Advances in endophenotyping schizophrenia. 2008, 7, 11-8	75

1244	Update on the treatment and management of schizophrenia and bipolar disorder. 2008 , 13, 1-10; quiz 11-2	22
1243	Microarray analysis reveals distinctive signaling between the bed nucleus of the stria terminalis, nucleus accumbens, and dorsal striatum. 2008 , 32, 283-98	16
1242	Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D(3) > D(2) antagonist, S33138. 2008 , 63, 187-229	39
1241	Possible involvement of post-dopamine D2 receptor signalling components in the pathophysiology of schizophrenia. 2008 , 11, 197-205	28
1240	Evidence for association between structural variants in lissencephaly-related genes and executive deficits in schizophrenia or bipolar patients from a Spanish isolate population. 2008 , 18, 313-7	20
1239	Theories of cognition, emotion and the social world: missing links in psychosis. 219-237	6
1238	RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia. 2008 , 28, 64-8	35
1237	Minocycline as adjunctive therapy for schizophrenia: an open-label study. 2008 , 31, 287-92	112
1236	Stargazin involvement with bipolar disorder and response to lithium treatment. 2008 , 18, 403-12	35
1235	Heritable strain differences in sensitivity to the startle gating-disruptive effects of D2 but not D3 receptor stimulation. 2008 , 19, 786-95	18
1234	Is brain banking of psychiatric cases valuable for neurobiological research?. 2008 , 63, 255-66	18
1233	Genomic convergence analysis of schizophrenia: mRNA sequencing reveals altered synaptic vesicular transport in post-mortem cerebellum. 2008 , 3, e3625	95
1232	Neuroanatomical pattern of mitochondrial complex I pathology varies between schizophrenia, bipolar disorder and major depression. 2008 , 3, e3676	139
1231	The complement system in schizophrenia. 2008 , 21, 200-10	104
1230	Genetic vulnerability. 31-46	
1229	Neurobiological endophenotypes of psychosis and schizophrenia. 61-80	6
1228	Environmental vulnerability and genetic-environmental interactions. 47-60	2
1227	The Offspring of Women with Severe Mental Disorder. 2009 , 193-204	

1226 Associative memory. 96-104

1225 . 2009, 10

1224 Association between the DRD2-141C Insertion/Deletion polymorphism and schizophrenia. 2009, 67, 191-4 28

1223 The DISC1 pathway modulates expression of neurodevelopmental, synaptogenic and sensory perception genes. 2009, 4, e4906 62

1222 The post-synaptic density of human postmortem brain tissues: an experimental study paradigm for neuropsychiatric illnesses. 2009, 4, e5251 63

1221 Evidence for X-chromosomal schizophrenia associated with microRNA alterations. 2009, 4, e6121 76

1220 Convergent approaches for defining functional imaging endophenotypes in schizophrenia. 2009, 3, 37 30

1219 New findings from genetic association studies of schizophrenia. 2009, 54, 9-14 27

1218 Lack of association between AKT1 variances versus clinical manifestations and social function in patients with schizophrenia. 2009, 23, 937-43 10

1217 NR1 knockdown mice as a representative model of the glutamate hypothesis of schizophrenia. 2009, 179, 51-8 30

1216 Hippocampus. 2009, 313-330

1215 DISC1 splice variants are upregulated in schizophrenia and associated with risk polymorphisms. 2009, 106, 15873-8 143

1214 Activation of glycogen synthase kinase-3 beta is required for hyperdopamine and D2 receptor-mediated inhibition of synaptic NMDA receptor function in the rat prefrontal cortex. 6.6 74
Journal of Neuroscience, 2009, 29, 15551-63

1213 Dysbindin and d-amino-acid-oxidase gene polymorphisms associated with positive and negative symptoms in schizophrenia. 2009, 60, 31-6 17

1212 Controversies surrounding the diagnosis of schizophrenia and other psychoses. 2009, 9, 1475-86 12

1211 From Attention to Goal-Directed Behavior. 2009, 3

1210 Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring. 2009, 35, 509-27 869

1209 The effect of COMT, BDNF, 5-HTT, NRG1 and DTNBP1 genes on hippocampal and lateral ventricular volume in psychosis. 2009, 39, 1783-97 62

1208	Neuregulin-1 modulates hippocampal gamma oscillations: implications for schizophrenia. 2009 , 19, 612-8	132
1207	Interaction between environmental and genetic factors modulates schizophrenic endophenotypes in the Snap-25 mouse mutant blind-drunk. 2009 , 18, 4576-89	61
1206	How high-resolution basal-state functional imaging can guide the development of new pharmacotherapies for schizophrenia. 2009 , 35, 1037-44	18
1205	Influence of functional variant of neuronal nitric oxide synthase on impulsive behaviors in humans. 2009 , 66, 41-50	122
1204	Analysis of a promoter polymorphism in the SMDF neuregulin 1 isoform in Schizophrenia. 2009 , 59, 205-12	5
1203	NMDA receptor phosphorylation at a site affected in schizophrenia controls synaptic and behavioral plasticity. <i>Journal of Neuroscience</i> , 2009 , 29, 11965-72	6.6 39
1202	D-aspartate: an atypical amino acid with neuromodulatory activity in mammals. 2009 , 20, 429-40	24
1201	Genetic animal models for schizophrenia: advantages and limitations of genetic manipulation in drosophila, zebrafish, rodents, and primates. 2009 , 179, 3-6	6
1200	Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action?. 2009 , 166, 812-20	82
1199	Influence of NOS1 on verbal intelligence and working memory in both patients with schizophrenia and healthy control subjects. 2009 , 66, 1045-54	42
1198	Novel therapies for schizophrenia: understanding the glutamatergic synapse and potential targets for altering N-methyl-D-aspartate neurotransmission. 2009 , 4, 220-38	11
1197	Background dopamine concentration dependently facilitates long-term potentiation in rat prefrontal cortex through postsynaptic activation of extracellular signal-regulated kinases. 2009 , 19, 2708-18	45
1196	Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study. 2009 , 194, 158-64	80
1195	ErbB4 genotype predicts left frontotemporal structural connectivity in human brain. 2009 , 34, 641-50	60
1194	Gene manipulation with stereotaxic viral infection for psychiatric research: spatiotemporal components for schizophrenia. 2009 , 179, 17-27	6
1193	Widespread reductions of cortical thickness in schizophrenia and spectrum disorders and evidence of heritability. 2009 , 66, 467-77	209
1192	Identifying relationships among genomic disease regions: predicting genes at pathogenic SNP associations and rare deletions. 2009 , 5, e1000534	337
1191	Neuropsychiatric disease and <i>Toxoplasma gondii</i> infection. 2009 , 16, 122-33	136

1190	A review of the fetal brain cytokine imbalance hypothesis of schizophrenia. 2009 , 35, 959-72	244
1189	Antipsychotic drug actions on gene modulation and signaling mechanisms. 2009 , 124, 74-85	67
1188	The Disrupted-in-Schizophrenia-1 Ser704Cys polymorphism and brain morphology in schizophrenia. 2009 , 172, 128-35	44
1187	Antisaccade performance is related to genetic loading for schizophrenia. 2009 , 43, 291-7	12
1186	Developmental vitamin D deficiency causes abnormal brain development. 2009 , 34 Suppl 1, S247-57	167
1185	Neuregulin 1 transgenic mice display reduced mismatch negativity, contextual fear conditioning and social interactions. 2009 , 1294, 116-27	103
1184	Association between myelin basic protein expression and left entorhinal cortex pre-alpha cell layer disorganization in schizophrenia. 2009 , 1301, 126-34	27
1183	Identification of neuroglycan C and interacting partners as potential susceptibility genes for schizophrenia in a Southern Chinese population. 2010 , 153B, 103-13	16
1182	Association study of NRG1, DTNBP1, RGS4, G72/G30, and PIP5K2A with schizophrenia and symptom severity in a Hungarian sample. 2010 , 153B, 792-801	31
1181	Increased inferior frontal activation during word generation: a marker of genetic risk for schizophrenia but not bipolar disorder?. 2009 , 30, 3287-98	31
1180	DTNBP1 is associated with imaging phenotypes in schizophrenia. 2009 , 30, 3783-94	29
1179	The impact of dystrobrevin-binding protein 1 (DTNBP1) on neural correlates of episodic memory encoding and retrieval. 2010 , 31, 203-9	15
1178	Impact of schizophrenia-risk gene dysbindin 1 on brain activation in bilateral middle frontal gyrus during a working memory task in healthy individuals. 2010 , 31, 266-75	35
1177	What are genes "for" or where are traits "from"? What is the question?. 2009 , 31, 198-208	35
1176	Increased D-amino acid oxidase expression in the bilateral hippocampal CA4 of schizophrenic patients: a post-mortem study. 2009 , 116, 1657-65	28
1175	The interplay between mitochondrial complex I, dopamine and Sp1 in schizophrenia. 2009 , 116, 1383-96	37
1174	Stereologic investigation of the posterior part of the hippocampus in schizophrenia. 2009 , 117, 395-407	128
1173	Microvessel length density, total length, and length per neuron in five subcortical regions in schizophrenia. 2009 , 117, 409-21	30

1172	In-vivo rodent models for the experimental investigation of prenatal immune activation effects in neurodevelopmental brain disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2009 , 33, 1061-79	9	266
1171	What do we know about neuropsychological aspects of schizophrenia?. 2009 , 19, 365-84		222
1170	Association between the G1001C polymorphism in the GRIN1 gene promoter and schizophrenia in the Iranian population. 2009 , 38, 178-81		24
1169	Clozapine-induced ERK1 and ERK2 signaling in prefrontal cortex is mediated by the EGF receptor. 2009 , 39, 185-98		22
1168	Cytoarchitecture cérébrale dans la schizophrénie. 2009 , 7, 23-30		2
1167	[Correlations between risk gene variants for schizophrenia and brain structure anomalies]. 2009 , 80, 40-2, 44-6, 48 passim		7
1166	Prenatal exposure to infection: a primary mechanism for abnormal dopaminergic development in schizophrenia. 2009 , 206, 587-602		83
1165	Effects of quetiapine on monoamine, GABA, and glutamate release in rat prefrontal cortex. 2009 , 206, 243-58		55
1164	Group II metabotropic glutamate receptors and schizophrenia. 2009 , 66, 3777-85		60
1163	Zinc: the brain's dark horse. 2009 , 63, 1029-49		206
1162	2-D DIGE analysis implicates cytoskeletal abnormalities in psychiatric disease. 2009 , 9, 3368-82		120
1161	Effect of the G72 (DAOA) putative risk haplotype on cognitive functions in healthy subjects. 2009 , 9, 60		8
1160	Dynamic integration of subplate neurons into the cortical barrel field circuitry during postnatal development in the Golli-tau-eGFP (GTE) mouse. 2009 , 587, 1903-15		60
1159	Proteomic analysis of membrane microdomain-associated proteins in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder reveals alterations in LAMP, STXBP1 and BASP1 protein expression. <i>Molecular Psychiatry</i> , 2009 , 14, 601-13	15.1	136
1158	Evidence for HTR1A and LHPP as interacting genetic risk factors in major depression. <i>Molecular Psychiatry</i> , 2009 , 14, 621-30	15.1	82
1157	Analysis of gene expression in two large schizophrenia cohorts identifies multiple changes associated with nerve terminal function. <i>Molecular Psychiatry</i> , 2009 , 14, 1083-94	15.1	141
1156	Schizophrenia: A point of disruption. 2009 , 458, 976-7		8
1155	Global change: China at the carbon crossroads. 2009 , 458, 977-9		15

1154	Schizophrenia; from structure to function with special focus on the mediodorsal thalamic prefrontal loop. 2009 , 120, 345-54		38
1153	Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor. 2009 , 11, 726-34		113
1152	SNAP-25 in neuropsychiatric disorders. 2009 , 1152, 93-9		76
1151	The uses of biomarkers in drug development. 2009 , 1180, 1-10		24
1150	Effects of zotepine on extracellular levels of monoamine, GABA and glutamate in rat prefrontal cortex. 2009 , 157, 656-65		50
1149	Proteomic analysis reveals novel binding partners of dysbindin, a schizophrenia-related protein. 2009 , 110, 1567-74		26
1148	Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications. 2009 , 111, 891-900		73
1147	Stress-induced prefrontal reorganization and executive dysfunction in rodents. <i>Neuroscience and Biobehavioral Reviews</i> , 2009 , 33, 773-83	9	359
1146	Delusions, illusions and hallucinations in epilepsy: 2. Complex phenomena and psychosis. 2009 , 85, 172-86		104
1145	Breaking the gene barrier in schizophrenia. 2009 , 15, 488-90		13
1144	Survey of schizophrenia and bipolar disorder candidate genes using chromatin immunoprecipitation and tiled microarrays (ChIP-chip). 2009 , 23, 341-52		14
1143	Anterior hippocampus in schizophrenia pathogenesis: molecular evidence from a proteome study. 2009 , 43, 310-22		31
1142	Modeling schizophrenia in flies. 2009 , 179, 107-15		8
1141	Dysbindin modulates prefrontal cortical glutamatergic circuits and working memory function in mice. 2009 , 34, 2601-8		90
1140	DTNBP1, NRG1, DAOA, DAO and GRM3 polymorphisms and schizophrenia: an association study. 2009 , 59, 142-50		31
1139	Neonatal infection with neurotropic influenza A virus affects working memory and expression of type III Nrg1 in adult mice. 2009 , 23, 733-41		28
1138	The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia. 2009 , 204, 295-305		264
1137	Neural basis of psychosis-related behaviour in the infection model of schizophrenia. 2009 , 204, 322-34		122

1136	Mice mutant for genes associated with schizophrenia: common phenotype or distinct endophenotypes?. 2009 , 204, 258-73	47
1135	Prepulse inhibition and genetic mouse models of schizophrenia. 2009 , 204, 282-94	153
1134	Early postnatal depletion of NMDA receptor development affects behaviour and NMDA receptor expression until later adulthood in rats--a possible model for schizophrenia. 2009 , 205, 96-101	29
1133	Associative learning and the genetics of schizophrenia. 2009 , 32, 359-65	26
1132	Neurodevelopmental mechanisms of schizophrenia: understanding disturbed postnatal brain maturation through neuregulin-1-ErbB4 and DISC1. 2009 , 32, 485-95	273
1131	BDNF mediates the neuroprotective effects of positive AMPA receptor modulators against MPP+-induced toxicity in cultured hippocampal and mesencephalic slices. 2009 , 56, 876-85	42
1130	GABA(A) receptors and their associated proteins: implications in the etiology and treatment of schizophrenia and related disorders. 2009 , 57, 481-95	88
1129	The genetics of schizophrenia. 2009 , 164, 288-99	48
1128	Genes, cognition and brain through a COMT lens. 2009 , 164, 72-87	181
1127	Attention network test (ANT) reveals gender-specific alterations of executive function in schizophrenia. 2009 , 168, 102-9	34
1126	No association found between the promoter variations of QKI and schizophrenia in the Chinese population. 2009 , 33, 33-6	4
1125	Phenotype of spontaneous orofacial dyskinesia in neuregulin-1 'knockout' mice. 2009 , 33, 330-3	7
1124	Do schizophrenia and bipolar disorders share a common disease susceptibility variant at the MMP3 gene?. 2009 , 33, 557-61	11
1123	One-carbon metabolism and schizophrenia: current challenges and future directions. 2009 , 15, 562-70	61
1122	Direct interaction of Dysbindin with the AP-3 complex via its mu subunit. 2009 , 54, 431-8	27
1121	Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs. 2009 , 55, 85-97	79
1120	Differential expression of glutamate transporter genes after chronic oral treatment with aripiprazole in rats. 2009 , 55, 619-28	25
1119	Schizophrenia and epilepsy: is there a shared susceptibility?. 2009 , 63, 227-35	91

1118	Neonatal poly:C treatment in mice results in schizophrenia-like behavioral and neurochemical abnormalities in adulthood. 2009 , 64, 297-305		102
1117	Association analysis between schizophrenia and the AP-3 complex genes. 2009 , 65, 113-5		8
1116	Expression of RGS4 splice variants in dorsolateral prefrontal cortex of schizophrenic and bipolar disorder patients. 2009 , 65, 541-5		37
1115	Sensorimotor gating depends on polymorphisms of the serotonin-2A receptor and catechol-O-methyltransferase, but not on neuregulin-1 Arg38Gln genotype: a replication study. 2009 , 66, 614-20		85
1114	Tolcapone effects on gating, working memory, and mood interact with the synonymous catechol-O-methyltransferase rs4818c/g polymorphism. 2009 , 66, 997-1004		62
1113	The mismatch negativity: a review of underlying mechanisms. 2009 , 120, 453-63		802
1112	Prenatal immune challenge induces developmental changes in the morphology of pyramidal neurons of the prefrontal cortex and hippocampus in rats. <i>Schizophrenia Research</i> , 2009 , 107, 99-109	3.6	84
1111	A possible association between schizophrenia and GRIK3 polymorphisms in a multicenter sample of Scandinavian origin (SCOPE). <i>Schizophrenia Research</i> , 2009 , 107, 242-8	3.6	14
1110	Increased diffusivity in superior temporal gyrus in patients with schizophrenia: a Diffusion Tensor Imaging study. <i>Schizophrenia Research</i> , 2009 , 108, 33-40	3.6	59
1109	Association of the 5'-upstream regulatory region of the alpha7 nicotinic acetylcholine receptor subunit gene (CHRNA7) with schizophrenia. <i>Schizophrenia Research</i> , 2009 , 109, 102-12	3.6	81
1108	Metabolic abnormalities in fronto-striatal-thalamic white matter tracts in schizophrenia. <i>Schizophrenia Research</i> , 2009 , 109, 159-66	3.6	48
1107	Linkage analysis of schizophrenia in African-American families. <i>Schizophrenia Research</i> , 2009 , 109, 70-9	3.6	10
1106	Family-based association study of SELENBP1 in schizophrenia. <i>Schizophrenia Research</i> , 2009 , 113, 268-72	3.6	13
1105	Exomic sequencing of the ionotropic glutamate receptor N-methyl-D-aspartate 3A gene (GRIN3A) reveals no association with schizophrenia. <i>Schizophrenia Research</i> , 2009 , 114, 25-32	3.6	12
1104	Animal models for schizophrenia via in utero gene transfer: understanding roles for genetic susceptibility factors in brain development. 2009 , 179, 9-15		11
1103	Prefrontal cognitive systems in schizophrenia: towards human genetic brain mechanisms. 2009 , 14, 277-98		76
1102	Phosphodiesterases in the central nervous system. 2009 , 71-92		55
1101	Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. 2009 , 10, 127-55		54

1100	Neurodegeneration in Psychiatric Illness. 2009 , 279-283	
1099	Encyclopedia of Neuroscience. 2009 , 3687-3689	
1098	Diffusion Tensor Imaging and Its Application to Schizophrenia and Related Disorders. 2009 , 251-270	2
1097	Role of the PACAP-PAC1-DISC1 and PACAP-PAC1-stathmin1 systems in schizophrenia and bipolar disorder: novel treatment mechanisms?. 2009 , 10, 1967-78	17
1096	Encyclopedia of Neuroscience. 2009 , 3866-3873	
1095	Encyclopedia of Neuroscience. 2009 , 3557-3988	
1094	Anatomical abnormalities of the anterior cingulate cortex in schizophrenia: bridging the gap between neuroimaging and neuropathology. 2009 , 35, 973-93	177
1093	Mutant models for genes associated with schizophrenia. 2009 , 37, 308-12	47
1092	Can the role of genetic factors in schizophrenia be enlightened by studies of candidate gene mutant mice behaviour?. 2009 , 10, 778-97	8
1091	Assessment of glutamate transporter GLAST (EAAT1)-deficient mice for phenotypes relevant to the negative and executive/cognitive symptoms of schizophrenia. 2009 , 34, 1578-89	137
1090	BL-1020: a novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia. 2009 , 19, 1-13	29
1089	Impact of interacting functional variants in COMT on regional gray matter volume in human brain. 2009 , 45, 44-51	109
1088	A putative high risk diplotype of the G72 gene is in healthy individuals associated with better performance in working memory functions and altered brain activity in the medial temporal lobe. 2009 , 45, 1002-8	32
1087	Genetic variation in schizophrenia-risk-gene dysbindin 1 modulates brain activation in anterior cingulate cortex and right temporal gyrus during language production in healthy individuals. 2009 , 47, 2016-22	30
1086	Glutamatergic Approaches to the Conceptualization and Treatment of Schizophrenia. 2009 , 39-89	5
1085	Methodological issues in molecular genetic studies of mental disorders. 2009 , 5, 49-69	11
1084	Kalirin regulates cortical spine morphogenesis and disease-related behavioral phenotypes. 2009 , 106, 13058-63	123
1083	Schizophrenia: Genetics. 2009 , 459-462	

1082	Association of the DTNBP1 genotype with cognition and personality traits in healthy subjects. 2009 , 39, 1657-65	17
1081	Recent advances in postmortem pathology and neurochemistry in schizophrenia. 2009 , 22, 154-60	38
1080	Mutation screening of the glutamate cysteine ligase modifier (GCLM) gene in patients with schizophrenia. 2009 , 19, 201-8	9
1079	The Validity of Psychiatric Diagnosis: Etiopathogenic and Clinical Approaches. 219-231	1
1078	Integrating retinoic acid signaling with brain function. 2009 , 45, 139-50	28
1077	Intrauterine environment-genome interaction and children's development (4): Brain-behavior phenotyping of genetically-engineered mice using a comprehensive behavioral test battery on research of neuropsychiatric disorders. 2009 , 34 Suppl 2, SP293-305	8
1076	Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia. 2009 , 15, 2594-602	63
1075	The role of genes involved in neuroplasticity and neurogenesis in the observation of a gene-environment interaction (GxE) in schizophrenia. 2009 , 9, 506-18	51
1074	Neonatal infection with neurotropic influenza A virus induces the kynurenine pathway in early life and disrupts sensorimotor gating in adult Tap1 ^{-/-} mice. 2010 , 13, 475-85	42
1073	Challenges and opportunities for drug discovery in psychiatric disorders: the drug hunters' perspective. 2010 , 13, 1269-84	91
1072	Therapeutic utility of NK3 receptor antagonists for the treatment of schizophrenia. 2010 , 16, 344-57	25
1071	Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. 2010 , 16, 522-37	210
1070	Habituation in prepulse inhibition is affected by a polymorphism on the NMDA receptor 2B subunit gene (GRIN2B). 2010 , 20, 191-8	16
1069	[Cognitive disorders in schizophrenic patients]. 2010 , 81, 39-54	5
1068	[Anti-NMDA-receptor encephalitis. An interdisciplinary clinical picture]. 2010 , 81, 396, 398, 400, passim	27
1067	Abstracts of the XXXII Congress of the Spanish Society of Pharmacology. May 12-14, 2010. Barcelona, Spain. 2010 , 66 Suppl 1, S3-135	4
1066	Gene expression of NMDA receptor subunits in the cerebellum of elderly patients with schizophrenia. 2010 , 260, 101-11	33
1065	Measurement and comparison of serum neuregulin 1 immunoreactivity in control subjects and patients with schizophrenia: an influence of its genetic polymorphism. 2010 , 117, 887-95	43

1064	Neurocognitive Disorders in DSM-V: Forensic Perspective. 2010 , 3, 271-288	9	
1063	Epigenetics and biomarkers in the staging of neuropsychiatric disorders. 2010 , 18, 347-66	17	
1062	Differential regulation of alpha7 nicotinic receptor gene (CHRNA7) expression in schizophrenic smokers. 2010 , 40, 185-95	74	
1061	Expression of the hippocampal NMDA receptor GluN1 subunit and its splicing isoforms in schizophrenia: postmortem study. 2010 , 35, 994-1002	40	
1060	The comparative neuroanatomy and neurochemistry of zebrafish CNS systems of relevance to human neuropsychiatric diseases. 2010 , 40, 46-57	278	
1059	Does gene deletion of AMPA GluA1 phenocopy features of schizoaffective disorder?. 2010 , 40, 608-21	64	
1058	Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. 2010 , 128, 419-32	402	
1057	The effects of a DTNBP1 gene variant on attention networks: an fMRI study. 2010 , 6, 54	10	
1056	Metabotropic glutamate receptor 7: at the interface of cognition and emotion. 2010 , 639, 123-31	65	
1055	Use of biomarkers in the discovery of novel anti-schizophrenia drugs. 2010 , 15, 137-41	10	
1054	Association study of SNAP25 and schizophrenia in Irish family and case-control samples. 2010 , 153B, 663-674	17	
1053	D-Serine metabolism in C6 glioma cells: Involvement of alanine-serine-cysteine transporter (ASCT2) and serine racemase (SRR) but not D-amino acid oxidase (DAO). 2010 , 88, 1829-40	18	
1052	Significance of vitamin A to brain function, behavior and learning. 2010 , 54, 489-95	80	
1051	Dopamine and psychosis: theory, pathomechanisms and intermediate phenotypes. <i>Neuroscience and Biobehavioral Reviews</i> , 2010 , 34, 689-700	9	94
1050	The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia. <i>Neuroscience and Biobehavioral Reviews</i> , 2010 , 34, 351-72	9	104
1049	Genetics and intermediate phenotypes of the schizophrenia--bipolar disorder boundary. <i>Neuroscience and Biobehavioral Reviews</i> , 2010 , 34, 897-921	9	107
1048	Genetic association studies of glutamate, GABA and related genes in schizophrenia and bipolar disorder: a decade of advance. <i>Neuroscience and Biobehavioral Reviews</i> , 2010 , 34, 958-77	9	124
1047	Effect of ligand binding on human D-amino acid oxidase: implications for the development of new drugs for schizophrenia treatment. 2010 , 19, 1500-12	41	

1046	Two-dimensional reference map for the basic proteome of the human dorsolateral prefrontal cortex (dlPFC) of the prefrontal lobe region of the brain. 2010 , 10, 2551-5		4
1045	Pharmacology of epigenetics in brain disorders. 2010 , 159, 285-303		47
1044	Basal ganglia pathology in schizophrenia: dopamine connections and anomalies. 2010 , 113, 287-302		106
1043	Temporal dysregulation of cortical gene expression in the isolation reared Wistar rat. 2010 , 113, 601-14		13
1042	Cytosolic protein interactions of the schizophrenia susceptibility gene dysbindin. 2010 , 113, 1491-503		31
1041	DTNBP1 (dysbindin) gene variants modulate prefrontal brain function in schizophrenic patients--support for the glutamate hypothesis of schizophrenias. <i>Genes, Brain and Behavior</i> , 2010 , 9, 489-97	3.6	22
1040	Complexin2 null mutation requires a 'second hit' for induction of phenotypic changes relevant to schizophrenia. <i>Genes, Brain and Behavior</i> , 2010 , 9, 592-602	3.6	21
1039	The neurobiology of D-amino acid oxidase and its involvement in schizophrenia. <i>Molecular Psychiatry</i> , 2010 , 15, 122-37	15.1	115
1038	DISC1 regulates cell-cell adhesion, cell-matrix adhesion and neurite outgrowth. <i>Molecular Psychiatry</i> , 2010 , 15, 778, 798-809	15.1	40
1037	Dysbindin-1, WAVE2 and Abi-1 form a complex that regulates dendritic spine formation. <i>Molecular Psychiatry</i> , 2010 , 15, 976-86	15.1	73
1036	From maps to mechanisms through neuroimaging of schizophrenia. 2010 , 468, 194-202		238
1035	Genetics as a tool for the dissociation of mental operations over the course of development. 2010 , 1191, 110-32		
1034	Reflections on the Relationship Between Psychiatric Genetics and Psychiatric Nosology. 2010 , 8, 449-458		
1033	Dopamine and the Electrophysiology of Prefrontal Cortical Networks. 2010 , 145-157		
1032	. 2010 ,		12
1031	The genetics of latent inhibition: studies of inbred and mutant mice. 225-251		1
1030	Predictably irrational: assaying cognitive inflexibility in mouse models of schizophrenia. 2010 , 4,		32
1029	Genetically determined measures of striatal D2 signaling predict prefrontal activity during working memory performance. 2010 , 5, e9348		71

1028	Expression of the Rap1 guanine nucleotide exchange factor, MR-GEF, is altered in individuals with bipolar disorder. 2010 , 5, e10392		4
1027	Epistatic and functional interactions of catechol-o-methyltransferase (COMT) and AKT1 on neuregulin1-ErbB signaling in cell models. 2010 , 5, e10789		16
1026	Impact of the AHI1 gene on the vulnerability to schizophrenia: a case-control association study. 2010 , 5, e12254		17
1025	Decreased Serum Hepatocyte Growth Factor (HGF) in Individuals with Schizophrenia Normalizes after Zinc and B-6 Therapy. 2010 , 3, P1.S6145		
1024	Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. 2010 , 36, 246-70		257
1023	Constitutive genetic deletion of the growth regulator Nogo-A induces schizophrenia-related endophenotypes. <i>Journal of Neuroscience</i> , 2010 , 30, 556-67	6.6	46
1022	Reduced laterality as a trait marker of schizophrenia--evidence from structural and functional neuroimaging. <i>Journal of Neuroscience</i> , 2010 , 30, 2289-99	6.6	102
1021	Nucleocytoplasmic shuttling of dysbindin-1, a schizophrenia-related protein, regulates synapsin I expression. 2010 , 285, 38630-40		18
1020	Computational modeling of synaptic neurotransmission as a tool for assessing dopamine hypotheses of schizophrenia. 2010 , 43 Suppl 1, S50-60		21
1019	Intermediate or brainless phenotypes for psychiatric research?. 2010 , 40, 1057-62		31
1018	Neuropsychiatry [Subject, Concepts, Methods, and Computational Models. 2010 , 27-80		1
1017	Catechol-O-methyltransferase Val 158 Met polymorphism and antisaccade eye movements in schizophrenia. 2010 , 36, 157-64		29
1016	Dysbindin gene (DTNBP1) in major depressive disorder (MDD) patients: lack of association with clinical phenotypes. 2010 , 11, 985-90		3
1015	Spontaneous seizures and altered gene expression in GABA signaling pathways in a mind bomb mutant zebrafish. <i>Journal of Neuroscience</i> , 2010 , 30, 13718-28	6.6	68
1014	De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia. 2010 , 107, 7863-8		298
1013	RNA-binding protein HuR regulates RGS4 mRNA stability in rabbit colonic smooth muscle cells. 2010 , 299, C1418-29		17
1012	Selection of reference gene expression in a schizophrenia brain cohort. 2010 , 44, 59-70		89
1011	ErbB4 in parvalbumin-positive interneurons is critical for neuregulin 1 regulation of long-term potentiation. 2010 , 107, 21818-23		179

1010	Disrupted-in-Schizophrenia-1 expression is regulated by beta-site amyloid precursor protein cleaving enzyme-1-neuregulin cascade. 2010 , 107, 5622-7		85
1009	Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. 2010 , 67, 578-88		338
1008	Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia. 2010 , 36, 271-88		57
1007	Gene expression of neuregulin-1 isoforms in different brain regions of elderly schizophrenia patients. 2010 , 11, 243-50		37
1006	Sensorimotor gating of schizophrenia patients depends on Catechol O-methyltransferase Val158Met polymorphism. 2010 , 36, 341-6		51
1005	Evidence for maternal-fetal genotype incompatibility as a risk factor for schizophrenia. 2010 , 2010, 576318		7
1004	Expressions of neuregulin 1beta and ErbB4 in prefrontal cortex and hippocampus of a rat schizophrenia model induced by chronic MK-801 administration. 2010 , 2010, 859516		15
1003	Fibroblast growth factors in schizophrenia. 2010 , 36, 1157-66		50
1002	Models of neurodevelopmental abnormalities in schizophrenia. 2010 , 4, 435-81		51
1001	Targeting alpha7 nicotinic acetylcholine receptors in the treatment of schizophrenia. 2010 , 16, 538-54		63
1000	More is less: a disinhibited prefrontal cortex impairs cognitive flexibility. <i>Journal of Neuroscience</i> , 2010 , 30, 17102-10	6.6	124
999	Acute effects of delta9-tetrahydrocannabinol on the auditory evoked mismatch negativity are modulated by the NRG1 gene. 2010 , 43, 194-5		10
998	Thalamic dysfunction in schizophrenia suggested by whole-night deficits in slow and fast spindles. 2010 , 167, 1339-48		218
997	Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. 2010 , 167, 261-80		887
996	A two-stage case-control association study of the dihydropyrimidinase-like 2 gene (DPYSL2) with schizophrenia in Japanese subjects. 2010 , 55, 469-72		17
995	Midbrain activation during Pavlovian conditioning and delusional symptoms in schizophrenia. 2010 , 67, 1246-54		84
994	Candidate gene studies in the GWAS era: the MET proto-oncogene, neurocognition, and schizophrenia. 2010 , 167, 369-72		8
993	The role of genetics in the etiology of schizophrenia. 2010 , 33, 35-66		157

992	The effect of G72 genotype on neural correlates of memory encoding and retrieval. 2010 , 53, 1001-6		6
991	Functional and dysfunctional synaptic plasticity in prefrontal cortex: roles in psychiatric disorders. 2010 , 67, 199-207		224
990	Catechol-o-methyltransferase valine(158)methionine genotype and resting regional cerebral blood flow in medication-free patients with schizophrenia. 2010 , 67, 287-90		19
989	Replication of association between working memory and Reelin, a potential modifier gene in schizophrenia. 2010 , 67, 983-91		47
988	Maternal influenza infection during pregnancy impacts postnatal brain development in the rhesus monkey. 2010 , 67, 965-73		128
987	Changes in the frontotemporal cortex and cognitive correlates in first-episode psychosis. 2010 , 68, 51-60		61
986	The potential role of major histocompatibility complex class I in schizophrenia. 2010 , 68, e29-30; author reply e31		4
985	A reappraisal of the association between Dysbindin (DTNBP1) and schizophrenia in a large combined case-control and family-based sample of German ancestry. <i>Schizophrenia Research</i> , 2010 , 118, 98-105	3.6	15
984	Progressive lateral ventricular enlargement in schizophrenia: a meta-analysis of longitudinal MRI studies. <i>Schizophrenia Research</i> , 2010 , 120, 54-62	3.6	157
983	Association of NPAS3 exonic variation with schizophrenia. <i>Schizophrenia Research</i> , 2010 , 120, 143-9	3.6	37
982	Neural markers of remission in first-episode schizophrenia: a volumetric neuroimaging study of the hippocampus and amygdala. <i>Schizophrenia Research</i> , 2010 , 122, 72-80	3.6	26
981	Gene-wide association study between the methylenetetrahydrofolate reductase gene (MTHFR) and schizophrenia in the Japanese population, with an updated meta-analysis on currently available data. <i>Schizophrenia Research</i> , 2010 , 124, 216-22	3.6	26
980	Identifying gene regulatory networks in schizophrenia. 2010 , 53, 839-47		88
979	Disrupted-in-schizophrenia 1 (DISC1) plays essential roles in mitochondria in collaboration with Mitofilin. 2010 , 107, 17785-90		115
978	Schizophrenia. 2010 , 188-195		1
977	Developmental regulation and individual differences of neuronal H3K4me3 epigenomes in the prefrontal cortex. 2010 , 107, 8824-9		183
976	Cortical neurons from intrauterine growth retardation rats exhibit lower response to neurotrophin BDNF. 2010 , 476, 104-9		20
975	Cloning and characterization of rabbit Rgs4 promoter in gut smooth muscle. 2010 , 451, 45-53		7

974	Disturbed synaptic connectivity in schizophrenia: convergence of genetic risk factors during neurodevelopment. 2010 , 83, 140-6		40
973	Neuregulin 1-erbB4 pathway in schizophrenia: From genes to an interactome. 2010 , 83, 132-9		65
972	The neuregulin signaling pathway and schizophrenia: from genes to synapses and neural circuits. 2010 , 83, 122-31		127
971	Combined effect of neonatal immune activation and mutant DISC1 on phenotypic changes in adulthood. 2010 , 206, 32-7		115
970	Epidemiology-driven neurodevelopmental animal models of schizophrenia. 2010 , 90, 285-326		288
969	Influence of the NR3A subunit on NMDA receptor functions. 2010 , 91, 23-37		116
968	Reelin-mediated signaling in neuropsychiatric and neurodegenerative diseases. 2010 , 91, 257-74		64
967	Preliminary evidence that polymorphisms in dopamine-related transcription factors LMX1A, LMX1B and PITX3 are associated with schizophrenia. 2010 , 34, 1094-7		15
966	An exploratory model for G x E interaction on hippocampal volume in schizophrenia; obstetric complications and hypoxia-related genes. 2010 , 34, 1259-65		31
965	Knockdown of DISC1 by in utero gene transfer disturbs postnatal dopaminergic maturation in the frontal cortex and leads to adult behavioral deficits. 2010 , 65, 480-9		233
964	Association study of catechol-O-methyltransferase (COMT) gene Val158Met polymorphism with auditory P300 in Chinese Han patients with schizophrenia. 2010 , 180, 153-5		14
963	Interaction of catechol-O-methyltransferase (COMT) Val108/158 Met genotype and risperidone treatment in Chinese Han patients with schizophrenia. 2010 , 176, 94-5		11
962	MicroRNA expression profiling in the prefrontal cortex of individuals affected with schizophrenia and bipolar disorders. <i>Schizophrenia Research</i> , 2010 , 124, 183-91	3.6	225
961	A genetic variation in the dysbindin gene (DTNBP1) is associated with memory performance in healthy controls. 2010 , 11, 431-438		18
960	P.3.f.005 Different forms of risperidone and haloperidol in sexual dysfunction among schizophrenic male patients. 2010 , 20, S515-S516		
959	P.3.f.006 Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviours in mice. 2010 , 20, S516		
958	Dysbindin modulates brain function during visual processing in children. 2010 , 49, 817-22		12
957	A pilot multivariate parallel ICA study to investigate differential linkage between neural networks and genetic profiles in schizophrenia. 2010 , 53, 1007-15		47

956	MicroRNAs and target site screening reveals a pre-microRNA-30e variant associated with schizophrenia. <i>Schizophrenia Research</i> , 2010 , 119, 219-27	3.6	76
955	Mistreating Psychology in the Decades of the Brain. 2010 , 5, 716-43		173
954	Handbook of Genomics and the Family. 2010 ,		4
953	Serotonin and Schizophrenia. 2010 , 21, 585-620		11
952	Quality Issues in Clinical Genetic Services. 2010 ,		6
951	Hippocampal pathology in schizophrenia. 2010 , 4, 529-53		131
950	Behavioral Neurobiology of Schizophrenia and Its Treatment. 2010 ,		6
949	Haloperidol promotes proliferation but inhibits differentiation in rat oligodendrocyte progenitor cell cultures. 2010 , 88, 611-20		30
948	Orientation and cellular distribution of membrane-bound catechol-O-methyltransferase in cortical neurons: implications for drug development. 2011 , 286, 34752-60		56
947	DISC1 in schizophrenia: genetic mouse models and human genomic imaging. 2011 , 37, 14-20		77
946	Schizophrenia susceptibility gene dysbindin regulates glutamatergic and dopaminergic functions via distinctive mechanisms in Drosophila. 2011 , 108, 18831-6		36
945	Plasticidad sináptica funcional y disfuncional en la corteza prefrontal: papel en los trastornos psiquiátricos. 2011 , 18, 18-27		1
944	Systematic resequencing of X-chromosome synaptic genes in autism spectrum disorder and schizophrenia. <i>Molecular Psychiatry</i> , 2011 , 16, 867-80	15.1	211
943	The neuroproteomics of schizophrenia. 2011 , 69, 163-72		109
942	Analyzing schizophrenia by DNA microarrays. 2011 , 69, 157-62		54
941	Lack of change in markers of presynaptic terminal abundance alongside subtle reductions in markers of presynaptic terminal plasticity in prefrontal cortex of schizophrenia patients. 2011 , 69, 71-9		38
940	Activation of thalamocortical networks by the N-methyl-D-aspartate receptor antagonist phencyclidine: reversal by clozapine. 2011 , 69, 918-27		60
939	Interactive effects of DAOA (G72) and catechol-O-methyltransferase on neurophysiology in prefrontal cortex. 2011 , 69, 1006-8		29

938	Genetic neuropathology of schizophrenia: new approaches to an old question and new uses for postmortem human brains. 2011 , 69, 140-5		72
937	Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies. 2011 , 70, 88-96		366
936	Convergence of two independent mental disease genes on the protein level: recruitment of dysbindin to cell-invasive disrupted-in-schizophrenia 1 aggresomes. 2011 , 70, 604-10		51
935	Abnormal trajectories of neurodevelopment and behavior following in utero insult in the rat. 2011 , 70, 842-51		113
934	Loss of function studies in mice and genetic association link receptor protein tyrosine phosphatase Rho to schizophrenia. 2011 , 70, 626-35		17
933	ErbB4 localization to interneurons: clearer insights into schizophrenia pathology. 2011 , 70, 602-3		4
932	Gestational MAM (Methylazoxymethanol) Administration: A Promising Animal Model for Psychosis Onset. 2011 , 25-77		1
931	The Developmental Vitamin D (DVD) Model of Schizophrenia. 2011 , 113-125		6
930	Sensory gating deficit is associated with catechol-O-methyltransferase polymorphisms in bipolar disorder. 2011 , 12, 376-84		10
929	Neurodevelopmental Origins of Schizophrenia. 2011 , 393-412		16
928	NOS1 ex1f-VNTR polymorphism influences prefrontal brain oxygenation during a working memory task. 2011 , 57, 1617-23		18
927	Model-based dynamical analysis of functional disconnection in schizophrenia. 2011 , 58, 870-7		33
926	Increased schedule-induced polydipsia in the rat following subchronic treatment with MK-801. <i>Schizophrenia Research</i> , 2011 , 125, 93-8	3.6	19
925	Are cavum septum pellucidum abnormalities more common in schizophrenia spectrum disorders? A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2011 , 125, 1-12	3.6	63
924	Neuroanatomical abnormalities in schizophrenia: a multimodal voxelwise meta-analysis and meta-regression analysis. <i>Schizophrenia Research</i> , 2011 , 127, 46-57	3.6	339
923	Density of metabotropic glutamate receptors 2 and 3 (mGluR2/3) in the dorsolateral prefrontal cortex does not differ with schizophrenia diagnosis but decreases with age. <i>Schizophrenia Research</i> , 2011 , 128, 56-60	3.6	22
922	Lack of association to a NRG1 missense polymorphism in schizophrenia or bipolar disorder in a Costa Rican population. <i>Schizophrenia Research</i> , 2011 , 131, 52-7	3.6	18
921	Pathways to psychosis: help-seeking behavior in the prodromal phase. <i>Schizophrenia Research</i> , 2011 , 132, 213-9	3.6	44

920	Association of an UCP4 (SLC25A27) haplotype with ultra-resistant schizophrenia. 2011 , 12, 185-93	14
919	15 Prenatal infections and long-term mental outcome: Modeling schizophrenia-related dysfunctions using the prenatal PolyI:C model in mice. 2011 ,	
918	The Human Condition. 2011 ,	9
917	Cerebral asymmetry in schizophrenia. 2011 , 17, 456-67	83
916	Ras and Rap signaling in synaptic plasticity and mental disorders. 2011 , 17, 54-78	102
915	The Dopamine Hypothesis of Schizophrenia: An Historical and Philosophical Analysis. 2011 , 18, 41-63	46
914	Animal Models of Schizophrenia and Related Disorders. 2011 ,	1
913	Is schizophrenia developmental adaptation to environmental menaces?. 2011 , 77, 756-62	
912	Association between a cannabinoid receptor gene (CNR1) polymorphism and cannabinoid-induced alterations of the auditory event-related P300 potential. 2011 , 496, 60-4	30
911	Altered MHC class I expression in dorsolateral prefrontal cortex of nonsmoker patients with schizophrenia. 2011 , 71, 289-93	31
910	Developmental history of the subplate zone, subplate neurons and interstitial white matter neurons: relevance for schizophrenia. 2011 , 29, 193-205	81
909	Synaptic changes in the brain of subjects with schizophrenia. 2011 , 29, 305-9	99
908	D-amino acid oxidase knockdown in the mouse cerebellum reduces NR2A mRNA. 2011 , 46, 167-75	15
907	Updating hippocampal representations: CA2 joins the circuit. 2011 , 34, 526-35	95
906	Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia. 2011 , 93, 13-24	194
905	Neuroimaging and the question of neurodegeneration in schizophrenia. 2011 , 95, 514-6	34
904	Schizophrenia: susceptibility genes, dendritic-spine pathology and gray matter loss. 2011 , 95, 275-300	85
903	Alterations in the expression of neuronal chloride transporters may contribute to schizophrenia. 2011 , 35, 410-4	20

902	Antipsychotic treatment and neuregulin 1-ErbB4 signalling in schizophrenia. 2011 , 35, 924-30	29
901	Interaction between FEZ1 and DISC1 in regulation of neuronal development and risk for schizophrenia. 2011 , 72, 559-71	77
900	Functional reduction of SK3-mediated currents precedes AMPA-receptor-mediated excitotoxicity in dopaminergic neurons. 2011 , 60, 1176-86	17
899	Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence. 2011 , 191, 78-90	101
898	Behavioral analysis of NR2C knockout mouse reveals deficit in acquisition of conditioned fear and working memory. 2011 , 95, 404-14	62
897	Vitamin D in fetal brain development. 2011 , 22, 629-36	79
896	[Schizophrenia, genetics and cognition]. 2011 , 37 Suppl 2, S127-32	1
895	Dysfunctional brain networks and genetic risk for schizophrenia: specific neurotransmitter systems. 2011 , 17, 89-96	24
894	Further Thoughts on the Dopamine Hypothesis of Schizophrenia. 2011 , 18, 73-75	2
893	The role of the cerebellum in schizophrenia: from cognition to molecular pathways. 2011 , 66 Suppl 1, 71-7	68
892	. 2011 ,	6
891	Postmortem studies of the brain cannabinoid system in schizophrenia. 184-192	
890	Challenges of analysing gene-environment interactions in mouse models of schizophrenia. 2011 , 11, 1411-20	16
889	Hodological resonance, hodological variance, psychosis, and schizophrenia: a hypothetical model. <i>Frontiers in Psychiatry</i> , 2011 , 2, 46	5
888	GSK-3: Functional Insights from Cell Biology and Animal Models. 2011 , 4, 40	313
887	Proton magnetic resonance spectroscopy in 22q11 deletion syndrome. 2011 , 6, e21685	26
886	Risk profiles of Alzheimer disease. 2011 , 38, 580-92	15
885	Neuropathology of Schizophrenia. 2011 , 372-392	4

884	Pathophysiology of Schizophrenia. 2011 , 31-65		8
883	Genetic animal models of schizophrenia related with the hypothesis of abnormal neurodevelopment. 2011 , 34, 1358-63		18
882	Pharmacogenomics of antipsychotics efficacy for schizophrenia. 2011 , 65, 3-19		26
881	Connectivity between mitochondrial functions and psychiatric disorders. 2011 , 65, 130-41		35
880	Animal models of schizophrenia. 2011 , 164, 1162-94		487
879	Effects of DTNBP1 genotype on brain development in children. 2011 , 52, 1287-94		15
878	Polymorphisms associated with normal memory variation also affect memory impairment in schizophrenia. <i>Genes, Brain and Behavior</i> , 2011 , 10, 410-7	3.6	35
877	A Src link in schizophrenia. 2011 , 17, 425-7		14
876	Variants of the RELA gene are associated with schizophrenia and their startle responses. 2011 , 36, 1921-31		34
875	Differential effects of prenatal and postnatal expressions of mutant human DISC1 on neurobehavioral phenotypes in transgenic mice: evidence for neurodevelopmental origin of major psychiatric disorders. <i>Molecular Psychiatry</i> , 2011 , 16, 293-306	15.1	128
874	Common functional polymorphisms of DISC1 and cortical maturation in typically developing children and adolescents. <i>Molecular Psychiatry</i> , 2011 , 16, 917-26	15.1	38
873	Catechol-O-methyltransferase gene Val108/158Met polymorphism in bipolar disorder. 2011 , 17, 46-50		1
872	Mean diffusivity and fractional anisotropy as indicators of disease and genetic liability to schizophrenia. 2011 , 45, 980-8		91
871	Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. 2011 , 132, 96-110		185
870	Strain dependent effects of prenatal stress on gene expression in the rat hippocampus. 2011 , 104, 334-9		39
869	Schizophrenia risk genes: Implications for future drug development and discovery. 2011 , 81, 1367-73		19
868	The chimeric gene CHRFA7A, a partial duplication of the CHR7A7 gene, is a dominant negative regulator of $\alpha 7$ nAChR function. 2011 , 82, 904-14		87
867	Schizophrenia and autism: both shared and disorder-specific pathogenesis via perinatal inflammation?. 2011 , 69, 26R-33R		254

866	Genetics of schizophrenia: new findings and challenges. 2011 , 12, 121-44	136
865	Progressive pathology is functionally linked to the domains of language and emotion: meta-analysis of brain structure changes in schizophrenia patients. 2011 , 261 Suppl 2, S166-71	32
864	Disease-relevant autoantibodies in first episode schizophrenia. 2011 , 258, 686-8	236
863	Neurocognitive-genetic and neuroimaging-genetic research paradigms in schizophrenia and bipolar disorder. 2011 , 118, 1621-39	22
862	Effects of chronic oral treatment with aripiprazole on the expression of NMDA receptor subunits and binding sites in rat brain. 2011 , 217, 127-42	18
861	Association of the Met-196-Arg variation of human tumor necrosis factor receptor 2 (TNFR2) with paranoid schizophrenia. 2011 , 43, 358-63	10
860	Consortium for the Human Information and Neurocognitive Endophenotype (CHINE) in mainland China: An example from neurological soft signs for neuropsychiatric disorders. 2011 , 56, 3409-3415	5
859	Recent developments in neuropsychological endophenotypes for schizophrenia: Development of the MATRICS battery, liability syndromes and the near future. 2011 , 56, 3385-3393	0
858	Synaptic Wnt signaling-a contributor to major psychiatric disorders?. 2011 , 3, 162-74	97
857	Evidence for association between Disrupted-in-Schizophrenia 1 (DISC1) gene polymorphisms and autism in Chinese Han population: a family-based association study. 2011 , 7, 14	27
856	Mitochondria in the striatum of subjects with schizophrenia: relationship to treatment response. 2011 , 65, 215-24	23
855	Genetic and pharmacological evidence for schizophrenia-related Disc1 interaction with GSK-3. 2011 , 65, 234-48	74
854	Differential developmental trajectories for CB1 cannabinoid receptor expression in limbic/associative and sensorimotor cortical areas. 2011 , 65, 278-86	109
853	Positive association of phencyclidine-responsive genes, PDE4A and PLAT, with schizophrenia. 2011 , 156B, 850-8	14
852	Genetic and neural dissociation of individual responses to emotional expressions in human infants. 2011 , 1, 57-66	67
851	Oxidative stress in schizophrenia: an integrated approach. <i>Neuroscience and Biobehavioral Reviews</i> , 2011 , 35, 878-93	9 304
850	Cannabis use in young people: the risk for schizophrenia. <i>Neuroscience and Biobehavioral Reviews</i> , 2011 , 35, 1779-87	9 122
849	Disrupted activity in the hippocampal-accumbens circuit of type III neuregulin 1 mutant mice. 2011 , 36, 488-96	22

848	Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. 2011 , 168, 930-46		201
847	From [classical]antipsychotics to [multidimensional stabilizers]do we need a new classification for novel drugs used in schizophrenia?. 2011 , 1, 541-552		1
846	Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders. 2012 , 12, 251-318		86
845	Genetic association studies of antioxidant pathway genes and schizophrenia. 2011 , 15, 2037-45		33
844	Prediction and prevention of schizophrenia: what has been achieved and where to go next?. 2011 , 10, 165-74		73
843	Effect of antipsychotics on spontaneous hyperactivity and hypersensitivity to MK-801-induced hyperactivity in rats prenatally exposed to methylazoxymethanol. 2011 , 25, 822-35		17
842	Common proteomic changes in the hippocampus in schizophrenia and bipolar disorder and particular evidence for involvement of cornu ammonis regions 2 and 3. 2011 , 68, 477-88		83
841	Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia?. 2011 , 1, 5-18		43
840	Translating glutamate: from pathophysiology to treatment. 2011 , 3, 102mr2		127
839	Specific regulation of NRG1 isoform expression by neuronal activity. <i>Journal of Neuroscience</i> , 2011 , 31, 8491-501	6.6	111
838	Effect of isolation rearing on the expression of AMPA glutamate receptors in the hippocampal formation. 2011 , 25, 1720-9		13
837	Convergent genomic studies identify association of GRIK2 and NPAS2 with chronic fatigue syndrome. 2011 , 64, 183-94		43
836	Expression of GABA signaling molecules KCC2, NKCC1, and GAD1 in cortical development and schizophrenia. <i>Journal of Neuroscience</i> , 2011 , 31, 11088-95	6.6	228
835	Cellular reprogramming: recent advances in modeling neurological diseases. <i>Journal of Neuroscience</i> , 2011 , 31, 16070-5	6.6	18
834	Progress in defining the biological causes of schizophrenia. 2011 , 13, e25		22
833	Age of onset of schizophrenia: perspectives from structural neuroimaging studies. 2011 , 37, 504-13		181
832	Behavioral alterations associated with targeted disruption of exons 2 and 3 of the Disc1 gene in the mouse. 2011 , 20, 4666-83		116
831	Do COMT, BDNF and NRG1 polymorphisms influence P50 sensory gating in psychosis?. 2011 , 41, 263-76		30

830	Executive functioning-related brain abnormalities associated with the genetic liability for schizophrenia: an activation likelihood estimation meta-analysis. 2011 , 41, 1239-52		26
829	Disrupted-in-Schizophrenia-1 (Disc1) is necessary for migration of the pyramidal neurons during mouse hippocampal development. 2011 , 20, 2834-45		49
828	Abnormalities in connectivity of white-matter tracts in patients with familial and non-familial schizophrenia. 2011 , 41, 1691-700		33
827	Posttranslational Histone Modifications and the Neurobiology of Psychosis. 2011 , 1-21		
826	Transcriptional repression of the α 7 nicotinic acetylcholine receptor subunit gene (CHRNA7) by activating protein-2 (AP-2). 2011 , 286, 42123-42132		13
825	D2 receptor overexpression in the striatum leads to a deficit in inhibitory transmission and dopamine sensitivity in mouse prefrontal cortex. 2011 , 108, 12107-12		59
824	Dysbindin-1 mutant mice implicate reduced fast-phasic inhibition as a final common disease mechanism in schizophrenia. 2011 , 108, E962-70		83
823	Effects of a CACNA1C genotype on attention networks in healthy individuals. 2011 , 41, 1551-61		82
822	Mitochondria in the striatum of subjects with schizophrenia. 2011 , 12, 48-56		22
821	Increased expression of receptor phosphotyrosine phosphatase- β is associated with molecular, cellular, behavioral and cognitive schizophrenia phenotypes. <i>Translational Psychiatry</i> , 2011 , 1, e8	8.6	31
820	Vitamin D. 2011 , 565-582		4
819	A brief review on recent developments in animal models of schizophrenia. 2011 , 43, 375-80		6
818	Study of OH radicals in human serum blood of healthy individuals and those with pathological schizophrenia. <i>International Journal of Molecular Sciences</i> , 2011 , 12, 401-10	6.3	37
817	"Attenuated psychotic symptoms syndrome" as a risk syndrome of psychosis, diagnosis in DSM-V: The debate. 2011 , 53, 57-65		18
816	Astrocyte and glutamate markers in the superficial, deep, and white matter layers of the anterior cingulate gyrus in schizophrenia. 2011 , 36, 1171-7		68
815	Presynaptic regulation of dopamine transmission in schizophrenia. 2011 , 37, 108-17		47
814	Glutamatergic synapse formation is promoted by α -containing nicotinic acetylcholine receptors. <i>Journal of Neuroscience</i> , 2012 , 32, 7651-61	6.6	106
813	NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia. 2012 , 38, 950-7		319

812	Schizophrenia-related RGS4 gene variations specifically disrupt prefrontal control of saccadic eye movements. 2012 , 42, 757-67		18
811	The DISC1 promoter: characterization and regulation by FOXP2. 2012 , 21, 2862-72		37
810	Multiple genes in the 15q13-q14 chromosomal region are associated with schizophrenia. 2012 , 22, 1-14		26
809	The catechol-O-methyltransferase Val(158)Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson's disease: a PET study. 2012 , 135, 2449-57		52
808	Aggregated proteins in schizophrenia and other chronic mental diseases: DISC1opathies. 2012 , 6, 134-41		39
807	Emerging methods in the molecular biology of neuropsychiatric disorders. 2012 , 106, 191-209		1
806	Functional gene group analysis identifies synaptic gene groups as risk factor for schizophrenia. <i>Molecular Psychiatry</i> , 2012 , 17, 996-1006	15.1	123
805	Epistatic interactions of AKT1 on human medial temporal lobe biology and pharmacogenetic implications. <i>Molecular Psychiatry</i> , 2012 , 17, 1007-16	15.1	34
804	Neuregulin directly decreases voltage-gated sodium current in hippocampal ErbB4-expressing interneurons. <i>Journal of Neuroscience</i> , 2012 , 32, 13889-95	6.6	22
803	Tau's role in the developing brain: implications for intellectual disability. 2012 , 21, 1681-92		59
802	Impairment in functional capacity as an endophenotype candidate in severe mental illness. 2012 , 38, 1318-26		20
801	Motor symptoms and schizophrenia. 2012 , 66, 77-92		203
800	Beyond dopamine: glutamate as a target for future antipsychotics. 2012 , 2012, 427267		22
799	The gene encoding the melanin-concentrating hormone receptor 1 is associated with schizophrenia in a Danish case-control sample. 2012 , 22, 62-9		10
798	Genetic associations between neuregulin-1 SNPs and neurocognitive function in multigenerational, multiplex schizophrenia families. 2012 , 22, 70-81		19
797	Neurophysiological effects of cannabinoids: implications for psychosis research. 2012 , 18, 4938-49		17
796	Genetic vulnerability to psychosis and cortical function: epistatic effects between DAAO and G72. 2012 , 18, 510-7		9
795	Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1). 2013 , 19, 1311-20		26

794	Disordered corticolimbic interactions during affective processing in children and adolescents at risk for schizophrenia revealed by functional magnetic resonance imaging and dynamic causal modeling. 2012 , 69, 231-42		54
793	The wnt pathway in mood disorders. 2012 , 10, 239-53		36
792	Innovative treatment approaches in schizophrenia enhancing neuroplasticity: aerobic exercise, erythropoetin and repetitive transcranial magnetic stimulation. 2012 , 13, 1595-605		12
791	Neuroimaging correlates of 22q11.2 deletion syndrome: implications for schizophrenia research. 2012 , 12, 2303-13		13
790	Clozapine induction of ERK1/2 cell signalling via the EGF receptor in mouse prefrontal cortex and striatum is distinct from other antipsychotic drugs. 2012 , 15, 1149-60		21
789	Adolescent risk pathways toward schizophrenia: sustained attention and the brain. 2012 , 12, 2339-47		6
788	The glutamate hypothesis of schizophrenia: neuroimaging and drug development. 2012 , 13, 1500-12		43
787	Exocytotic Machinery as a Target for the Development of New Drugs for Schizophrenia. 2012 , 375-408		
786	An environmental analysis of genes associated with schizophrenia: hypoxia and vascular factors as interacting elements in the neurodevelopmental model. <i>Molecular Psychiatry</i> , 2012 , 17, 1194-205	15.1	73
785	Chronic adolescent exposure to delta-9-tetrahydrocannabinol in COMT mutant mice: impact on indices of dopaminergic, endocannabinoid and GABAergic pathways. 2012 , 37, 1773-83		50
784	From antipsychotic to anti-schizophrenia drugs: role of animal models. 2012 , 33, 515-21		28
783	Early trauma and familial risk in the development of the extended psychosis phenotype in adolescence. 2012 , 126, 266-73		44
782	Behavioral animal models of antipsychotic drug actions. 2012 , 361-406		26
781	Genetics of schizophrenia from a clinical perspective. 2012 , 24, 393-404		9
780	Effects of cognitive remediation on neurocognitive functions and psychiatric symptoms in schizophrenia inpatients. <i>Schizophrenia Research</i> , 2012 , 142, 165-70	3.6	22
779	Interhemispheric hypoconnectivity in schizophrenia: fiber integrity and volume differences of the corpus callosum in patients and unaffected relatives. 2012 , 59, 926-34		88
778	La recherche en psychiatrie. 2012 , 31-85		
777	The Long and the Short of it: Gene and Environment Interactions During Early Cortical Development and Consequences for Long-Term Neurological Disease. <i>Frontiers in Psychiatry</i> , 2012 , 3, 50	5	37

776	Evaluating the links between schizophrenia and sleep and circadian rhythm disruption. 2012 , 119, 1061-75	76
775	Substantial genetic overlap between schizotypy and neuroticism: a twin study. 2012 , 42, 732-42	34
774	Mapping prodromal psychosis: a critical review of neuroimaging studies. 2012 , 27, 181-91	58
773	A window into the brain: an in vivo study of the retina in schizophrenia using optical coherence tomography. 2012 , 203, 89-94	81
772	Hippocampal volume reduction in chromosome 22q11.2 deletion syndrome (22q11.2DS): a longitudinal study of morphometry and symptomatology. 2012 , 203, 1-5	19
771	Abnormal functional motor lateralization in healthy siblings of patients with schizophrenia. 2012 , 203, 54-60	10
770	The cerebellum and neuropsychiatric disorders. 2012 , 198, 527-32	51
769	Patterns of deficits in brain function in bipolar disorder and schizophrenia: a cluster analytic study. 2012 , 200, 272-80	24
768	Exploring the relationships between tobacco smoking and schizophrenia in first-degree relatives. 2012 , 200, 674-8	12
767	Dysequilibrium of neuronal proliferation and apoptosis in a pharmacological animal model of psychosis. 2012 , 56, 519-27	10
766	Biochemical fractionation and stable isotope dilution liquid chromatography-mass spectrometry for targeted and microdomain-specific protein quantification in human postmortem brain tissue. 2012 , 11, 1670-81	29
765	DNA methylation in schizophrenia: progress and challenges of epigenetic studies. 2012 , 4, 96	59
764	TCF4 sequence variants and mRNA levels are associated with neurodevelopmental characteristics in psychotic disorders. <i>Translational Psychiatry</i> , 2012 , 2, e112	8.6 51
763	COMT haplotype analyses in Malaysians with schizophrenia. 2012 , 195, 83-4	4
762	Estrogens and memory in physiological and neuropathological conditions. 2012 , 37, 1379-96	60
761	Use-dependent inhibition of synaptic transmission by the secretion of intravesicularly accumulated antipsychotic drugs. 2012 , 74, 830-44	41
760	To poly(I:C) or not to poly(I:C): advancing preclinical schizophrenia research through the use of prenatal immune activation models. 2012 , 62, 1308-21	178
759	Contributions of the D-serine pathway to schizophrenia. 2012 , 62, 1484-503	90

758	Synergistic interactions between PDE4B and GSK-3: DISC1 mutant mice. 2012 , 62, 1252-62	72
757	Tracing the development of psychosis and its prevention: what can be learned from animal models. 2012 , 62, 1273-89	89
756	Mouse models of genetic effects on cognition: relevance to schizophrenia. 2012 , 62, 1204-20	91
755	Metabotropic glutamate receptors as therapeutic targets for schizophrenia. 2012 , 62, 1461-72	74
754	Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia. 2012 , 62, 1152-61	95
753	N-methyl-D-aspartate receptor 2B subunit (GRIN2B) gene variation is associated with alerting, but not with orienting and conflicting in the Attention Network Test. 2012 , 63, 259-65	6
752	Novel evidence of the involvement of calreticulin in major psychiatric disorders. 2012 , 37, 276-81	15
751	D-serine and schizophrenia: an update. 2012 , 12, 801-12	21
750	Hyperdopaminergic modulation of inhibitory transmission is dependent on GSK-3 β signaling-mediated trafficking of GABAA receptors. 2012 , 122, 308-20	18
749	Strong preferences of dopamine and l-dopa towards lipid head group: importance of lipid composition and implication for neurotransmitter metabolism. 2012 , 122, 681-90	43
748	Disruption of spine homeostasis causes dopaminergic compensatory up-regulation, resulting in schizophrenia. 2012 , 79, 304-7	1
747	Medial-frontal cortex hypometabolism in chronic phencyclidine exposed rats assessed by high resolution magic angle spin 11.7 T proton magnetic resonance spectroscopy. 2012 , 61, 128-31	13
746	A promoter variant in the chitinase 3-like 1 gene is associated with serum YKL-40 level and personality trait. 2012 , 513, 204-8	17
745	Mismatch negativity (MMN) reduction in schizophrenia-impaired prediction--error generation, estimation or salience?. 2012 , 83, 222-31	77
744	Error processing-associated event-related potentials in schizophrenia and unaffected siblings. 2012 , 84, 74-9	40
743	Reconstructing Models from Proteomics Data. 2012 , 23-80	
742	Modeling resilience to schizophrenia in genetically modified mice: a novel approach to drug discovery. 2012 , 12, 785-99	17
741	Sensitive periods in epigenetics: bringing us closer to complex behavioral phenotypes. 2012 , 4, 445-57	53

740	Modeling interneuron dysfunction in schizophrenia. 2012 , 34, 152-8		12
739	Long-term perturbation of spine plasticity results in distinct impairments of cognitive function. 2012 , 123, 781-9		10
738	Animal models of schizophrenia emphasizing construct validity. 2012 , 105, 411-44		10
737	Severe cross-modal object recognition deficits in rats treated sub-chronically with NMDA receptor antagonists are reversed by systemic nicotine: implications for abnormal multisensory integration in schizophrenia. 2012 , 37, 2322-31		32
736	CHAPTER 4:Glutamatergic Approaches for the Treatment of Schizophrenia. 2012 , 56-98		1
735	Impaired visual cortical plasticity in schizophrenia. 2012 , 71, 512-20		88
734	The impact of a Dysbindin schizophrenia susceptibility variant on fiber tract integrity in healthy individuals: a TBSS-based diffusion tensor imaging study. 2012 , 60, 847-53		25
733	Brain connectivity in psychiatric imaging genetics. 2012 , 62, 2250-60		52
732	Schizophrenia, neuroimaging and connectomics. 2012 , 62, 2296-314		503
731	The reduction of superoxide dismutase activity is associated with the severity of neurological soft signs in patients with schizophrenia. 2012 , 39, 52-6		12
730	Association between schizophrenia and genetic variation in DCC: a case-control study. <i>Schizophrenia Research</i> , 2012 , 137, 26-31	3.6	44
729	Cortical-basal ganglia imbalance in schizophrenia patients and unaffected first-degree relatives. <i>Schizophrenia Research</i> , 2012 , 138, 120-7	3.6	34
728	An odor-specific threshold deficit implicates abnormal cAMP signaling in youths at clinical risk for psychosis. <i>Schizophrenia Research</i> , 2012 , 138, 280-4	3.6	9
727	Association study of a new schizophrenia susceptibility locus of 10q24.32-33 in a Han Chinese population. <i>Schizophrenia Research</i> , 2012 , 138, 63-8	3.6	45
726	Longitudinal progression of frontal and temporal lobe changes in schizophrenia. <i>Schizophrenia Research</i> , 2012 , 139, 1-6	3.6	59
725	BDNF Val66Met and spontaneous dyskinesias in non-clinical psychosis. <i>Schizophrenia Research</i> , 2012 , 140, 65-70	3.6	13
724	Metabotropic glutamate receptors for new treatments in schizophrenia. 2012 , 297-365		30
723	Influence of DRD2 and ANKK1 polymorphisms on the manifestation of withdrawal syndrome symptoms in alcohol addiction. 2012 , 64, 1126-34		17

722	In utero electroporation as a tool for genetic manipulation in vivo to study psychiatric disorders: from genes to circuits and behaviors. 2012 , 18, 169-79		41
721	NMDA receptor hypofunction induces dysfunctions of energy metabolism and semaphorin signaling in rats: a synaptic proteome study. 2012 , 38, 579-91		22
720	Hypothesis review: are clathrin-mediated endocytosis and clathrin-dependent membrane and protein trafficking core pathophysiological processes in schizophrenia and bipolar disorder?. <i>Molecular Psychiatry</i> , 2012 , 17, 669-81	15.1	60
719	Current Antipsychotics. 2012 ,		5
718	Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features. 2012 , 12, 37		114
717	MEKK1-MKK4-JNK-AP1 pathway negatively regulates Rgs4 expression in colonic smooth muscle cells. 2012 , 7, e35646		14
716	The p250GAP gene is associated with risk for schizophrenia and schizotypal personality traits. 2012 , 7, e35696		17
715	Dopamine D4 receptor activation increases hippocampal gamma oscillations by enhancing synchronization of fast-spiking interneurons. 2012 , 7, e40906		46
714	Wiki-pi: a web-server of annotated human protein-protein interactions to aid in discovery of protein function. 2012 , 7, e49029		45
713	The effects of psychosis risk variants on brain connectivity: a review. <i>Frontiers in Psychiatry</i> , 2012 , 3, 18	5	11
712	Connectomic intermediate phenotypes for psychiatric disorders. <i>Frontiers in Psychiatry</i> , 2012 , 3, 32	5	77
711	Molecular Mechanisms in Synaptic Plasticity. 2012 ,		0
710	Cognitive remediation in schizophrenia. <i>Clinical Psychopharmacology and Neuroscience</i> , 2012 , 10, 125-35	3,4	30
709	The Unique Properties of the Prefrontal Cortex and Mental Illness. 2012 ,		6
708	Functional validation of candidate genetic susceptibility factors for major mental illnesses. 69-78		
707	Isochromosome 13 in a patient with childhood-onset schizophrenia, ADHD, and motor tic disorder. 2012 , 5, 2		4
706	Genetic Risk and Outcome of Psychosis (GROUP), a multi-site longitudinal cohort study focused on gene-environment interaction: objectives, sample characteristics, recruitment and assessment methods. 2012 , 21, 205-21		179
705	Synaptic underpinnings of altered hippocampal function in glutaminase-deficient mice during maturation. 2012 , 22, 1027-39		16

704	Association study of GRIK1 gene polymorphisms in schizophrenia: case-control and family-based studies. 2012 , 27, 345-51	12
703	Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110 inhibition as a potential therapeutic strategy. 2012 , 109, 12165-70	106
702	A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. <i>Molecular Psychiatry</i> , 2012 , 17, 389-401	15.1 347
701	Association study of interleukin-4 polymorphisms with paranoid schizophrenia in the Polish population: a critical approach. 2012 , 39, 7941-7	3
700	Application of reprogrammed patient cells to investigate the etiology of neurological and psychiatric disorders. 2012 , 7, 179-188	6
699	The effects of PRX-07034, a novel 5-HT ₆ antagonist, on cognitive flexibility and working memory in rats. 2012 , 220, 687-96	33
698	Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models. 2012 , 220, 647-72	82
697	Delayed preattentive functioning in early psychosis patients with cannabis use. 2012 , 222, 507-18	19
696	Association of PDE4B polymorphisms and schizophrenia in Northwestern Han Chinese. 2012 , 131, 1047-56	65
695	Deletion of PLCB1 gene in schizophrenia-affected patients. 2012 , 16, 844-51	52
694	The neural correlates of performance in adolescents at risk for schizophrenia: inefficiently increased cortico-striatal responses measured with fMRI. 2012 , 46, 12-21	26
693	Gene expression profiling of the brain: pondering facts and fiction. 2012 , 45, 3-7	12
692	Glutamate signaling in the pathophysiology and therapy of schizophrenia. 2012 , 100, 665-77	106
691	Cortical interneurons, immune factors and oxidative stress as early targets for schizophrenia. 2012 , 35, 1866-70	35
690	Akt1 deficiency in schizophrenia and impairment of hippocampal plasticity and function. 2012 , 22, 230-40	64
689	OPCML gene as a schizophrenia susceptibility locus in Thai population. 2012 , 46, 373-7	9
688	A preliminary investigation of the impact of catechol-O-methyltransferase genotype on the absorption and metabolism of green tea catechins. 2012 , 51, 47-55	24
687	A schizophrenia rat model induced by early postnatal phencyclidine treatment and characterized by Magnetic Resonance Imaging. 2013 , 250, 1-8	9

686	Combination of prenatal immune challenge and restraint stress affects prepulse inhibition and dopaminergic/GABAergic markers. 2013 , 45, 156-64		39
685	Impaired impulse control is associated with a 5-HT _{2A} receptor polymorphism in schizophrenia. 2013 , 208, 105-10		9
684	Schizophrenia susceptibility and NMDA-receptor mediated signalling: an association study involving 32 tagSNPs of DAO, DAOA, PPP3CC, and DTNBP1 genes. 2013 , 14, 33		20
683	Functional dysconnectivity in schizophrenia and its relationship to neural synchrony. 2013 , 13, 755-65		16
682	A neuregulin 1 transmembrane domain mutation causes imbalanced glutamatergic and dopaminergic receptor expression in mice. 2013 , 248, 670-80		30
681	Impaired motor cortex responses in non-psychotic first-degree relatives of schizophrenia patients: a cathodal tDCS pilot study. 2013 , 6, 821-9		21
680	Potential molecular mechanisms for decreased synaptic glutamate release in dysbindin-1 mutant mice. <i>Schizophrenia Research</i> , 2013 , 146, 254-63	3.6	24
679	In vivo 7 Tesla imaging of the dentate granule cell layer in schizophrenia. <i>Schizophrenia Research</i> , 2013 , 147, 362-7	3.6	26
678	Proteomic similarities between heterozygous reeler mice and schizophrenia. 2013 , 74, e5-e10		11
677	Analysis of miR-137 expression and rs1625579 in dorsolateral prefrontal cortex. 2013 , 47, 1215-21		101
676	Neuregulin 1- β regulates cell adhesion molecule L1 expression in the cortex and hippocampus of mice. 2013 , 441, 7-12		8
675	Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease. 2013 , 34, 47-64		408
674	Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. 2013 , 52, 976-90		149
673	Association between polymorphisms in the genes for tumor suppressor protein p53 and its regulator NAD(P)H: quinone oxidoreductase 1 (NQO1) and schizophrenia in a Syrian study cohort. 2013 , 44, 121-6		2
672	Mechanisms underlying cortical resonant states: implications for levodopa-induced dyskinesia. 2013 , 24, 415-29		12
671	Gene expression of glutamate transporters SLC1A1, SLC1A3 and SLC1A6 in the cerebellar subregions of elderly schizophrenia patients and effects of antipsychotic treatment. 2013 , 14, 490-9		12
670	Glutamate and glutamine: a review of in vivo MRS in the human brain. 2013 , 26, 1630-46		145
669	Association between psychotic symptoms and cortical thickness reduction across the schizophrenia spectrum. 2013 , 23, 61-70		57

668	Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder. <i>Schizophrenia Research</i> , 2013 , 145, 36-42	3.6	93
667	Altered asymmetry of the anterior cingulate cortex in subjects at genetic high risk for psychosis. <i>Schizophrenia Research</i> , 2013 , 150, 512-8	3.6	18
666	Myosin Vb gene is associated with schizophrenia in Chinese Han population. 2013 , 207, 13-8		9
665	Association study of neuregulin-1 gene polymorphisms in a North Indian schizophrenia sample. <i>Schizophrenia Research</i> , 2013 , 144, 24-30	3.6	28
664	Network dysfunction during associative learning in schizophrenia: Increased activation, but decreased connectivity: an fMRI study. <i>Schizophrenia Research</i> , 2013 , 148, 38-49	3.6	28
663	Characterization of [11C]RO5013853, a novel PET tracer for the glycine transporter type 1 (GlyT1) in humans. 2013 , 75, 282-290		22
662	Is aberrant functional connectivity a psychosis endophenotype? A resting state functional magnetic resonance imaging study. 2013 , 74, 458-66		166
661	fMRI assessment of thalamocortical connectivity during attentional performance. 2013 , 31, 1112-8		9
660	Network of brain protein level changes in glutaminase deficient fetal mice. 2013 , 80, 236-49		19
659	DNA methylation signatures of peripheral leukocytes in schizophrenia. 2013 , 15, 95-101		62
658	Inverse cancer comorbidity: a serendipitous opportunity to gain insight into CNS disorders. 2013 , 14, 293-304		82
657	Differential expression of parvalbumin in neonatal phencyclidine-treated rats and socially isolated rats. 2013 , 124, 548-57		32
656	Free radicals, antioxidant defense systems, and schizophrenia. 2013 , 46, 200-6		211
655	Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. 2013 , 263, 367-77		160
654	Cannabinoid receptors couple to NMDA receptors to reduce the production of NO and the mobilization of zinc induced by glutamate. 2013 , 19, 1766-82		54
653	Maternal immune activation during gestation interacts with Disc1 point mutation to exacerbate schizophrenia-related behaviors in mice. <i>Journal of Neuroscience</i> , 2013 , 33, 7654-66	6.6	106
652	The dynamics of DNA methylation in schizophrenia and related psychiatric disorders. 2013 , 38, 138-66		193
651	NMDA receptors and memory encoding. 2013 , 74, 32-40		186

650	Sequencing studies in human genetics: design and interpretation. 2013 , 14, 460-70	200
649	Direct and mediated effects of cognitive function with multidimensional outcome measures in schizophrenia: the role of functional capacity. 2013 , 35, 882-95	8
648	Substantial genetic link between IQ and working memory: implications for molecular genetic studies on schizophrenia. the European twin study of schizophrenia (EUTwinsS). 2013 , 162B, 413-8	18
647	Disruption of thalamocortical activity in schizophrenia models: relevance to antipsychotic drug action. 2013 , 16, 2145-63	23
646	Schizophrenia candidate gene ERBB4: covert routes of vulnerability to psychosis detected at the population level. 2013 , 39, 349-57	12
645	Association of GSK-3 β genetic variation with GSK-3 β expression, prefrontal cortical thickness, prefrontal physiology, and schizophrenia. 2013 , 170, 868-76	50
644	Type III neuregulin 1 is required for multiple forms of excitatory synaptic plasticity of mouse cortico-amygdala circuits. <i>Journal of Neuroscience</i> , 2013 , 33, 9655-66	6.6 30
643	[Brain development before onset of the first psychotic episode and during outcome of schizophrenia]. 2013 , 81, 260-4	2
642	Preclinical evaluation of non-imidazole histamine H3 receptor antagonists in comparison to atypical antipsychotics for the treatment of cognitive deficits associated with schizophrenia. 2013 , 16, 889-904	32
641	Catecholaminergic gene variants: contribution in ADHD and associated comorbid attributes in the eastern Indian probands. 2013 , 2013, 918410	6
640	Brain vs behavior: an effect size comparison of neuroimaging and cognitive studies of genetic risk for schizophrenia. 2013 , 39, 518-26	72
639	Does extracellular proteolysis control mammalian cognition?. 2013 , 24, 365-74	11
638	Glutamate in schizophrenia: a focused review and meta-analysis of ^1H -MRS studies. 2013 , 39, 120-9	327
637	A genome-wide RNAi screen in <i>Caenorhabditis elegans</i> identifies the nicotinic acetylcholine receptor subunit ACR-7 as an antipsychotic drug target. 2013 , 9, e1003313	18
636	A gender-specific association of interleukin 1 receptor antagonist polymorphism with schizophrenia susceptibility. 2013 , 25, 349-55	7
635	A genome-wide quantitative linkage scan of niacin skin flush response in families with schizophrenia. 2013 , 39, 68-76	14
634	Behavioral phenotypes in schizophrenic animal models with multiple combinations of genetic and environmental factors. 2013 , 121, 185-91	31
633	Genome-wide linkage analyses of 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. 2013 , 170, 521-32	105

632	Phencyclidine-induced decrease of synaptic connectivity via inhibition of BDNF secretion in cultured cortical neurons. 2013 , 23, 847-58		26
631	Prenatal Programming of Psychopathology: The Role of Epigenetic Mechanisms / PRENATALNO PROGRAMIRANJE PSIHIJATRIJSKIH POREMEĆAJA: ULOGA EPIGENETSKIH MEHANIZAMA. 2013 , 32, 313-324		9
630	Fronto-parietal white matter microstructural deficits are linked to performance IQ in a first-episode schizophrenia Han Chinese sample. 2013 , 43, 2047-56		13
629	Developmental vulnerability of synapses and circuits associated with neuropsychiatric disorders. 2013 , 126, 165-82		85
628	Development of liability syndromes for schizophrenia: where did they come from and where are they going?. 2013 , 162B, 687-97		3
627	The touchscreen operant platform for testing working memory and pattern separation in rats and mice. 2013 , 8, 2006-21		126
626	Role of disrupted in schizophrenia 1 (DISC1) in stress-induced prefrontal cognitive dysfunction. <i>Translational Psychiatry</i> , 2013 , 3, e328	8.6	28
625	Genetic association, mutation screening, and functional analysis of a Kozak sequence variant in the metabotropic glutamate receptor 3 gene in bipolar disorder. 2013 , 70, 591-8		28
624	The computational anatomy of psychosis. <i>Frontiers in Psychiatry</i> , 2013 , 4, 47	5	423
623	Group II metabotropic glutamate receptors modify N-methyl-D-aspartate receptors via Src kinase. 2013 , 3, 926		28
622	Neurodevelopmental impairment following neonatal immune challenge in mice. 2013 , 142, 221-225		
621	Spine Homeostasis as a Novel Therapeutic Target for Schizophrenia. 2013 , S1,		1
620	Estudos traducionais de neuropsiquiatria e esquizofrenia: modelos animais genéticos e de neurodesenvolvimento. 2013 , 40, 41-50		4
619	The neuroimmunology of schizophrenia. <i>Clinical Psychopharmacology and Neuroscience</i> , 2013 , 11, 107-173,4		44
618	Migration Status, Familial Risk for Mental Disorder, and Schizotypal Personality Traits. 2013 , 9, 552-571		2
617	Hippocampal neuroligin-2 overexpression leads to reduced aggression and inhibited novelty reactivity in rats. 2013 , 8, e56871		40
616	Effects of the dopamine D2 allosteric modulator, PAOPA, on the expression of GRK2, arrestin-3, ERK1/2, and on receptor internalization. 2013 , 8, e70736		13
615	The coherent organization of mental life depends on mechanisms for context-sensitive gain-control that are impaired in schizophrenia. 2013 , 4, 307		38

614	High-frequency neural oscillations and visual processing deficits in schizophrenia. 2013 , 4, 621		37
613	Mismatch negativity: translating the potential. <i>Frontiers in Psychiatry</i> , 2013 , 4, 171	5	83
612	Omega-3 fatty acid deficiency disrupts endocytosis, neuritogenesis, and mitochondrial protein pathways in the mouse hippocampus. 2013 , 4, 208		15
611	Developmental regulation of spatio-temporal patterns of cortical circuit activation. 2012 , 6, 65		7
610	NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia. 2013 , 7, 31		159
609	Persistent deficits in hippocampal synaptic plasticity accompany losses of hippocampus-dependent memory in a rodent model of psychosis. 2013 , 7, 12		19
608	Genetic association of catechol-O-methyltransferase val(158)met polymorphism in Saudi schizophrenia patients. 2014 , 13, 3079-88		9
607	The polymorphism of YWHAE, a gene encoding 14-3-3epsilon, and brain morphology in schizophrenia: a voxel-based morphometric study. 2014 , 9, e103571		13
606	The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia. <i>Frontiers in Pharmacology</i> , 2014 , 4, 169	5.6	70
605	Distinct phenotypes of new transmembrane-domain neuregulin 1 mutant mice and the rescue effects of valproate on the observed schizophrenia-related cognitive deficits. 2014 , 8, 126		19
604	The role of prefrontal catecholamines in attention and working memory. 2014 , 8, 33		55
603	Kynurenines in CNS disease: regulation by inflammatory cytokines. 2014 , 8, 12		215
602	The impact of environmental factors in severe psychiatric disorders. 2014 , 8, 19		174
601	GlyT-1 Inhibitors: From Hits to Clinical Candidates. 2014 , 51-99		8
600	Use of Behavioral Analysis in Animal Models for Schizophrenia Research. 2014 , 17, 12		
599	Dopamine Receptor Imaging in Schizophrenia. 2014 , 341-360		1
598	A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia. 2014 , 14, 351		74
597	Life History Theory's Best Chance: Illuminating Cluster B Personality Disorders. 2014 , 25, 360-362		0

596	Extensive brain structural network abnormality in first-episode treatment-naive patients with schizophrenia: morphometrical and covariation study. 2014 , 44, 2489-501		23
595	Distinctively higher plasma G72 protein levels in patients with schizophrenia than in healthy individuals. <i>Molecular Psychiatry</i> , 2014 , 19, 636-7	15.1	27
594	Impaired hippocampal neuroligin-2 function by chronic stress or synthetic peptide treatment is linked to social deficits and increased aggression. 2014 , 39, 1148-58		60
593	MRS of Psychiatric Disorders. 2014 , 222-228		2
592	Schizophrenia and Mitochondrial Dysfunction. 2014 , 6, 1		1
591	Recent progress in understanding subtype specific regulation of NMDA receptors by G Protein Coupled Receptors (GPCRs). <i>International Journal of Molecular Sciences</i> , 2014 , 15, 3003-24	6.3	18
590	Pharmacology of hallucinations: several mechanisms for one single symptom?. 2014 , 2014, 307106		46
589	Effects of psychotropic drugs on brain plasticity in humans. 2014 , 32, 163-81		5
588	Drug elucidation: invertebrate genetics sheds new light on the molecular targets of CNS drugs. <i>Frontiers in Pharmacology</i> , 2014 , 5, 177	5.6	9
587	The calcium-sensitive Sigma-1 receptor prevents cannabinoids from provoking glutamate NMDA receptor hypofunction: implications in antinociception and psychotic diseases. 2014 , 17, 1943-55		36
586	Increased glutamine in patients undergoing long-term treatment for schizophrenia: a proton magnetic resonance spectroscopy study at 3 T. 2014 , 71, 265-72		67
585	GABA and glutamate in schizophrenia: a 7 T ¹ H-MRS study. 2014 , 6, 398-407		102
584	Neonatal exposure to MK-801 reduces mRNA expression of mGlu3 receptors in the medial prefrontal cortex of adolescent rats. 2014 , 68, 202-8		4
583	Dysbindin-1 loss compromises NMDAR-dependent synaptic plasticity and contextual fear conditioning. 2014 , 24, 204-13		24
582	A Neuregulin-1 schizophrenia susceptibility variant causes perihippocampal fiber tract anomalies in healthy young subjects. 2014 , 4, 215-26		10
581	Antipsychotic treatment modulates glutamate transport and NMDA receptor expression. 2014 , 264 Suppl 1, S67-82		17
580	Deep resequencing of 17 glutamate system genes identifies rare variants in DISC1 and GRIN2B affecting risk of opioid dependence. 2014 , 19, 955-64		20
579	Increased burst-firing of ventral tegmental area dopaminergic neurons in D-amino acid oxidase knockout mice in vivo. 2014 , 40, 2999-3009		11

578	The need for experience focused counselling (EFC) with voice hearers in training and practice: a review of the literature. 2014 , 21, 391-402		6
577	New approaches to the management of schizophrenia: focus on aberrant hippocampal drive of dopamine pathways. 2014 , 8, 887-96		20
576	Altered hippocampal-parahippocampal function during stimulus encoding: a potential indicator of genetic liability for schizophrenia. 2014 , 71, 236-47		43
575	Epigenetics, stress, and their potential impact on brain network function: a focus on the schizophrenia diatheses. <i>Frontiers in Psychiatry</i> , 2014 , 5, 71	5	19
574	Traditional knowledge and formulations of medicinal plants used by the traditional medical practitioners of bangladesh to treat schizophrenia like psychosis. 2014 , 2014, 679810		18
573	Transcriptomic evidence for immaturity of the prefrontal cortex in patients with schizophrenia. 2014 , 7, 41		30
572	The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. 2014 , 48, 277-86		221
571	Pleckstrin homology domain containing 6 protein (PLEKHA6) polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients. 2014 , 51, 190-5		8
570	Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings. <i>Schizophrenia Research</i> , 2014 , 152, 325-32	3.6	120
569	An exploratory association study of the influence of dysbindin and neuregulin polymorphisms on brain morphometry in patients with schizophrenia and healthy subjects from South India. 2014 , 10, 62-8		11
568	Transcription factor 4 (TCF4) and schizophrenia: integrating the animal and the human perspective. 2014 , 71, 2815-35		43
567	Discovery of innovative therapeutics: today's realities and tomorrow's vision. 2. Pharma's challenges and their commitment to innovation. 2014 , 57, 5525-53		34
566	The epigenome and postnatal environmental influences in psychotic disorders. 2014 , 49, 337-48		29
565	Quetiapine and aripiprazole signal differently to ERK, p90RSK and c-Fos in mouse frontal cortex and striatum: role of the EGF receptor. 2014 , 15, 30		15
564	HDL cholesterol and the risk of depression over 5 years. <i>Molecular Psychiatry</i> , 2014 , 19, 637-8	15.1	15
563	Genetic insight of schizophrenia: past and future perspectives. 2014 , 535, 97-100		39
562	Modulation of behavioral networks by selective interneuronal inactivation. <i>Molecular Psychiatry</i> , 2014 , 19, 580-7	15.1	26
561	Augmentation strategies in partial responder and/or treatment-resistant schizophrenia patients treated with clozapine. 2014 , 15, 2329-45		35

560	Histological correlates of N40 auditory evoked potentials in adult rats after neonatal ventral hippocampal lesion: animal model of schizophrenia. <i>Schizophrenia Research</i> , 2014 , 159, 450-7	3.6	9
559	Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia. 2014 , 231, 3647-62		46
558	Applications of blood-based protein biomarker strategies in the study of psychiatric disorders. 2014 , 122, 45-72		64
557	Insights from Proteomic Studies on Schizophrenia Preclinical Models: What Can We Learn for Drug Discovery?. 2014 , 56-56		1
556	Potential contribution of dopaminergic gene variants in ADHD core traits and co-morbidity: a study on eastern Indian probands. 2014 , 34, 549-64		12
555	The polymorphism of YWHAЕ, a gene encoding 14-3-3epsilon, and orbitofrontal sulcogyral pattern in patients with schizophrenia and healthy subjects. 2014 , 51, 166-71		14
554	Perineuronal nets and schizophrenia: the importance of neuronal coatings. <i>Neuroscience and Biobehavioral Reviews</i> , 2014 , 45, 85-99	9	61
553	Chronic administration of haloperidol and clozapine induces differential effects on the expression of Arc and c-Fos in rat brain. 2014 , 28, 947-54		6
552	What causes aberrant salience in schizophrenia? A role for impaired short-term habituation and the GRIA1 (GluA1) AMPA receptor subunit. <i>Molecular Psychiatry</i> , 2014 , 19, 1060-70	15.1	55
551	Individualizing clozapine and risperidone treatment for schizophrenia patients. 2014 , 15, 95-110		5
550	Decreased gray matter volume in the left middle temporal gyrus as a candidate biomarker for schizophrenia: a study of drug naive, first-episode schizophrenia patients and unaffected siblings. <i>Schizophrenia Research</i> , 2014 , 159, 43-50	3.6	36
549	Psychosis-proneness correlates with expression levels of dopaminergic genes. 2014 , 29, 304-6		15
548	DISC1 dynamically regulates synaptic N-methyl-D-aspartate responses in excitatory neurons. 2014 , 75, 348-50		5
547	Neural activation abnormalities during self-referential processing in schizophrenia: an fMRI study. 2014 , 222, 165-71		17
546	Relationship between brain glutamate levels and clinical outcome in individuals at ultra high risk of psychosis. 2014 , 39, 2891-9		69
545	Novel rare variants in F-box protein 45 (FBXO45) in schizophrenia. <i>Schizophrenia Research</i> , 2014 , 157, 149-56	3.6	9
544	Hippocampus age-related microstructural changes in schizophrenia: a case-control mean diffusivity study. <i>Schizophrenia Research</i> , 2014 , 157, 214-7	3.6	5
543	Grey-matter texture abnormalities and reduced hippocampal volume are distinguishing features of schizophrenia. 2014 , 223, 179-86		22

542	Effect of glutamate transporter EAAT2 gene variants and gray matter deficits on working memory in schizophrenia. 2014 , 29, 219-25	26
541	Risk genes for schizophrenia: translational opportunities for drug discovery. 2014 , 143, 34-50	24
540	Regulation of N-methyl-D-aspartate receptors by disrupted-in-schizophrenia-1. 2014 , 75, 414-424	36
539	Pathological aggression. 86-96	
538	Schizophrenia. 189-207	1
537	The Neurobiology of Schizophrenia. 2015 , 303-319	
536	Schizophrenia. 2015 , 1, 15067	432
535	Evidence of Mitochondrial Dysfunction within the Complex Genetic Etiology of Schizophrenia. 2015 , 1, 201-19	50
534	Postsynaptic density levels of the NMDA receptor NR1 subunit and PSD-95 protein in prefrontal cortex from people with schizophrenia. 2015 , 1, 15037	38
533	Ketamine and phencyclidine: the good, the bad and the unexpected. 2015 , 172, 4254-76	114
532	Association of metabotropic glutamate receptor 3 gene polymorphisms with schizophrenia risk: evidence from a meta-analysis. 2015 , 11, 823-33	6
531	Dendritic spine morphology and dynamics in health and disease. 2015 , 121	6
530	Investigation of gene effects and epistatic interactions between Akt1 and neuregulin 1 in the regulation of behavioral phenotypes and social functions in genetic mouse models of schizophrenia. 2014 , 8, 455	18
529	ErbB4 in Laminated Brain Structures: A Neurodevelopmental Approach to Schizophrenia. 2015 , 9, 472	11
528	Approaching a network connectivity-driven classification of the psychosis continuum: a selective review and suggestions for future research. 2014 , 8, 1047	44
527	Testosterone Depletion Induces Demethylation of Murine Reelin Promoter CpG Dinucleotides: A Preliminary Study. 2015 , 2015, 286369	2
526	Mitochondrial and metabolic abnormalities in neurodevelopmental disorders. 2015 , 02, 177-180	
525	Evaluating historical candidate genes for schizophrenia. <i>Molecular Psychiatry</i> , 2015 , 20, 555-62	15.1 219

524	The schizophrenia risk gene product miR-137 alters presynaptic plasticity. 2015 , 18, 1008-16		136
523	Potential primary roles of glial cells in the mechanisms of psychiatric disorders. 2015 , 9, 154		26
522	Effects of pubertal cannabinoid administration on attentional set-shifting and dopaminergic hyper-responsivity in a developmental disruption model of schizophrenia. 2014 , 18,		38
521	Complexin2 modulates working memory-related neural activity in patients with schizophrenia. 2015 , 265, 137-45		8
520	Cortical Surface Area Differentiates Familial High Risk Individuals Who Go on to Develop Schizophrenia. 2015 , 78, 413-20		24
519	The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies. 2015 , 1338, 38-57		150
518	Task-based functional connectivity as an indicator of genetic liability to schizophrenia. <i>Schizophrenia Research</i> , 2015 , 162, 118-23	3.6	11
517	Inhibition of parvalbumin-expressing interneurons results in complex behavioral changes. <i>Molecular Psychiatry</i> , 2015 , 20, 1499-507	15.1	65
516	Glutamate and dopamine in schizophrenia: an update for the 21st century. 2015 , 29, 97-115		428
515	Advances in Cognitive Neurodynamics (IV). 2015 ,		1
514	Genetic variability testing of neurodevelopmental genes in schizophrenic patients. 2015 , 56, 205-11		11
513	DNA methylation pattern of gene promoters of major neurotransmitter systems in older patients with schizophrenia with severe and mild cognitive impairment. 2015 , 30, 558-65		22
512	The neuropathology of schizophrenia: A selective review of past studies and emerging themes in brain structure and cytoarchitecture. 2015 , 303, 82-102		86
511	Targeted training modifies oscillatory brain activity in schizophrenia patients. 2015 , 7, 807-14		21
510	Laminar and dorsoventral molecular organization of the medial entorhinal cortex revealed by large-scale anatomical analysis of gene expression. 2015 , 11, e1004032		37
509	Contingent negative variation in patients with deficit schizophrenia or bipolar I disorder with psychotic features: measurement and correlation with clinical characteristics. 2015 , 69, 196-203		14
508	Transcription factor SP4 phosphorylation is altered in the postmortem cerebellum of bipolar disorder and schizophrenia subjects. 2015 , 25, 1650-1660		8
507	Altered basolateral amygdala encoding in an animal model of schizophrenia. <i>Journal of Neuroscience</i> , 2015 , 35, 6394-400	6.6	8

506	Dysplasticity, metaplasticity, and schizophrenia: Implications for risk, illness, and novel interventions. 2015 , 27, 615-35		41
505	Understanding schizophrenia as a disorder of consciousness: biological correlates and translational implications from quantum theory perspectives. <i>Clinical Psychopharmacology and Neuroscience</i> , 2015 , 13, 36-47	3.4	10
504	ERBB4 polymorphism and family history of psychiatric disorders on age-related cortical changes in healthy children. 2015 , 9, 128-40		1
503	What determines continuing grey matter changes in first-episode schizophrenia and affective psychosis?. 2015 , 45, 817-28		22
502	Regional white matter abnormalities in drug-naive, first-episode schizophrenia patients and their healthy unaffected siblings. 2015 , 49, 246-54		23
501	Dysbindin (DTNBP1) variants are associated with hallucinations in schizophrenia. 2015 , 30, 486-91		18
500	Sterol Regulatory Element Binding Transcription Factor-1 Gene Variation and Medication Load Influence White Matter Structure in Schizophrenia. 2015 , 71, 112-119		12
499	Maternal vitamin D deficiency alters fetal brain development in the BALB/c mouse. 2015 , 286, 192-200		68
498	The role of schizotypy in the study of the etiology of schizophrenia spectrum disorders. 2015 , 41 Suppl 2, S408-16		174
497	Increased SNARE Protein-Protein Interactions in Orbitofrontal and Anterior Cingulate Cortices in Schizophrenia. 2015 , 78, 361-73		40
496	The role of the thalamus in schizophrenia from a neuroimaging perspective. <i>Neuroscience and Biobehavioral Reviews</i> , 2015 , 54, 57-75	9	105
495	Systematic Integration of Brain eQTL and GWAS Identifies ZNF323 as a Novel Schizophrenia Risk Gene and Suggests Recent Positive Selection Based on Compensatory Advantage on Pulmonary Function. 2015 , 41, 1294-308		36
494	EPA guidance on the early detection of clinical high risk states of psychoses. 2015 , 30, 405-16		235
493	The Use of Induced Pluripotent Stem Cell Technology to Advance Autism Research and Treatment. 2015 , 12, 534-45		18
492	Postnatal Phencyclidine (PCP) as a Neurodevelopmental Animal Model of Schizophrenia Pathophysiology and Symptomatology: A Review. 2016 , 29, 403-428		24
491	New discoveries in schizophrenia genetics reveal neurobiological pathways: A review of recent findings. 2015 , 58, 704-14		27
490	Reduced protein synthesis in schizophrenia patient-derived olfactory cells. <i>Translational Psychiatry</i> , 2015 , 5, e663	8.6	56
489	Association study of GRM7 polymorphisms and schizophrenia in the Chinese Han population. 2015 , 604, 109-12		5

488	Psychiatry and Neuroscience Update. 2015 ,		0
487	Pregnenolone sulfate normalizes schizophrenia-like behaviors in dopamine transporter knockout mice through the AKT/GSK3 β pathway. <i>Translational Psychiatry</i> , 2015 , 5, e528	8.6	28
486	HINT1 is involved in the behavioral abnormalities induced by social isolation rearing. 2015 , 607, 40-45		16
485	Translational Perspectives for Computational Neuroimaging. 2015 , 87, 716-32		117
484	Mechanisms of Long Non-coding RNAs in Mammalian Nervous System Development, Plasticity, Disease, and Evolution. 2015 , 88, 861-877		275
483	IQ and schizophrenia in a Swedish national sample: their causal relationship and the interaction of IQ with genetic risk. 2015 , 172, 259-65		69
482	Myelin, myelin-related disorders, and psychosis. <i>Schizophrenia Research</i> , 2015 , 161, 85-93	3.6	89
481	Mitochondrial dysfunction in schizophrenia: pathways, mechanisms and implications. <i>Neuroscience and Biobehavioral Reviews</i> , 2015 , 48, 10-21	9	147
480	Assessment of disease-related cognitive impairments using the novel object recognition (NOR) task in rodents. 2015 , 285, 176-93		131
479	Elevated levels of kynurenic acid during gestation produce neurochemical, morphological, and cognitive deficits in adulthood: implications for schizophrenia. 2015 , 90, 33-41		64
478	Common variants of the PINK1 and PARL genes do not confer genetic susceptibility to schizophrenia in Han Chinese. 2015 , 290, 585-92		1
477	Neurodevelopment, GABA system dysfunction, and schizophrenia. 2015 , 40, 190-206		127
476	Mismatch negativity indexes illness-specific impairments of cortical plasticity in schizophrenia: a comparison with bipolar disorder and Alzheimer's disease. 2015 , 95, 145-55		65
475	Dysconnectivity within the default mode in first-episode schizophrenia: a stochastic dynamic causal modeling study with functional magnetic resonance imaging. 2015 , 41, 144-53		68
474	Genetic variants in AKT1 gene were associated with risk and survival of OSCC in Chinese Han Population. 2015 , 44, 45-50		23
473	Recent genetic findings in schizophrenia and their therapeutic relevance. 2015 , 29, 85-96		124
472	Structural magnetic resonance imaging markers of susceptibility and transition to schizophrenia: a review of familial and clinical high risk population studies. 2015 , 29, 144-54		42
471	The neurobiology and treatment of first-episode schizophrenia. <i>Molecular Psychiatry</i> , 2015 , 20, 84-97	15.1	127

470	Proteomic and genomic evidence implicates the postsynaptic density in schizophrenia. <i>Molecular Psychiatry</i> , 2015 , 20, 424-32	15.1	105
469	The Disrupted-in-Schizophrenia-1 Ser704Cys polymorphism and brain neurodevelopmental markers in schizophrenia and healthy subjects. 2015 , 56, 11-7		12
468	Modeling Cognitive Impairment. 2016 , 69-84		1
467	Planar Cell Polarity Gene Mutations in Autism Spectrum Disorder, Intellectual Disabilities, and Related Deletion/Duplication Syndromes. 2016 , 189-219		7
466	Animal Models of Psychotic Disorders. 2016 , 23, 55-67		
465	Modeling Affective Symptoms of Schizophrenia. 2016 , 23, 85-102		2
464	Effect of MK-801 and Clozapine on the Proteome of Cultured Human Oligodendrocytes. 2016 , 10, 52		26
463	Inflammation and Elevation of Interleukin-12p40 in Patients with Schizophrenia. 2016 , 9, 16		16
462	Group II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic Drugs. <i>Frontiers in Pharmacology</i> , 2016 , 7, 130	5.6	37
461	Genetic Consideration of Schizotypal Traits: A Review. 2016 , 7, 1769		26
460	Expression of the Longest RGS4 Splice Variant in the Prefrontal Cortex Is Associated with Single Nucleotide Polymorphisms in Schizophrenia Patients. <i>Frontiers in Psychiatry</i> , 2016 , 7, 26	5	6
459	The PSD. 2016 , 125-147		2
458	Gene Environment Interactions in Schizophrenia: Evidence from Genetic Mouse Models. 2016 , 2016, 2173748		249
457	Maternal Nutritional Deficiencies and Schizophrenia. 2016 , 243-264		1
456	Targeting Cognitive Deficits in Schizophrenia via GABAA Receptors. 2016 , 149-164		
455	Possibility of a sex-specific role for a genetic variant in FRMPD4 in schizophrenia, but not cognitive function. 2016 , 27, 33-8		6
454	Reversal of dendritic phenotypes in 16p11.2 microduplication mouse model neurons by pharmacological targeting of a network hub. 2016 , 113, 8520-5		34
453	Preclinical Reproductive and Developmental Toxicity Profile of a Glycine Transporter Type 1 (Glyt1) Inhibitor. 2016 , 107, 148-56		2

452	Glial biomarkers in human central nervous system disease. 2016 , 64, 1755-71		31
451	Exploiting expression patterns across multiple tissues to map expression quantitative trait loci. 2016 , 17, 257		11
450	Currently recognized genes for schizophrenia: High-resolution chromosome ideogram representation. 2016 , 171B, 181-202		19
449	Proteomic analysis of the postsynaptic density implicates synaptic function and energy pathways in bipolar disorder. <i>Translational Psychiatry</i> , 2016 , 6, e959	8.6	35
448	Developmental restoration of LTP deficits in heterozygous CaMKII β KO mice. 2016 , 116, 2140-2151		5
447	Schizophrenia interactome with 504 novel protein-protein interactions. 2016 , 2, 16012		38
446	Using deep belief network modelling to characterize differences in brain morphometry in schizophrenia. 2016 , 6, 38897		91
445	Association of DISC1, BDNF, and COMT polymorphisms with exploratory eye movement of schizophrenia in a Chinese Han population. 2016 , 26, 258-265		4
444	OCT in Central Nervous System Diseases. 2016 ,		1
443	Catecholaminergic neuronal network dysfunction in the frontal lobe of a genetic mouse model of schizophrenia. 2016 , 28, 117-23		4
442	Phosphodiesterase Inhibition and Regulation of Dopaminergic Frontal and Striatal Functioning: Clinical Implications. 2016 , 19,		28
441	Other Neurological Disorders: Migraine, Neurosarcoidosis, Schizophrenia, Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS). 2016 , 167-183		1
440	Monkey Prefrontal Neurons Reflect Logical Operations for Cognitive Control in a Variant of the AX Continuous Performance Task (AX-CPT). <i>Journal of Neuroscience</i> , 2016 , 36, 4067-79	6.6	22
439	COMT, BDNF, and DTNBP1 polymorphisms and cognitive functions in patients with brain tumors. 2016 , 18, 1425-33		34
438	Phencyclidine-induced disruption of oscillatory activity in prefrontal cortex: Effects of antipsychotic drugs and receptor ligands. 2016 , 26, 614-25		14
437	DNA Damage in Major Psychiatric Diseases. 2016 , 30, 251-67		32
436	Association study of MiRSNPs with schizophrenia, tardive dyskinesia and cognition. <i>Schizophrenia Research</i> , 2016 , 174, 29-34	3.6	15
435	Synaptic and cellular changes induced by the schizophrenia susceptibility gene G72 are rescued by N-acetylcysteine treatment. <i>Translational Psychiatry</i> , 2016 , 6, e807	8.6	4

434	Working memory genetics in schizophrenia and related disorders: An RDoC perspective. 2016 , 171B, 121-31		28
433	The Influence of the CB1 Receptor Ligands on the Schizophrenia-Like Effects in Mice Induced by MK-801. 2016 , 30, 658-676		17
432	Does COMT val158met polymorphism influence P50 sensory gating, eye tracking or saccadic inhibition dysfunctions in schizophrenia?. 2016 , 246, 738-744		7
431	Not All Differences between Patients with Schizophrenia and Healthy Subjects Are Pathological: Performance on the Conners' Continuous Performance Test. 2016 , 31, 983-995		4
430	Understanding the impact of 5-HTTLPR, antidepressants, and acute tryptophan depletion on brain activation during facial emotion processing: A review of the imaging literature. <i>Neuroscience and Biobehavioral Reviews</i> , 2016 , 71, 176-197	9	20
429	miRNAs in NMDA receptor-dependent synaptic plasticity and psychiatric disorders. 2016 , 130, 1137-46		8
428	Regulating levels of the neuromodulator d-serine in human brain: structural insight into pLG72 and d-amino acid oxidase interaction. 2016 , 283, 3353-70		12
427	Acute and chronic effects of clozapine on cholinergic transmission in cultured mouse superior cervical ganglion neurons. 2016 , 30, 297-305		3
426	Positive Allosteric Modulation of the Muscarinic M1 Receptor Improves Efficacy of Antipsychotics in Mouse Glutamatergic Deficit Models of Behavior. 2016 , 359, 354-365		15
425	Neuropsychological and Structural Neuroimaging Endophenotypes in Schizophrenia. 2016 , 1-35		1
424	Neurodevelopmental Theories of Schizophrenia: Twenty-First Century Perspectives. 2016 , 1-46		
423	Molecular cause and functional impact of altered synaptic lipid signaling due to a prg-1 gene SNP. 2016 , 8, 25-38		26
422	Sub-chronic Antipsychotic Drug Administration Reverses the Expression of Neuregulin 1 and ErbB4 in a Cultured MK801-Induced Mouse Primary Hippocampal Neuron or a Neurodevelopmental Schizophrenia Model. 2016 , 41, 2049-64		13
421	Relationship between ST8SIA2, polysialic acid and its binding molecules, and psychiatric disorders. 2016 , 1860, 1739-52		30
420	Altered CSNK1E, FABP4 and NEFH protein levels in the dorsolateral prefrontal cortex in schizophrenia. <i>Schizophrenia Research</i> , 2016 , 177, 88-97	3.6	17
419	Dopamine transporter mutant animals: a translational perspective. 2016 , 30, 5-15		33
418	Global quantitative analysis of phosphorylation underlying phencyclidine signaling and sensorimotor gating in the prefrontal cortex. <i>Molecular Psychiatry</i> , 2016 , 21, 205-15	15.1	11
417	Are there glutamate abnormalities in subjects at high risk mental state for psychosis? A review of the evidence. <i>Schizophrenia Research</i> , 2016 , 171, 166-75	3.6	22

416	Decreases in ganglion cell layer and inner plexiform layer volumes correlate better with disease severity in schizophrenia patients than retinal nerve fiber layer thickness: Findings from spectral optic coherence tomography. 2016 , 32, 9-15		55
415	Brain Biomarkers of Vulnerability and Progression to Psychosis. 2016 , 42 Suppl 1, S127-32		24
414	Genetic assessment of additional endophenotypes from the Consortium on the Genetics of Schizophrenia Family Study. <i>Schizophrenia Research</i> , 2016 , 170, 30-40	3.6	46
413	The involvement of N-methyl-D-aspartate receptor (NMDAR) subunit NR1 in the pathophysiology of schizophrenia. 2016 , 48, 209-19		19
412	Phosphodiesterase 10A in Schizophrenia: A PET Study Using [(11)C]IMA107. 2016 , 173, 714-21		26
411	Shared and distinct gray matter abnormalities in schizophrenia, schizophrenia relatives and bipolar disorder in association with cognitive impairment. <i>Schizophrenia Research</i> , 2016 , 171, 140-8	3.6	22
410	BEND3 is involved in the human-specific repression of calreticulin: Implication for the evolution of higher brain functions in human. 2016 , 576, 577-80		4
409	The role of the COMT val158met polymorphism in mediating aversive learning in visual cortex. 2016 , 125, 633-642		8
408	Sex/gender differences in the brain and cognition in schizophrenia. <i>Neuroscience and Biobehavioral Reviews</i> , 2016 , 67, 57-78	9	129
407	Limited Evidence for Association of Genome-Wide Schizophrenia Risk Variants on Cortical Neuroimaging Phenotypes. 2016 , 42, 1027-36		9
406	Serum soluble urokinase-type plasminogen activator receptor levels in male patients with acute exacerbation of schizophrenia. 2016 , 236, 179-181		4
405	Genetics and psychotic disorders: A fresh look at consanguinity. 2016 , 59, 104-10		7
404	Decreased gene expression activity as a result of a mutation in the calreticulin gene promoter in a family case of schizoaffective disorder. 2016 , 10, 269-74		2
403	Long-Term Effects of Prenatal Hypoxia on Schizophrenia-Like Phenotype in Heterozygous Reeler Mice. <i>Molecular Neurobiology</i> , 2016 , 53, 3267-3276	6.2	13
402	Using human brain imaging studies as a guide toward animal models of schizophrenia. 2016 , 321, 77-98		21
401	Mismatch Negativity in First-Episode Schizophrenia: A Meta-Analysis. 2017 , 48, 3-10		62
400	DRD2 co-expression network and a related polygenic index predict imaging, behavioral and clinical phenotypes linked to schizophrenia. <i>Translational Psychiatry</i> , 2017 , 7, e1006	8.6	30
399	Neuregulin-1 mutant mice indicate motor and sensory deficits, indeed few references for schizophrenia endophenotype model. 2017 , 322, 177-185		5

398	In Vivo Systems Response Profiling and Multivariate Classification of CNS Active Compounds: A Structured Tool for CNS Drug Discovery. 2017 , 8, 785-797		9
397	Brain activation induced by psychological stress in nonpsychotic siblings of patients with schizophrenia. 2017 , 1-2, 74-80		0
396	The early growth response protein 1-miR-30a-5p-neurogenic differentiation factor 1 axis as a novel biomarker for schizophrenia diagnosis and treatment monitoring. <i>Translational Psychiatry</i> , 2017 , 7, e998 ^{8.6}		37
395	Neuropeptide Y neuronal network dysfunction in the frontal lobe of a genetic mouse model of schizophrenia. 2017 , 62, 27-35		6
394	Hippocampal-prefrontal connectivity as a translational phenotype for schizophrenia. 2017 , 27, 93-106		42
393	Effects of Hallucinogens on Neuronal Activity. 2018 , 36, 75-105		8
392	The group II metabotropic glutamate receptor agonist LY354740 and the D2 receptor antagonist haloperidol reduce locomotor hyperactivity but fail to rescue spatial working memory in GluA1 knockout mice. 2017 , 45, 912-921		10
391	The influence of the glutamatergic system on cognition in schizophrenia: A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2017 , 77, 369-387	9	31
390	Associations of NEUROD2 polymorphisms and change of cognitive dysfunctions in schizophrenia and schizoaffective disorder after eight weeks of antipsychotic treatment. 2017 , 22, 280-297		9
389	Investigational dopamine antagonists for the treatment of schizophrenia. 2017 , 26, 687-698		12
388	Immunopathology of the Nervous System. 2017 , 123-219		
387	Challenges and opportunities for the development of new antipsychotic drugs. 2017 , 143, 10-24		20
386	Schizophrenia and neurogenesis: A stem cell approach. <i>Neuroscience and Biobehavioral Reviews</i> , 2017 , 80, 414-442	9	26
385	The MAM-E17 schizophrenia rat model: Comprehensive behavioral analysis of pre-pubertal, pubertal and adult rats. 2017 , 332, 75-83		14
384	The role of MACF1 in nervous system development and maintenance. 2017 , 69, 9-17		18
383	Caveolin-1 regulation of disrupted-in-schizophrenia-1 as a potential therapeutic target for schizophrenia. 2017 , 117, 436-444		16
382	Microvascular anomaly conditions in psychiatric disease. Schizophrenia - angiogenesis connection. <i>Neuroscience and Biobehavioral Reviews</i> , 2017 , 77, 327-339	9	32
381	A case of GABAR antibodies in schizophrenia. 2017 , 17, 9		2

380	Family-based case-control study of homotopic connectivity in first-episode, drug-naive schizophrenia at rest. 2017 , 7, 43312		16
379	Pre-clinical investigation of Diabetes Mellitus as a risk factor for schizophrenia. 2017 , 326, 154-164		1
378	Basal ganglia and ventricle volume in first-episode psychosis. A family and clinical study. 2017 , 269, 90-96		14
377	Meta-analysis supports GWAS-implicated link between GRM3 and schizophrenia risk. <i>Translational Psychiatry</i> , 2017 , 7, e1196	8.6	35
376	The association between gene variants and longitudinal structural brain changes in psychosis: a systematic review of longitudinal neuroimaging genetics studies. 2017 , 3, 40		5
375	A Polygenic Risk Score of glutamatergic SNPs associated with schizophrenia predicts attentional behavior and related brain activity in healthy humans. 2017 , 27, 928-939		9
374	Combined study of genetic and epigenetic biomarker risperidone treatment efficacy in Chinese Han schizophrenia patients. <i>Translational Psychiatry</i> , 2017 , 7, e1170	8.6	25
373	No Evidence That Schizophrenia Candidate Genes Are More Associated With Schizophrenia Than Noncandidate Genes. 2017 , 82, 702-708		123
372	A group II metabotropic glutamate receptor 3 (mGlu3, GRM3) isoform implicated in schizophrenia interacts with canonical mGlu3 and reduces ligand binding. 2017 , 31, 1519-1526		6
371	Lack of GSK3 β activation and modulation of synaptic plasticity by dopamine in 5-HT1A-receptor KO mice. 2017 , 113, 124-136		10
370	Adaptive Sparse Multiple Canonical Correlation Analysis With Application to Imaging (Epi)Genomics Study of Schizophrenia. 2018 , 65, 390-399		22
369	The Genetics of Cognition in Schizophrenia: Combining Mouse and Human Studies. 2017 , 115-142		
368	Schizophrenia and depression, two poles of endocannabinoid system deregulation. <i>Translational Psychiatry</i> , 2017 , 7, 1291	8.6	24
367	Excessive activation of AhR signaling disrupts neuronal migration in the hippocampal CA1 region in the developing mouse. 2017 , 42, 25-30		15
366	Risk-Conferring Glutamatergic Genes and Brain Glutamate Plus Glutamine in Schizophrenia. <i>Frontiers in Psychiatry</i> , 2017 , 8, 79	5	14
365	Microglia and Brain Plasticity in Acute Psychosis and Schizophrenia Illness Course: A Meta-Review. <i>Frontiers in Psychiatry</i> , 2017 , 8, 238	5	79
364	A Neurophysiological Perspective on a Preventive Treatment against Schizophrenia Using Transcranial Electric Stimulation of the Corticothalamic Pathway. 2017 , 7,		10
363	The Epigenetic Link between Prenatal Adverse Environments and Neurodevelopmental Disorders. 2017 , 8,		89

362	Chlorpromazine Increases the Expression of Polysialic Acid (PolySia) in Human Neuroblastoma Cells and Mouse Prefrontal Cortex. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	11
361	Brain, blood, cerebrospinal fluid, and serum biomarkers in schizophrenia. 2018 , 265, 25-38		42
360	Hippocampal Subfield Volumes in Patients With First-Episode Psychosis. 2018 , 44, 552-559		41
359	Non-coding RNA dysregulation in the amygdala region of schizophrenia patients contributes to the pathogenesis of the disease. <i>Translational Psychiatry</i> , 2018 , 8, 44	8.6	36
358	Schizophrenia polygenic risk score predicts mnemonic hippocampal activity. 2018 , 141, 1218-1228		21
357	Beyond static measures: A review of functional magnetic resonance spectroscopy and its potential to investigate dynamic glutamatergic abnormalities in schizophrenia. 2018 , 32, 497-508		26
356	Role of the mesolimbic dopamine system in relief learning. 2018 , 43, 1651-1659		14
355	Altered avalanche dynamics in a developmental NMDAR hypofunction model of cognitive impairment. <i>Translational Psychiatry</i> , 2018 , 8, 3	8.6	16
354	Do patterns of synaptic pruning underlie psychoses, autism and ADHD?. 2018 , 24, 212-217		2
353	Neuregulin-2 ablation results in dopamine dysregulation and severe behavioral phenotypes relevant to psychiatric disorders. <i>Molecular Psychiatry</i> , 2018 , 23, 1233-1243	15.1	28
352	A gene-based review of RGS4 as a putative risk gene for psychiatric illness. 2018 , 177, 267-273		9
351	Polygenic risk for schizophrenia, transition and cortical gyrification: a high-risk study. 2018 , 48, 1532-1539		15
350	Genderwise clinical response of antipsychotics among schizophrenic patients: a prospective observational study from Lahore, Pakistan. 2018 , 22, 177-183		2
349	The interaction of NOS1AP, DISC1, DAOA, and GSK3B confers susceptibility of early-onset schizophrenia in Chinese Han population. 2018 , 81, 187-193		8
348	Genetic Variations of (rs947267 and rs3918342) and Genes (rs165599 and rs4680) in Schizophrenia and Bipolar I Disorder. 2018 , 9, 429-438		2
347	A CRITICAL REVIEW ON HYPOTHESIS, PATHOPHYSIOLOGY OF SCHIZOPHRENIA, AND ROLE OF VITAMINS IN ITS MANAGEMENT. 2018 , 11, 25		
346	Brain Networks Reorganization During Maturation and Healthy Aging-Emphases for Resilience. <i>Frontiers in Psychiatry</i> , 2018 , 9, 601	5	14
345	Cystine/Glutamate Antiporter and Aripiprazole Compensate NMDA Antagonist-Induced Dysfunction of Thalamocortical L-Glutamatergic Transmission. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	29

344	XRCC4 rs6869366 polymorphism is associated with susceptibility to both nicotine dependence and/or schizophrenia. 2018 , 45, 53-56		
343	Activation of IL-8 and its participation in cancer in schizophrenia patients: new evidence for the autoimmune hypothesis of schizophrenia. 2018 , 14, 3393-3403		6
342	Fok-I, Bsm-I, and Taq-I Variants of Vitamin D Receptor Polymorphism in the Development of Autism Spectrum Disorder: A Literature Review. 2018 , 10, e3228		9
341	A Longitudinal Multimodal Neuroimaging Study to Examine Relationships Between Resting State Glutamate and Task Related BOLD Response in Schizophrenia. <i>Frontiers in Psychiatry</i> , 2018 , 9, 632	5	21
340	Childhood-Onset Schizophrenia: Insights from Induced Pluripotent Stem Cells. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	16
339	Multi-Target Approach for Drug Discovery against Schizophrenia. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	38
338	Patterns of schizophrenia symptoms: hidden structure in the PANSS questionnaire. <i>Translational Psychiatry</i> , 2018 , 8, 237	8.6	5
337	Neural Stem Cell Dysfunction in Human Brain Disorders. 2018 , 66, 283-305		2
336	Human Neural Stem Cells. 2018 ,		1
335	Exploring the moderating effects of dopaminergic polymorphisms and childhood adversity on brain morphology in schizophrenia-spectrum disorders. 2018 , 281, 61-68		8
334	Conspiracy Theories: Evolved Functions and Psychological Mechanisms. 2018 , 13, 770-788		93
333	The neuropathological investigation of the brain in a monkey model of autism spectrum disorder with ABCA13 deletion. 2018 , 71, 130-139		11
332	Longitudinal and cross-sectional investigations of long-term potentiation-like cortical plasticity in bipolar disorder type II and healthy individuals. <i>Translational Psychiatry</i> , 2018 , 8, 103	8.6	13
331	De Novo Design, Synthesis, and Biological Evaluation of 3,4-Disubstituted Pyrrolidine Sulfonamides as Potent and Selective Glycine Transporter 1 Competitive Inhibitors. 2018 , 61, 7486-7502		14
330	Discovery of Novel Aminotetralines and Aminochromanes as Selective and Competitive Glycine Transporter 1 (GlyT1) Inhibitors. 2018 , 61, 7503-7524		7
329	Effects of DISC1 Polymorphisms on Resting-State Spontaneous Neuronal Activity in the Early-Stage of Schizophrenia. <i>Frontiers in Psychiatry</i> , 2018 , 9, 137	5	5
328	Pharmacogenetics and cognitive symptoms in schizophrenia patients treated with antipsychotics. 2018 , 19, 927-930		1
327	Altered Expression Profile of IgLON Family of Neural Cell Adhesion Molecules in the Dorsolateral Prefrontal Cortex of Schizophrenic Patients. 2018 , 11, 8		23

326	Synaptic phospholipids as a new target for cortical hyperexcitability and E/I balance in psychiatric disorders. <i>Molecular Psychiatry</i> , 2018 , 23, 1699-1710	15.1	21
325	EZH1 is an antipsychotic-sensitive epigenetic modulator of social and motivational behavior that is dysregulated in schizophrenia. 2018 , 119, 149-158		6
324	Current Concepts and Treatments of Schizophrenia. 2018 , 23,		138
323	An Update on Promising Biomarkers in Schizophrenia. 2018 , 16, 153-163		7
322	An Overview of Animal Models Related to Schizophrenia. 2019 , 64, 5-17		69
321	NMDAR Hypofunction Animal Models of Schizophrenia. 2019 , 12, 185		48
320	Developing zebrafish experimental animal models relevant to schizophrenia. <i>Neuroscience and Biobehavioral Reviews</i> , 2019 , 105, 126-133	9	8
319	Endophenotypes in Schizophrenia: Digging Deeper to Identify Genetic Mechanisms. 2019 , 4,		6
318	Progress in iPSC-Based Modeling of Psychiatric Disorders. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	23
317	Translating preclinical findings in clinically relevant new antipsychotic targets: focus on the glutamatergic postsynaptic density. Implications for treatment resistant schizophrenia. <i>Neuroscience and Biobehavioral Reviews</i> , 2019 , 107, 795-827	9	10
316	Reviews on Biomarker Studies in Aging and Anti-Aging Research. 2019 ,		2
315	Identification of neuron-type specific promoters in monkey genome and their functional validation in mice. 2019 , 518, 619-624		6
314	Selective optogenetic inhibition of medial prefrontal glutamatergic neurons reverses working memory deficits induced by neuropathic pain. 2019 , 160, 805-823		8
313	RETRACTED ARTICLE: A review of 45 candidate genes: Association of single nucleotide polymorphism to schizophrenia Risk. 2019 , 38, i-xvi		
312	Early life exposures, neurodevelopmental disorders, and transposable elements. 2019 , 11, 100174		15
311	Elevated serum anti-NMDA receptor antibody levels in first-episode patients with schizophrenia. 2019 , 81, 213-219		10
310	Polymorphisms in Dopaminergic Genes in Schizophrenia and Their Implications in Motor Deficits and Antipsychotic Treatment. 2019 , 13, 355		2
309	Anti-NMDA receptor antibody positivity in acute psychotic states: An exploratory study. 2019 , 43, 95-98		2

308	Hippocampal-prefrontal coherence mediates working memory and selective attention at distinct frequency bands and provides a causal link between schizophrenia and its risk gene GRIA1. <i>Translational Psychiatry</i> , 2019 , 9, 142	8.6	27
307	Oscillations in cortico-basal ganglia circuits: implications for Parkinson's disease and other neurologic and psychiatric conditions. 2019 , 122, 203-231		13
306	Psychiatric Symptoms in Amyotrophic Lateral Sclerosis: Beyond a Motor Neuron Disorder. 2019 , 13, 175		33
305	Tonic Activation of GluN2C/GluN2D-Containing NMDA Receptors by Ambient Glutamate Facilitates Cortical Interneuron Maturation. <i>Journal of Neuroscience</i> , 2019 , 39, 3611-3626	6.6	27
304	Multiscale Simulations of Biological Membranes: The Challenge To Understand Biological Phenomena in a Living Substance. 2019 , 119, 5607-5774		130
303	Prefrontal Coexpression of Schizophrenia Risk Genes Is Associated With Treatment Response in Patients. 2019 , 86, 45-55		14
302	Genetic Modulation of Neurocognitive Development in Cancer Patients throughout the Lifespan: a Systematic Review. 2019 , 29, 190-219		6
301	Disrupted-in-schizophrenia 1 overexpression disrupts hippocampal coding and oscillatory synchronization. 2019 , 29, 802-816		11
300	Schizophrenia-associated MicroRNA-Gene Interactions in the Dorsolateral Prefrontal Cortex. 2019 , 17, 623-634		15
299	Bioavailability and Neuroprotectivity of 3-(3, 4-dimethoxy phenyl)-1-4 (methoxy phenyl) prop-2-en-1-one against Schizophrenia: an approach. 2019 , 39, 392-398		2
298	A DISC1 point mutation promotes oligomerization and impairs information processing in a mouse model of schizophrenia. 2019 , 165, 369-378		4
297	Glutamate Dehydrogenase-Deficient Mice Display Schizophrenia-Like Behavioral Abnormalities and CA1-Specific Hippocampal Dysfunction. 2019 , 45, 127-137		12
296	Interaction between childhood adversity and functional polymorphisms in the dopamine pathway on first-episode psychosis. <i>Schizophrenia Research</i> , 2019 , 205, 51-57	3.6	10
295	Prefrontal fatty acid composition in schizophrenia and bipolar disorder: Association with reelin expression. <i>Schizophrenia Research</i> , 2020 , 215, 493-498	3.6	7
294	mGluR5 hypofunction is integral to glutamatergic dysregulation in schizophrenia. <i>Molecular Psychiatry</i> , 2020 , 25, 750-760	15.1	21
293	Molecular alterations in the medial temporal lobe in schizophrenia. <i>Schizophrenia Research</i> , 2020 , 217, 71-85	3.6	10
292	NMDA receptor hypofunction for schizophrenia revisited: Perspectives from epigenetic mechanisms. <i>Schizophrenia Research</i> , 2020 , 217, 60-70	3.6	30
291	Prenatal exposure to environmental insults and enhanced risk of developing Schizophrenia and Autism Spectrum Disorder: focus on biological pathways and epigenetic mechanisms. <i>Neuroscience and Biobehavioral Reviews</i> , 2020 , 117, 253-278	9	48

290	Distinct changes in chronic pain sensitivity and oxytocin receptor expression in a new rat model (Wisket) of schizophrenia. 2020 , 714, 134561		9
289	Zebrafish as a Model of Neurodevelopmental Disorders. 2020 , 445, 3-11		25
288	Genetic variability of serotonin pathway associated with schizophrenia onset, progression, and treatment. 2020 , 183, 113-127		3
287	Neuroinflammation and glial cell activation in mental disorders. 2020 , 2, 100034		11
286	Multiple rare inherited variants in a four generation schizophrenia family offer leads for complex mode of disease inheritance. <i>Schizophrenia Research</i> , 2020 , 216, 288-294	3.6	6
285	Schizophrenia in a genomic era: a review from the pathogenesis, genetic and environmental etiology to diagnosis and treatment insights. 2020 , 30, 1-9		16
284	Cilia interactome with predicted protein-protein interactions reveals connections to Alzheimer's disease, aging and other neuropsychiatric processes. 2020 , 10, 15629		8
283	Sleep-related memory consolidation in the psychosis spectrum phenotype. 2020 , 174, 107273		1
282	Electrochemical method for determination of levodopa in the presence of uric acid using In2S3 nanospheres on 3D graphene-modified ITO glass electrode. 2020 , 31, 13680-13687		3
281	A meta-analysis of ultra-high field glutamate, glutamine, GABA and glutathione 1HMRS in psychosis: Implications for studies of psychosis risk. <i>Schizophrenia Research</i> , 2020 , 226, 61-69	3.6	18
280	Altered dopaminergic pathways and therapeutic effects of intranasal dopamine in two distinct mouse models of autism. 2020 , 13, 111		15
279	Interaction of Catechol-O-methyltransferase Val Met polymorphism and sex influences association of parietal intrinsic functional connectivity and immediate verbal memory. 2020 , 10, e01784		3
278	Overview of schizophrenia research and treatment in Pakistan. 2020 , 6, e05545		0
277	Changes in subunit composition of NMDA receptors in animal models of schizophrenia by repeated administration of methamphetamine. 2020 , 103, 109984		4
276	Developmental alterations in the transcriptome of three distinct rodent models of schizophrenia. 2020 , 15, e0232200		3
275	Are Circadian Disturbances a Core Pathophysiological Component of Schizophrenia?. 2020 , 35, 325-339		15
274	Functional impairment of cortical AMPA receptors in schizophrenia. <i>Schizophrenia Research</i> , 2020 ,	3.6	6
273	Syndapin I Loss-of-Function in Mice Leads to Schizophrenia-Like Symptoms. 2020 , 30, 4306-4324		6

272	Juvenile Delinquency. 2020 ,		
271	The relationship of genetic susceptibilities for psychosis with physiological fluctuation in functional MRI data. 2020 , 297, 111031		0
270	Perspective on medication decisions following remission from first-episode psychosis. <i>Schizophrenia Research</i> , 2020 , 225, 82-89	3.6	3
269	Association of a Reproducible Epigenetic Risk Profile for Schizophrenia With Brain Methylation and Function. 2020 , 77, 628-636		19
268	Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats. 2020 , 11, 246		71
267	Behavioral abnormalities and phosphorylation deficits of extracellular signal-regulated kinases 1 and 2 in rat offspring of the maternal immune activation model. 2020 , 217, 112805		1
266	Ribosomal Protein S6 Hypofunction in Postmortem Human Brain Links mTORC1-Dependent Signaling and Schizophrenia. <i>Frontiers in Pharmacology</i> , 2020 , 11, 344	5.6	9
265	Serotonin and schizophrenia. 2020 , 31, 711-743		4
264	Dissimilarity in Sulcal Width Patterns in the Cortex can be Used to Identify Patients With Schizophrenia With Extreme Deficits in Cognitive Performance. 2021 , 47, 552-561		2
263	Role of Ash1l in Tourette syndrome and other neurodevelopmental disorders. 2021 , 81, 79-91		6
262	Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders?. <i>Frontiers in Pharmacology</i> , 2020 , 11, 635763	5.6	2
261	N-methyl-D-aspartate Receptor Antibody and White Matter Deficits in Schizophrenia Treatment-Resistance. 2021 , 47, 1463-1472		0
260	The beta component of gamma-band auditory steady-state responses in patients with schizophrenia.		
259	Grey and white matter micro-structure is associated with polygenic risk for schizophrenia.		0
258	Schizophrenia-associated SLC39A8 polymorphism is a loss-of-function allele altering glutamate receptor and innate immune signaling. <i>Translational Psychiatry</i> , 2021 , 11, 136	8.6	4
257	Cytokine Imbalance in Schizophrenia. From Research to Clinic: Potential Implications for Treatment. <i>Frontiers in Psychiatry</i> , 2021 , 12, 536257	5	15
256	Longitudinal allometry of sulcal morphology in health and schizophrenia.		
255	Neuregulins in Neurodegenerative Diseases. 2021 , 13, 662474		6

254	Deep learning based automatic diagnosis of first-episode psychosis, bipolar disorder and healthy controls. 2021 , 89, 101882		4
253	Visual cortical plasticity and the risk for psychosis: An interim analysis of the North American Prodrome Longitudinal Study. <i>Schizophrenia Research</i> , 2021 , 230, 26-37	3.6	0
252	miR-936 is Increased in Schizophrenia and Inhibits Neural Development and AMPA Receptor-Mediated Synaptic Transmission. 2021 , 47, 1795-1805		0
251	Effect of antioxidant, malondialdehyde, macro-mineral, and trace element serum concentrations in Bangladeshi patients with schizophrenia: A case-control study. 2021 , 4, e291		2
250	Schizophrenia: a classic battle ground of nature versus nurture debate. 2021 , 66, 1037-1046		0
249	Reduced cortical GABA and glutamate in high schizotypy. 2021 , 238, 2459-2470		2
248	Interneuron Heterotopia in the Lis1 Mutant Mouse Cortex Underlies a Structural and Functional Schizophrenia-Like Phenotype. 2021 , 9, 693919		1
247	Anxiety and executive functions relationships in schizophrenia: A meta-analysis. 2021 , 177, 110643		
246	COUP-TFI specifies the medial entorhinal cortex identity and induces differential cell adhesion to determine the integrity of its boundary with neocortex. 2021 , 7,		1
245	Glutamatergic dysfunction leads to a hyper-dopaminergic phenotype through deficits in short-term habituation: a mechanism for aberrant salience.		2
244	Grey and white matter microstructure is associated with polygenic risk for schizophrenia. <i>Molecular Psychiatry</i> , 2021 ,	15.1	5
243	Effects of Dietary Food Components on Cognitive Functions in Older Adults. 2021 , 13,		1
242	Epigenetics of Schizophrenia. 2021 , 305, 114218		5
241	Nrg1 haploinsufficiency alters inhibitory cortical circuits. 2021 , 157, 105442		1
240	Schizophrenia risk-gene Crmp2 deficiency causes precocious critical period plasticity and deteriorated binocular vision. 2021 , 66, 2225-2237		
239	Early Detection and Intervention as Approaches for Preventing Schizophrenia. 617-631		1
238	Will Modulation of Neuropeptide Receptors Produce the Next Generation of Antipsychotic Drugs? A Focus on the Neurokinin and Neurotensin Systems. 381-424		1
237	Contributions of Glutamate and GABA Systems to the Neurobiology and Treatment of Schizophrenia. 433-461		5

236	Dysbindin-1 and Its Protein Family. 2009 , 107-241	35
235	Neuregulin 1 and Schizophrenia. 2009 , 243-265	1
234	Redox Dysregulation in Schizophrenia: Genetic Susceptibility and Pathophysiological Mechanisms. 2009 , 285-311	9
233	Neurosteroids in Cortical Development and the Etiology of Schizophrenia. 2008 , 299-324	1
232	Challenging the Genetic Complexity of Schizophrenia by Use of Intermediate Phenotypes. 2009 , 41-56	2
231	Mitochondrial Complex I as a Possible Novel Peripheral Biomarker for Schizophrenia. 2009 , 71-83	1
230	GeneEnvironment Interactions for Searchers: Collaboration between Epidemiology and Molecular Genetics. 2010 , 19-50	1
229	The Neuropathology of Schizophrenia: Central Role for the Hippocampus?. 2010 , 149-165	3
228	Microarray database mining and cell differentiation defects in schizophrenia. 2011 , 696, 67-74	6
227	The Early Development of Processing Emotions in Face and Voice. 2013 , 95-116	8
226	Complexity and the Onset of Psychosis. 2013 , 317-333	1
225	NatureNurture Integration. 2014 , 45-65	6
224	Mitochondrial Dysfunction in Psychiatric Disorders. 2015 , 231-244	1
223	The Therapeutic Potential of Ketogenic Diet Throughout Life: Focus on Metabolic, Neurodevelopmental and Neurodegenerative Disorders. 2019 , 1178, 77-101	7
222	Risk and Protective Factors for Delinquency. 2020 , 47-81	1
221	Neuropathological Background of MK-801 for Inducing Murine Model of Schizophrenia. 2017 , 337-354	1
220	Neuroimaging Studies in Psychotic Disorders. 2019 , 371-378	1
219	Funktionell-neuroanatomische und neuropathologische Grundlagen psychischer Erkrankungen. 2008 , 109-128	1

218	The Aberrant Connectivity Hypothesis in Schizophrenia. 2009 , 301-323	2
217	Funktionell-neuroanatomische und neuropathologische Grundlagen psychischer Erkrankungen. 2011 , 167-188	0
216	Neurological and Neuropsychological Endophenotypes in Schizophrenia Spectrum Disorders. 2011 , 325-349	1
215	The Schizophrenia Construct After 100 Years of Challenges. 2011 , 1-44	3
214	Cerebellum and Schizophrenia □The Cerebellum Volume Reduction Theory of Schizophrenia. 2013 , 1907-1921	1
213	Genetic Markers in Psychiatry. 2019 , 1192, 53-93	2
212	Diffusion Tensor Imaging and its Application to Schizophrenia and Related Disorders. 2014 , 317-334	1
211	Complexins. 2017 ,	1
210	Psychosis and Schizophrenia. 2008 , 371-389	1
209	Defizite der sensomotorischen Filterleistung bei psychiatrischen Erkrankungen. 2008 , 19, 139-163	11
208	Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and gene expression.	1
207	Epigenetic and transgenerational mechanisms in infection-mediated neurodevelopmental disorders. <i>Translational Psychiatry</i> , 2017 , 7, e1113	8.6 47
206	The role of cerebellar genes in pathology of autism and schizophrenia. 2008 , 7, 279	2
205	Features of Duration Mismatch Negativity Around the Onset of Overt Psychotic Disorders: A Longitudinal Study. 2021 , 31, 2416-2424	4
204	Dissimilarity in sulcal width patterns in the cortex can be used to identify patients with schizophrenia with extreme deficits in cognitive performance.	1
203	CUB and Sushi Multiple Domains 1 (CSMD1) opposes the complement cascade in neural tissues.	5
202	Analysis of proteins in computational models of synaptic plasticity.	1
201	Glycosylation enzyme mRNA expression in dorsolateral prefrontal cortex of elderly patients with schizophrenia: Evidence for dysregulation of multiple glycosylation pathways.	5

200	A neuron-optimized CRISPR/dCas9 activation system for robust and specific gene regulation.	5
199	Neurodevelopmental involvement in schizophrenia: the olfactory epithelium as an alternative model for research. 2007 , 070508225918001-???	1
198	Aggregation of scaffolding protein DISC1 dysregulates phosphodiesterase 4 in Huntington's disease. 2017 , 127, 1438-1450	26
197	Cellular Functions of PDE4 Enzymes. 2006 ,	3
196	Schizophrenia. 2008 , 329-353	1
195	Neuregulin-1 regulates cell adhesion via an ErbB2/phosphoinositide-3 kinase/Akt-dependent pathway: potential implications for schizophrenia and cancer. 2007 , 2, e1369	50
194	MicroRNA expression aberration as potential peripheral blood biomarkers for schizophrenia. 2011 , 6, e21635	171
193	Effects of metabotropic glutamate receptor 3 genotype on phonetic mismatch negativity. 2011 , 6, e24929	14
192	Mutation of Semaphorin-6A disrupts limbic and cortical connectivity and models neurodevelopmental psychopathology. 2011 , 6, e26488	32
191	Catechol-O-methyltransferase Val158Met polymorphism associates with individual differences in sleep physiologic responses to chronic sleep loss. 2011 , 6, e29283	44
190	Association analysis of 94 candidate genes and schizophrenia-related endophenotypes. 2012 , 7, e29630	104
189	The schizophrenia-associated Kv11.1-3.1 isoform results in reduced current accumulation during repetitive brief depolarizations. 2012 , 7, e45624	21
188	Differential expression of exosomal microRNAs in prefrontal cortices of schizophrenia and bipolar disorder patients. 2013 , 8, e48814	159
187	Pregnenolone rescues schizophrenia-like behavior in dopamine transporter knockout mice. 2012 , 7, e51455	43
186	Association Study of N-Methyl-D-Aspartate Receptor Subunit 2B (GRIN2B) Polymorphisms and Schizophrenia Symptoms in the Han Chinese Population. 2015 , 10, e0125925	16
185	Cerebral Inefficient Activation in Schizophrenia Patients and Their Unaffected Parents during the N-Back Working Memory Task: A Family fMRI Study. 2015 , 10, e0135468	11
184	A complex network approach reveals a pivotal substructure of genes linked to schizophrenia. 2018 , 13, e0190110	16
183	Neuregulin 1 Type I Overexpression Is Associated with Reduced NMDA Receptor-Mediated Synaptic Signaling in Hippocampal Interneurons Expressing PV or CCK. 2018 , 5,	17

182	A Neuron-Optimized CRISPR/dCas9 Activation System for Robust and Specific Gene Regulation. 2019 , 6,	60
181	Common mechanisms of excitatory and inhibitory imbalance in schizophrenia and autism spectrum disorders. 2015 , 15, 146-67	256
180	Neurodevelopment in schizophrenia: the role of the wnt pathways. 2013 , 11, 535-58	34
179	Neurotransmission. 2007 , 81-100	2
178	The use of neurophysiological endophenotypes to understand the genetic basis of schizophrenia. 2005 , 7, 125-35	114
177	Intermediate phenotypes in schizophrenia: a selective review. 2005 , 7, 165-79	47
176	Endophenotypes in the personality disorders. 2005 , 7, 139-51	27
175	Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled?. 2006 , 8, 303-9	11
174	Personalized medicine in psychiatry: ethical challenges and opportunities. 2009 , 11, 427-34	26
173	Indicated prevention of schizophrenia. 2008 , 105, 532-9	19
172	Minocycline for negative symptoms of schizophrenia and possible mechanistic actions: the BeneMin RCT. 2019 , 6, 1-66	1
171	Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models. 2010 , 4, 189-200	81
170	Impaired Potentiation of Theta Oscillations During a Visual Cortical Plasticity Paradigm in Individuals With Schizophrenia. <i>Frontiers in Psychiatry</i> , 2020 , 11, 590567	5 4
169	Phosphodiesterase 4B: Master Regulator of Brain Signaling. 2020 , 9,	11
168	Brain-Derived Neurotrophic Factor Serum Level and Severity Symptom of Batakese Male Patients with Schizophrenia in North Sumatera, Indonesia. 2019 , 7, 1957-1961	6
167	Relations of genetic variants in superoxide dismutase 2 and dystrobrevin-binding protein 1 to methamphetamine psychosis among methamphetamine dependents in Taiwan. 2019 , 33, 83	1
166	Minocycline for Schizophrenia: A critical review. 2012 , 02, 399-406	4
165	Neuronal networks in mental diseases and neuropathic pain: Beyond brain derived neurotrophic factor and collapsin response mediator proteins. 2016 , 6, 18-30	5

164	Gene environment interaction in periphery and brain converge to modulate behavioral outcomes: Insights from the SP1 transient early in life interference rat model. 2016 , 6, 294-302	1
163	Do Apparent Overlaps between Schizophrenia and Autistic Spectrum Disorders Reflect Superficial Similarities or Etiological Commonalities?. 2011 , 4, 124-133	28
162	Cell autonomous regulation of hippocampal circuitry via Aph1b- β secretase/neuregulin 1 signalling. 2014 , 3,	17
161	Effect of polymorphisms of three genes mediating monoamine signalling on brain morphometry in schizophrenia and healthy subjects. <i>Clinical Psychopharmacology and Neuroscience</i> , 2015 , 13, 68-82	3-4 8
160	Selective behavioural impairments in mice heterozygous for the cross disorder psychiatric risk gene DLG2.	1
159	The beta component of gamma-band auditory steady-state responses in patients with schizophrenia. 2021 , 11, 20387	0
158	Family Factors in Schizophrenia and Bipolar Disorder. 2005 , 205-223	3
157	Rgs4.	
156	Mecanismos de acci3n de los medicamentos antipsic3ticos de segunda generaci3n en la esquizofrenia: conocimientos obtenidos a partir de los estudios de im3genes cerebrales. 2005 , 12, 231-244	
155	Bibliography. 2006 , 185-193	
154	¿Hay una asociaci3n entre el gen de la COMT y los endofenotipos de la onda P300?. 2006 , 13, 244-248	
153	Acquiring the Excitatory and the Inhibitory Action of Dopamine in the Prefrontal Cortex During Postnatal Development. 2007 , 175-187	
152	Prefrontal Cortical Synaptic Plasticity: The Roles of Dopamine and Implication for Schizophrenia. 2007 , 165-174	1
151	????????????????? ?P?????????2007, 119, 119-125	
150	Molecular Genetic Study of Schizophrenia Based on Neurodevelopmental Hypothesis. 2007 , 101-116	
149	Model Organisms and Neurogenetics. 2007 , 117-134	
148	Pharmacogenetics and Pharmacogenomics in Psychiatry: Clinical Applications. 2007 , 173-194	
147	Toward a Unified Model of Neurogenetics. 2007 , 135-152	

146 Neuroimaging Biomarkers in Schizophrenia. **2008**, 235-271

145 Perspectives for an Integrated Biomarker Approach to Drug Discovery and Development. **2008**, 355-403

144 Biomarkers in Schizophrenia. **2008**, 23-55

1

143 Blood and Brain Gene Expression in Major Psychiatric Disorders: A Search for Biomarkers. **2008**, 1-21

1

142 Genetics and Psychiatry. **2008**, 853-883

141 Proteomics Providing Insights into Major Psychiatric Disorders. 349-377

140 Schizophrenia: Biological Mechanisms. 1

139 Role of Members of the Nur (NR4A) Transcription Factors in Dopamine-Related Neurodegenerative and Neuropsychiatric Disorders. **2009**, 195-210

138 The Use of Neurocognitive Endophenotypes in Large-Scale Family Genetic Studies of Schizophrenia. **2009**, 177-193

137 Emotion Recognition Deficits as a Neurocognitive Marker of Schizophrenia Liability. **2009**, 163-176

136 Psychische Erkrankungen. **2009**, 747-776

135 Molecular Genetics of Schizophrenia: Focus on Symptom Dimensions. **2009**, 95-124

3

134 Prediction of Psychosis Through the Prodromal Syndrome. **2010**, 251-266


133 Brain Anatomical Abnormalities in Schizophrenia: Neurodevelopmental Origins and Patterns of Progression over Time. **2010**, 113-148

132 Genetic counseling in schizophrenia. **2009**, 322-332

131 Biochemical alterations in schizophrenia. **2009**, 114-130

130 Postnatal Maturation of Dopamine Actions in the Prefrontal Cortex. **2009**, 177-186

129 Genetic Dissection of Dopamine-Mediated Prefrontal-Striatal Mechanisms and Its Relationship to Schizophrenia. **2009**, 187-200

- 128 Genetische Aspekte der Neuropsychologie psychischer Störungen. **2010**, 145-164
- 127 Inhibition of Glycine Transporter-1 Improves the Functional Outcome of Schizophrenia. **2010**, 577-610 ○
- 126 Früherkennung und Frühbehandlung schizophrener Psychosen. **2010**, 119-131
- 125 Childhood Neuropsychiatric Risk. **2010**, 369-405
- 124 Genetic Counselling in Disorders of Low Penetrance. **2010**, 371-379
- 123 Schizophrenia and related disorders. **2010**, 48-63
- 122 Nicotinic Cholinergic Signaling in the Human Brain - Systems Perspective. 161-188
- 121 Childhood Onset Schizophrenia. **2011**, 199-221
- 120 Advanced Human Cognition: A Faustian Deal. **2011**, 171-200
- 119 Mapping Prodromal Psychosis. **2011**, 445-471 1
- 118 Neurophysiology of Cognitive Dysfunction in Schizophrenia. **2011**, 449-480
- 117 Animal Models of Schizophrenia. 462-481
- 116 How Will Research in Neuroscience Influence the Practice of Psychiatry in the Next Ten Years?. **2011**, 6,
- 115 Antipsychotic drugs. **2012**, 553-563
- 114 Schizophrenie. **2012**, 437-496
- 113 Glycogen Synthase Kinase-3 in Neurological Diseases. **2012**, 153-188 2
- 112  Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia. 319-354
- 111 Candidate Genes Involved in the Expression of Psychotic Symptoms: A Focus on Hallucinations. **2013**, 231-252 1

- 110 Von der Grundlagenforschung zum klinischen Einsatz in Diagnostik und Therapie. **2013**, 79-85
- 109 Is the Current Diagnosis of Schizophrenia Useful or Harmful?. **2014**, 03, 157-160 1
- 108 Encyclopedia of Psychopharmacology. **2014**, 1-8
- 107 Systems Biopsychiatry: The Cognitive Neurodynamics of Schizophrenia in an Integrated Systemic View. **2015**, 575-581
- 106 [Augmented antipsychotic therapy with pantogam active in patients with schizophrenia]. **2015**, 115, 28-34 0
- 105 Two Hit Neurodevelopmental Mechanisms in Schizophrenia: Focus on Animal Models and the Role of BDNF. **2015**, 335-351 0
- 104 CHAPTER 6: Drugs that Target the Glutamate Synapse: Implications for the Glutamate Hypothesis of Schizophrenia. **2015**, 115-140
- 103 Modelos reduccionista e multinível na esquizofrenia: alcances e limites. **2015**, 18, 743-757
- 102 ¿Es posible prevenir la enfermedad mental grave?. **2017**, 15, 89-91
- 101 3.0 T fMRI in Psychiatry. **2017**, 357-372
- 100 Psychische Erkrankungen. **2018**, 813-845
- 99 Prefrontal co-expression of schizophrenia risk genes is associated with treatment response in patients.
- 98 Rethinking schizophrenia through the lens of evolution: shedding light on the enigma. 4, 0
- 97 Schizophrenia: A Complex Mental Illness. **2019**, 417-426
- 96 Traumatic shock and electroshock: the difficult relationship between anatomic pathology and psychiatry in the early 20 century. **2019**, 111, 79-85 0
- 95 Mothers of schizophrenic patients: medical and psychological aspects of the problem. **2019**, 10, 6-17 0
- 94 Catechol-O-methyltransferase gene expression in stress-induced and non-stress induced schizophrenia. **2020**, 30, 10-18
- 93 Formation and synaptic control of active transient working memory representations. 0

92	Schizophrenia Genomics: Convergence on Synaptic Development, Adult Synaptic Plasticity, or Both?. 2021 ,		4
91	Other Neurological Disorders: Migraine, Neurosarcoidosis, Schizophrenia, Obstructive Sleep Apnea-Hypopnea Syndrome and Bipolar Disorder. 2020 , 317-342		1
90	Cerebellum and Schizophrenia [The Cerebellum Volume Reduction Theory of Schizophrenia. 2020 , 1-17		
89	Association analyses of the DAOA/G30 and d-amino-acid oxidase genes in schizophrenia: Further evidence for a role in schizophrenia. 2007 , 9, 169-177		
88	Schizophrenie, Entzündung und glutamaterge Neurotransmission: ein pathophysiologisches Modell. 2006 , 93-123		
87	The Relevance of Epigenetics to Major Psychosis. 2009 , 411-434		
86	Von der Grundlagenforschung zum klinischen Einsatz in Diagnostik und Therapie. 2007 , 623-629		
85	Soziale Kognition [Bildgebung. 2008 , 357-366		
84	Diagnose, Biologie und Neuropathophysiologie der Schizophrenie. 2008 , 36-43		2
83	Genetische Aspekte neuropsychologischer Störungen bei schizophrenen Patienten. 2008 , 44-57		
82	Association Analysis Between Common Variants of the Gene and Three Mental Disorders in the Han Chinese Population. <i>Genetic Testing and Molecular Biomarkers</i> , 2020 , 24, 649-657	1.6	0
81	Genetics of developmental psychiatric disorders: pathways to discovery. <i>Journal of Psychiatry and Neuroscience</i> , 2005 , 30, 349-54	4.5	3
80	Schizophrenia: an integrative approach to modelling a complex disorder. <i>Journal of Psychiatry and Neuroscience</i> , 2006 , 31, 157-67	4.5	20
79	Sex steroid-related candidate genes in psychiatric disorders. <i>Journal of Psychiatry and Neuroscience</i> , 2008 , 33, 319-30	4.5	46
78	Diabetes mellitus during pregnancy and increased risk of schizophrenia in offspring: a review of the evidence and putative mechanisms. <i>Journal of Psychiatry and Neuroscience</i> , 2008 , 33, 395-404	4.5	64
77	Paliperidone: the evidence of its therapeutic value in schizophrenia. <i>Core Evidence</i> , 2008 , 2, 261-71	4.9	12
76	Elevated DISC1 transcript levels in PBMCs during acute psychosis in patients with schizophrenia. <i>Translational Biomedicine</i> , 2011 , 2,		4
75	A Study of the Association between SNP8NRG241930 in the 5' End of Neuroglin 1 Gene with Schizophrenia in a Group of Iranian Patients. <i>Cell Journal</i> , 2011 , 13, 91-6	2.4	4

74	Schizophrenia: current concepts and approaches to patient care. <i>American Health and Drug Benefits</i> , 2008 , 1, 13-22	1.7	2
73	What happens in the brain of schizophrenia patients?: an investigation from the viewpoint of neuropathology. <i>Nagoya Journal of Medical Science</i> , 2013 , 75, 11-28	0.7	11
72	Histamine H receptors and its antagonism as a novel mechanism for antipsychotic effect: a current preclinical & clinical perspective. <i>International Journal of Health Sciences</i> , 2016 , 10, 564-575	1.1	7
71	Deletion of AMPA receptor GluA1 subunit gene (<i>Gria1</i>) causes circadian rhythm disruption and aberrant responses to environmental cues. <i>Translational Psychiatry</i> , 2021 , 11, 588	8.6	0
70	Duration Mismatch Negativity Predicts Remission in First-Episode Schizophrenia Patients.. <i>Frontiers in Psychiatry</i> , 2021 , 12, 777378	5	0
69	Sparser and Less Efficient Hippocampal-Prefrontal Projections account for Developmental Network Dysfunction in a Model of Psychiatric Risk Mediated by Gene-Environment Interaction. <i>Journal of Neuroscience</i> , 2021 ,	6.6	0
68	Cerebellum and Schizophrenia: The Cerebellum Volume Reduction Theory of Schizophrenia. 2022 , 2177-2192		
67	Neuropsychiatric disorders: An immunological perspective. <i>Advances in Immunology</i> , 2021 , 152, 83-155	5.6	1
66	A Comprehensive Review of Receptor-Type Tyrosine-Protein Phosphatase Gamma (PTPRG) Role in Health and Non-Neoplastic Disease.. <i>Biomolecules</i> , 2022 , 12,	5.9	1
65	Reduction of layer 5 mediated long-range cortical communication by antipsychotic drugs.		0
64	Neurobiological Highlights of Cognitive Impairment in Psychiatric Disorders.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	1
63	Recent Reports on Redox Stress-Induced Mitochondrial DNA Variations, Neuroglial Interactions, and NMDA Receptor System in Pathophysiology of Schizophrenia.. <i>Molecular Neurobiology</i> , 2022 , 1	6.2	2
62	What genes are differentially expressed in individuals with schizophrenia? A systematic review.. <i>Molecular Psychiatry</i> , 2022 ,	15.1	0
61	Selective behavioural impairments in mice heterozygous for the cross disorder psychiatric risk gene <i>DLG2</i> .. <i>Genes, Brain and Behavior</i> , 2022 , e12799	3.6	1
60	Psychiatric genomics: brain pathophysiology and genetic factors. 2022 , 269-287		
59	Perceptual pathways to hallucinogenesis.. <i>Schizophrenia Research</i> , 2022 ,	3.6	0
58	Longitudinal Allometry of Sulcal Morphology in Health and Schizophrenia.. <i>Journal of Neuroscience</i> , 2022 ,	6.6	
57	NTNG2 Mutation: A candidate gene for a new brain-skin disorder with early neuropsychiatric manifestation? An analysis based on 3000 patients. <i>Acta Medica Alanya</i> ,		

56	The Homer1 family of proteins at the crossroad of dopamine-glutamate signaling: an emerging molecular "Lego" in the pathophysiology of psychiatric disorders. A systematic review and translational insight.. <i>Neuroscience and Biobehavioral Reviews</i> , 2022 , 104596	9	2
55	Fundamental Clock of Biological Aging: Convergence of Molecular, Neurodegenerative, Cognitive and Psychiatric Pathways: Non-Equilibrium Thermodynamics Meet Psychology.. <i>International Journal of Molecular Sciences</i> , 2021 , 23,	6.3	1
54	Kalirin as a Novel Treatment Target for Cognitive Dysfunction in Schizophrenia.. <i>CNS Drugs</i> , 2021 ,	6.7	0
53	Glutamate, Glutamatergic Drugs and Schizophrenia. 2022 , 493-521		
52	Data_Sheet_1.PDF. 2018 ,		
51	Image_1.pdf. 2020 ,		
50	Image_2.pdf. 2020 ,		
49	Image_3.pdf. 2020 ,		
48	Table_1.pdf. 2020 ,		
47	Table_2.pdf. 2020 ,		
46	Table_3.pdf. 2020 ,		
45	Data_Sheet_1.doc. 2018 ,		
44	Data_Sheet_1.PDF. 2018 ,		
43	Data_Sheet_2.PDF. 2018 ,		
42	Data_Sheet_3.PDF. 2018 ,		
41	Data_Sheet_4.PDF. 2018 ,		
40	Data_Sheet_5.PDF. 2018 ,		
39	Psychotic Disorders. 2022 , 537-555		

38	Joint Sparse Collaborative Regression on Imaging Genetics Study of Schizophrenia.. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2022 , PP,	3	
37	Comprehensive and integrative analyses identify TYW5 as a schizophrenia risk gene.. <i>BMC Medicine</i> , 2022 , 20, 169	11.4	o
36	Alternative Therapy of Psychosis: Potential Phytochemicals and Drug Targets in the Management of Schizophrenia. <i>Frontiers in Pharmacology</i> , 2022 , 13,	5.6	o
35	New drug targets in psychiatry: Neurobiological considerations in the genomics era. <i>Neuroscience and Biobehavioral Reviews</i> , 2022 , 139, 104763	9	o
34	Investigating Olfactory Bulb Volume Reduction as a Potential Biomarker for Some Neuropsychiatric Disorders: A Narrative Review. <i>Journal of Clinical and Basic Research</i> , 2021 , 5, 9-20	0.3	
33	Methylome-wide Association Study of Patients with Recent-onset Psychosis. <i>Clinical Psychopharmacology and Neuroscience</i> , 2022 , 20, 462-473	3.4	
32	Schizophrenia and psychedelic state: Dysconnection versus hyper-connection. A perspective on two different models of psychosis stemming from dysfunctional integration processes.		o
31	Psychosis-associated Valine to Leucine mutation in Neuregulin1 disrupts expression of a schizophrenia susceptibility gene network within the hippocampus and alters adult hippocampal neurogenesis.		
30	Association between variants of MTHFR genes and psychiatric disorders: A meta-analysis. 13,		o
29	Evidence that the frontal pole has a significant role in the pathophysiology of schizophrenia. 2022 , 317, 114850		o
28	Biological hypotheses, risk factors, and biomarkers of schizophrenia. 2023 , 120, 110626		o
27	Genetic Influences on Cognitive Dysfunction in Schizophrenia. 2022 ,		o
26	Bifurcation Analysis of Brain Connectivity Regulated Neural Oscillations in Schizophrenia. 2022 , 32,		o
25	Novel genomic risk loci and improved prediction for treatment-resistant schizophrenia are revealed by leveraging polygenic overlap with body-mass index.		o
24	Lessons learned from parsing genetic risk for schizophrenia into biological pathways. 2022 ,		1
23	Synaptic plasticity in Schizophrenia pathophysiology. 2022 ,		o
22	Cognitive Dysfunction in Schizophrenia: A Perspective from the Clinic to Genetic Brain Mechanisms. 2009 , 38, 420-424		1
21	Early life stress and the role of environmental and molecular moderators in the ontology of pathological and resilient behavioral phenotypes. 1, 3		o

20	Reduced cortical neuron number and neuron density in schizophrenia with focus on area 24: a post-mortem case-control study.	0
19	Accelerated cortical thinning precedes and predicts conversion to psychosis: The NAPLS3 longitudinal study of youth at clinical high-risk.	0
18	How can we obtain truly translational mouse models to improve clinical outcomes in schizophrenia?. 2022 , 15,	1
17	Gene expression meta-analysis in patients with schizophrenia reveals up-regulation of RGS2 and RGS16 in Brodmann Area 10.	0
16	Glutamatergic dysfunction leads to a hyper-dopaminergic phenotype through deficits in short-term habituation: a mechanism for aberrant salience.	2
15	CCPNet136: automated detection of schizophrenia using carbon chain pattern and iterative TQWT technique with EEG signals.	0
14	Gene Expression and Epigenetic Regulation in the Prefrontal Cortex of Schizophrenia. 2023 , 14, 243	0
13	Mapping miRNA Research in Schizophrenia: A Scientometric Review. 2023 , 24, 436	1
12	Concerted roles of LRRTM1 and SynCAM 1 in organizing prefrontal cortex synapses and cognitive functions. 2023 , 14,	0
11	¿Es posible prevenir la enfermedad mental grave?. 2023 , 21, s101-103	0
10	Correlation of rs35753505 polymorphism in Neuregulin 1 gene with psychopathology and intelligence of people with schizophrenia. 2023 , 867, 147285	0
9	Synaptic plasticity in schizophrenia pathophysiology. 2023 , 14, 244-252	0
8	Multiple serum anti-glutamate receptor antibody levels in clozapine-treated/naïve patients with treatment resistant schizophrenia.	0
7	Dysregulated Signaling at Postsynaptic Density: A Systematic Review and Translational Appraisal for the Pathophysiology, Clinics, and Antipsychotics Treatment of Schizophrenia. 2023 , 12, 574	2
6	Gene and schizophrenia in the pregenome and postgenome-wide association studies era: a bibliometric analysis and network visualization. 2023 , 33, 37-49	0
5	Cognitive functioning in early-onset psychosis. 2023 , 127-152	0
4	The synaptic hypothesis of schizophrenia version III: a master mechanism.	0
3	Associations between prefrontal PI (16:0/20:4) lipid, TNC mRNA, and APOA1 protein in schizophrenia: A trans-omics analysis in post-mortem brain. 14,	0

- 2 Polygenic overlap with body-mass index improves prediction of treatment-resistant schizophrenia. **2023**, 115217 ○
- 1 The Effect of Probiotic Supplementation on the GutBrain Axis in Psychiatric Patients. **2023**, 45, 4080-4099 ○